Unnamed: 0,title,date,stock,sentiment
934347.0,"Shares of several healthcare companies are trading lower in sympathy with the overall market following an increase in coronavirus cases in some US states that have reopened, leading to concerns of a potential second wave of the virus.",2020-06-11 12:48:00-04:00,NVS,positive
934348.0,"The Daily Biotech Pulse: Sorrento Submits EUA Application For Rapid Coronavirus Test, Decision Day For Viela, Lantern Pharma IPO",2020-06-11 08:12:00-04:00,NVS,neutral
934349.0,Novartis Says FDA Approves Updated Beovu Label to Include Additional Safety Information,2020-06-11 05:34:00-04:00,NVS,positive
934350.0,"The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid",2020-06-05 07:34:00-04:00,NVS,positive
934351.0,Novartis Phase IIIb ARGON Study Meets Primary Endpoint in a Comparison of Enerzair Breezhaler (QVM149) vs Free Combination of Two Existing Inhaled Treatments in Uncontrolled Asthma,2020-06-05 05:22:00-04:00,NVS,positive
934352.0,"The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic",2020-06-04 08:13:00-04:00,NVS,positive
934353.0,Novartis Says PREVENT Data Show Cosentyx Helps Patients Realize Early and Lasting Relief in Axial Spondyloarthritis,2020-06-04 05:33:00-04:00,NVS,positive
934354.0,"The Daily Biotech Pulse: Regulatory Delay For Novartis' Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study",2020-06-03 07:39:00-04:00,NVS,negative
934355.0,"FDA Extends Review Of SBLA, Submitted By Novartis, For Ofatumumab In Relapsing Multiple Sclerosis",2020-06-02 16:42:00-04:00,NVS,positive
934356.0,European Medicines Authority Says Novartis' Piqray Received Positive Opinion From CHMP,2020-05-29 06:36:00-04:00,NVS,positive
934357.0,"Shares of several healthcare companies are trading higher amid market strength. Strength potentially related to coronavirus efforts including testing, vaccine development and treatment measures from several names in the sector.",2020-05-28 12:33:00-04:00,NVS,positive
934358.0,"'Novartis agrees to manufacture a #coronavirus vaccine being developed by Harvard, Mass Eye & Ear and Mass. General...' -Tweet From CNBC's Squawk Box",2020-05-28 08:52:00-04:00,NVS,positive
934359.0,Novartis Data Highlight Benefit of Early Treatment Initiation in Patients With Secondary Progressive Multiple Sclerosis (,2020-05-28 05:21:00-04:00,NVS,positive
934360.0,"The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas",2020-05-27 07:25:00-04:00,NVS,positive
934361.0,Novartis Announces Exploratory Analysis To Be Presented During ASCO 2020 Demonstrating Kisqali Shows 'Overall Survival Benefit In Hr+/Her2- Advanced Breast Cancer With Consistent Findings In Patients With More Aggressive Disease',2020-05-27 07:09:00-04:00,NVS,negative
934362.0,Novartis Announces New Late-breaking Ofatumumab Data at EAN Demonstrating Robust Efficacy and Safety in the Treatment of Relapsing Forms of Multiple Sclerosis,2020-05-27 05:36:00-04:00,NVS,positive
934363.0,"The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering",2020-05-19 08:24:00-04:00,NVS,positive
934364.0,Novartis Announces AveXis Receives EC Approval and Activates Day One Access Program for Zolgensma for Patients With Spinal Muscular Atrophy,2020-05-19 05:27:00-04:00,NVS,positive
934365.0,"The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings",2020-05-12 08:06:00-04:00,NVS,negative
934366.0,"The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight",2020-05-10 15:40:00-04:00,NVS,neutral
934367.0,Chinese Regulators Approved Novartis' Mayzent to Treat Relapsing MS in Adults,2020-05-09 09:00:00-04:00,NVS,positive
934368.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,NVS,negative
934369.0,"Codexis Reports Achieved Wave 2 Milestone Associated With CodeEvolver Platform, License Deal With Novartis",2020-05-06 16:27:00-04:00,NVS,neutral
934370.0,Incyte Issues Press Release Highlighting FDA Approval Of Novartis' Tabrecta,2020-05-06 14:41:00-04:00,NVS,positive
934371.0,Novartis Press Release Confirms FDA Approval Of Tabrecta For Metastatic Non-Small Cell Lung Cancer With METex14,2020-05-06 14:31:00-04:00,NVS,negative
934372.0,FDA Approves Novartis' Tabrecta For Metastatic Non-Small Cell Lung Cancer,2020-05-06 14:14:00-04:00,NVS,negative
934373.0,"EXUMA Biotech Is 'Revolutionizing CAR-T Therapy,' Increasing Patient Access, CEO Says",2020-05-06 12:42:00-04:00,NVS,neutral
934374.0,"The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO",2020-05-01 07:54:00-04:00,NVS,neutral
934375.0,Novartis Receives CHMP Positive Opinion for Enerzair Breezhaler for Uncontrolled Asthma,2020-05-01 05:20:00-04:00,NVS,positive
934376.0,"The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda",2020-04-29 08:40:00-04:00,NVS,positive
934377.0,Novartis Cosentyx Gains Fourth Indication in Eu With First-in-class Approval in Axial Spondyloarthritis Spectrum,2020-04-29 05:23:00-04:00,NVS,positive
934378.0,"The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update",2020-04-28 07:36:00-04:00,NVS,neutral
934379.0,"Earnings Scheduled For April 28, 2020",2020-04-28 04:55:00-04:00,NVS,neutral
934380.0,"'Psyched': ATAI Closes $24M Convertible Round, MindMed To Begin Trading On OTCQB, Investor Presentations Available Online",2020-04-25 14:48:00-04:00,NVS,neutral
934381.0,"The Daily Biotech Pulse: Immunic To Develop COVID Treatment, Gilead Strikes IO Partnership",2020-04-22 07:51:00-04:00,NVS,negative
934382.0,Novartis Kymriah Receives FDA Regenerative Medicine Advanced Therapy Designation in Follicular Lymphoma,2020-04-22 05:19:00-04:00,NVS,positive
934383.0,"The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives",2020-04-21 08:19:00-04:00,NVS,positive
934384.0,Novartis Announces New Mayzent Data Show Sustained Effect in Delaying Disability for Up to Five Years in Patients With Secondary Progressive MS,2020-04-21 05:46:00-04:00,NVS,neutral
934385.0,Novartis NOVN.S has won the go-ahead from the U.S. Food and Drug Administration to conduct a randomized trial of malaria drug hydroxychloroquine against COVID-19 disease,2020-04-20 05:22:00-04:00,NVS,positive
934386.0,Novartis Announces Data in Neurology Reinforcing the Real-world and Long-term Effectiveness and Safety of Aimovig as a Preventive Treatment Across the Full Spectrum of Migraine,2020-04-16 05:21:00-04:00,NVS,positive
934387.0,Shares of several healthcare companies are trading higher as markets gain on positive coronavirus outlook. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic.,2020-04-14 10:59:00-04:00,NVS,positive
934388.0,Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several US hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.,2020-04-06 09:42:00-04:00,NVS,positive
934389.0,"The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO",2020-04-03 07:36:00-04:00,NVS,neutral
934390.0,"The Daily Biotech Pulse: Novartis Scraps Deal To Sell Sandoz Assets, Nevro Pre-Announces Q1 Shortfall, Affimed Granted Orphan Drug Designation",2020-04-02 07:57:00-04:00,NVS,positive
934391.0,"Novartis Announces Mutual Agreement to Terminate Sale of Sandoz US Generic Oral Solids, Dermatology Portfolio to Aurobindo",2020-04-02 05:17:00-04:00,NVS,positive
934392.0,Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates,2020-03-31 17:15:00-04:00,NVS,neutral
934393.0,Intellia Therapeutics Announces FDA Has Accepted IND Application Submitted By Collaborator Norvartis For CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate,2020-03-31 07:43:00-04:00,NVS,positive
934394.0,U.S. HHS Says Accepted 30M Doses of Hydroxychloroquine Sulfate Donated by Novartis's Sandoz as Possible Treatments for Covid-19 Patients,2020-03-29 20:29:00-04:00,NVS,positive
934395.0,"Novartis CEO Talks Coronavirus Vaccine Progress, Timeline",2020-03-27 12:48:00-04:00,NVS,positive
934396.0,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus legislation has boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",2020-03-27 09:22:00-04:00,NVS,positive
934397.0,Novartis' AveXis Reports Receives Positive CHMP Opinion For Zolgensma For Spinal Muscular Atrophy,2020-03-27 09:16:00-04:00,NVS,positive
934398.0,Novartis Reports Its Cosentyx Gains Positive CHMP Opinion For New Indication In Axial Spondyloarthritis Spectrum,2020-03-27 09:11:00-04:00,NVS,positive
934399.0,"Shares of several healthcare companies are trading higher following Senate passage of a $2 trillion economic stimulus package, which has lifted stocks across sectors.",2020-03-26 11:49:00-04:00,NVS,positive
934400.0,Novartis and Life Sciences Companies Commit Expertise and Assets to the Fight Against COVID-19 Pandemic alongside Bill & Melinda Gates Foundatio,2020-03-26 05:25:00-04:00,NVS,positive
934401.0,"Chloroquine, Hydroxychloroquine And Coronavirus: What You Should Know",2020-03-24 17:16:00-04:00,NVS,neutral
934402.0,"The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test",2020-03-24 08:20:00-04:00,NVS,negative
934403.0,"Novartis' AveXis Unit Says Zolgensma Data Shows Rapid, Significant, Clinically Meaningful Benefit in Sma Including Prolonged Event-free Survival, Motor Milestone Achievement and Durability Now Up to 5 Years Post-dosing",2020-03-24 05:26:00-04:00,NVS,positive
934404.0,"Novartis' Sandoz Reports Purchase Of US Distribution Rights For Daptomycin, Fosaprepitant, Antibiotic For Infections, Antiemetic Drug For Nausea, Vomiting, Respectively",2020-03-23 16:06:00-04:00,NVS,positive
934405.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,NVS,neutral
934406.0,"Novartis Receives Approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma for Patients with Spinal Muscular Atrophy",2020-03-19 05:39:00-04:00,NVS,positive
934407.0,"Novartis Highlights Publication Of 3 Pivotal Trials Showing Durable, Potent Efficacy Of Inclisiran In New England Journal Of Medicine",2020-03-18 17:03:00-04:00,NVS,neutral
934408.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,NVS,neutral
934409.0,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 09:40:00-04:00,NVS,negative
934410.0,"Intec Pharma Posts Q4 Net Loss Of $6.6M, Down By Nearly Half Year-Over-Year",2020-03-13 14:43:00-04:00,NVS,negative
934411.0,Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.,2020-03-13 09:29:00-04:00,NVS,positive
934412.0,"The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings",2020-03-13 07:52:00-04:00,NVS,negative
934413.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,NVS,negative
934414.0,Shares of several healthcare companies are trading lower as equities sell off amid continued global coronavirus concerns. The virus has caused global economic disruption and negatively impacted stocks across sectors.,2020-03-12 09:26:00-04:00,NVS,negative
934415.0,Shares of several healthcare companies are trading lower. Movement appears market related amid selloff in equities. The global coronavirus outbreak has caused volatility in global markets and impacted stocks across sectors.,2020-03-11 07:15:00-04:00,NVS,neutral
934416.0,Shares of several healthcare companies are trading higher as markets rebound following Monday's selloff. US President Trump on Monday indicated the US may implement payroll tax cuts and other measures to support the economy amid the coronavirus outbreak.,2020-03-10 07:54:00-04:00,NVS,positive
934417.0,36 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-03-04 08:00:00-05:00,NVS,neutral
934418.0,Shares of several drugmakers and healthcare companies are trading higher following US Super Tuesday results in which Joe Biden won the highest number of delegates. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.,2020-03-04 07:48:00-05:00,NVS,positive
934419.0,Novartis Says Still Does Not Anticipate a Supply Chain Disruption Due to the New Coronavirus,2020-03-04 05:33:00-05:00,NVS,negative
934420.0,"The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More",2020-03-03 07:51:00-05:00,NVS,positive
934421.0,Novartis Receives Health Canada Approval For Mayzent To Treat Secondary Progressive Multiple Sclerosis With Active Disease,2020-03-03 06:04:00-05:00,NVS,positive
934422.0,Novartis' Sandoz To Pay $195M For Price-Fixing,2020-03-02 23:31:00-05:00,NVS,negative
934423.0,US Dept. Of Justice Says Novartis Unit Sandoz Has Agreed To Pay $195M To Resolve Antitrust Claims,2020-03-02 16:32:00-05:00,NVS,positive
934424.0,"Novartis Offers update On Use, Safety Of Beovu In Patients with Wet AMD: says To Date Safety Data Continue To Support Favorable Benefit-Risk Profile",2020-03-02 10:13:00-05:00,NVS,positive
934425.0,'Novartis employee claims she was fired for complaining about incorrect data' -STAT News,2020-02-28 15:28:00-05:00,NVS,negative
934426.0,Regeneron Snags Upgrade On Reduced Prospects For Rival Eye Disorder Drug,2020-02-25 11:46:00-05:00,NVS,negative
934427.0,Guggenheim Securities Downgrades Novartis to Neutral,2020-02-25 07:26:00-05:00,NVS,positive
934428.0,Novartis and DNDi to Collaborate on Development of New Oral Drug to Treat Visceral Leishmaniasis,2020-02-25 05:35:00-05:00,NVS,positive
934429.0,"Regeneron Shares Higher; It Was Earlier Repored The ASRS Announced Reports Of Vasculitis Tied To Beovu, A Drug From Competitor Novartis",2020-02-24 14:16:00-05:00,NVS,positive
934430.0,Novartis Confirms ASRS Reports Of Vasculitis Tied To Beovu; ASRS Reports Show 14 Cases Of Vasculitis Since Approval,2020-02-24 13:48:00-05:00,NVS,positive
934431.0,Shares of several healthcare and biotech companies are trading lower amid continued spread of coronavirus including notable upticks in Iran and Italy. NOTE: The virus has raised fear of a global economic slowdown.,2020-02-24 08:37:00-05:00,NVS,negative
934432.0,"Novartis Receives EC Approval for Beovu, Next-generation Anti-VEGF Treatment for Wet AMD",2020-02-17 07:46:00-05:00,NVS,positive
934433.0,"The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO",2020-02-13 08:05:00-05:00,NVS,negative
934434.0,"Zydus, Novartis Settle Patent Suit on Generic Version of Jadenu",2020-02-12 13:18:00-05:00,NVS,neutral
934435.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-12 11:45:00-05:00,NVS,neutral
934436.0,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data",2020-02-12 09:18:00-05:00,NVS,positive
934437.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-11 10:17:00-05:00,NVS,neutral
934438.0,"The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology",2020-02-11 07:23:00-05:00,NVS,positive
934439.0,"Novartis announces MET Inhibitor Capmatinib for Treatment of METex14 Mutated Advanced Non-small Cell Lung Cancer, Granted Priority FDA Review",2020-02-11 05:30:00-05:00,NVS,negative
934440.0,"The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns",2020-02-07 07:32:00-05:00,NVS,negative
934441.0,"The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data",2020-02-05 07:43:00-05:00,NVS,neutral
934442.0,"United Therapeutics Reports Defeat Of Prelim. Injunction Motion In Litigation With Sandoz, RareGen",2020-02-04 17:05:00-05:00,NVS,negative
934443.0,Stocks That Hit 52-Week Highs On Wednesday,2020-01-29 10:16:00-05:00,NVS,neutral
934444.0,"The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut",2020-01-29 08:30:00-05:00,NVS,neutral
934445.0,Novartis CEO Says Could See a Coronavirus Vaccine in Around a Year,2020-01-29 05:39:00-05:00,NVS,neutral
934446.0,Novartis CEO Says Key Risk That Impacts Shares of Healthcare Companies is U.S. Healthcare Reform,2020-01-29 05:37:00-05:00,NVS,neutral
934447.0,"Earnings Scheduled For January 29, 2020",2020-01-29 04:06:00-05:00,NVS,neutral
934448.0,Novartis Announces EU Approval of Mayzent for Adult Patients with Secondary Progressive MS with Active Disease,2020-01-20 19:19:00-05:00,NVS,positive
934449.0,7 Blockbuster Drugs Expected To Be Launched In 2020,2020-01-20 14:18:00-05:00,NVS,positive
934450.0,Stocks That Hit 52-Week Highs On Friday,2020-01-17 13:23:00-05:00,NVS,neutral
934451.0,Inclisiran To Be Studied In UK Patients Under NHS Clinical Trial Expected To Start Later This Year,2020-01-13 13:16:00-05:00,NVS,neutral
934452.0,"Novartis CEO Says ""Don't Believe In Big M&A""; Says Company Expects To Double Business In China By 2024",2020-01-13 11:52:00-05:00,NVS,neutral
934453.0,Novartis Announces Ligelizumab More Effective Than Xolair at Inhibiting Immunoglobulin E Pathway,2020-01-09 05:34:00-05:00,NVS,positive
934454.0,Novartis Completes Tender Offer for All Outstanding Shares of The Medicines Company for $85/Share,2020-01-06 05:06:00-05:00,NVS,positive
934455.0,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus",2019-12-29 18:38:00-05:00,NVS,neutral
934456.0,Stocks That Hit 52-Week Highs On Friday,2019-12-27 11:27:00-05:00,NVS,neutral
934457.0,"The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict",2019-12-24 07:24:00-05:00,NVS,negative
934458.0,A Perspective On Biopharma's Record M&A Run In 2019,2019-12-23 14:57:00-05:00,NVS,neutral
934459.0,Stocks That Hit 52-Week Highs On Monday,2019-12-23 10:20:00-05:00,NVS,neutral
934460.0,550 Cases Confirmed of H1N1 Virus with 26 Deaths Reported in Past 3 Weeks in Sana'a Yemen,2019-12-22 11:54:00-05:00,NVS,neutral
934461.0,"The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic",2019-12-19 07:52:00-05:00,NVS,negative
934462.0,Novartis to Give Away 100 doses of its $2.1M/Patient Zolgensma for Spinal Muscular Atrophy in 2020,2019-12-19 05:31:00-05:00,NVS,neutral
934463.0,30 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-12-18 08:11:00-05:00,NVS,neutral
934464.0,Aduro Biotech On Dec. 11 Received Notification For Novartis That Novartis Removed ADU-S100 from Portfolio Based On Clinical Data; Removal Was Not Result Of Any Safety Concern,2019-12-17 16:28:00-05:00,NVS,positive
934465.0,Why Gossamer Bio Shares Are Plunging,2019-12-16 15:01:00-05:00,NVS,positive
934466.0,Novartis Announces LUSTER Phase III Studies Patients with Uncontrolled GINA 4/5 Asthma did Not Meet Clinically Relevant Threshold,2019-12-16 05:40:00-05:00,NVS,negative
934467.0,EMA Reports Committee Recommended Granting Marketing Authorization For Novartis' Beovu For Treatment Of Neovascular Age-Related Macular Degeneration,2019-12-13 06:19:00-05:00,NVS,positive
934468.0,Novartis Reports Its Pharma Canada Sites In Ontario Certified In Accordance With Applicable Requirements to Treat Eligible Patients With Kymriah,2019-12-12 07:27:00-05:00,NVS,positive
934469.0,Intec Announces Termination Of Feasibility And Option Agreement With Novartis For The Development Of Accordion Pill; Novartis To Pay Intec $1.5M,2019-12-11 07:33:00-05:00,NVS,positive
934470.0,"The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint",2019-12-11 07:21:00-05:00,NVS,negative
934471.0,"The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend",2019-12-06 07:39:00-05:00,NVS,positive
934472.0,Novartis Says Phase III Data on New Inhaled Dual Combination QMF149 Show Significant Improvement Across Key Asthma Outcomes Versus Monotherapy,2019-12-06 05:38:00-05:00,NVS,positive
934473.0,Novartis Research Head Says Looks Forward To Bringing Gene Therapy For Friedreich's Ataxia To Patients 'Very Soon',2019-12-05 08:45:00-05:00,NVS,neutral
934474.0,"The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission",2019-12-05 07:14:00-05:00,NVS,positive
934475.0,Novartis Says Expects to Sustain Long-term Growth With a Robust Pipeline of 25+ Potential Blockbusters,2019-12-05 05:25:00-05:00,NVS,positive
934476.0,Novartis Tender Offer for The Medicines Company Commences,2019-12-05 05:09:00-05:00,NVS,neutral
934477.0,Amazon's Amazon Web Services Reports Strategic Collaboration With Novartis To Accelerate Digital Transformation Of Its Business Operations,2019-12-04 09:02:00-05:00,NVS,positive
934478.0,The Gene Therapy Names Moving On The Audentes Buyout Deal,2019-12-03 11:53:00-05:00,NVS,neutral
934479.0,Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.,2019-12-02 11:31:00-05:00,NVS,negative
934480.0,"The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More",2019-12-01 09:30:00-05:00,NVS,neutral
934481.0,Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates,2019-11-29 08:13:00-05:00,NVS,neutral
934482.0,"National Business Daily Reports Drugmakers including Johnson & Johnson, Roche, Novartis and Merck have Agreed to Massively Cut the Prices of Some Drugs to Get Included in China's Medical Reimbursement List",2019-11-29 05:38:00-05:00,NVS,neutral
934483.0,"The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug",2019-11-26 08:06:00-05:00,NVS,positive
934484.0,"PreMarket Prep Recap: Merger Monday, Tesla Two-Step, Street Fades Netflix Downgrade",2019-11-25 15:31:00-05:00,NVS,neutral
934485.0,Novartis Confirms Deal To Acquire Medicines Company For $9.7B,2019-11-25 08:28:00-05:00,NVS,neutral
934486.0,18 Stocks Moving In Monday's Pre-Market Session,2019-11-25 07:15:00-05:00,NVS,neutral
934487.0,Novartis Confirms Agreement to Acquire the Medicines Company for $85/Share,2019-11-24 15:35:00-05:00,NVS,positive
934488.0,Novartis Nears Deal to Buy Medicines Co. for $85/Share; ~$7B,2019-11-23 14:27:00-05:00,NVS,neutral
934489.0,"Cramer Gives His Opinion on Ford, American Tower And More",2019-11-20 12:00:00-05:00,NVS,neutral
934490.0,Medicines Company Shares Soar On Rumored Buyout Interest From Novartis,2019-11-19 09:50:00-05:00,NVS,positive
934491.0,Novartis Declines Comment on Media Report That It is Considering Offer for The Medicines Co,2019-11-19 05:38:00-05:00,NVS,neutral
934492.0,FDA Approves Novartis' Sickle Cell Disease Treatment Adakveo 100 Mg/10 Ml Injection,2019-11-15 14:55:00-05:00,NVS,positive
934493.0,EU's CHMP Gives Positive Opinion For Novartis' Mayzent For Adult Patients With Secondary Progressive Multiple Sclerosis,2019-11-15 06:35:00-05:00,NVS,positive
934494.0,"EU's CHMP Recommends Conditional Marketing Authorization For Roche's Polivy To Treat Relapsed, Refractory Diffuse Large B-Cell Lymphoma; Separately Reports Marketing Authorization For Novartis' Isturisa",2019-11-15 06:33:00-05:00,NVS,positive
934495.0,Sandoz Presents Real-world Data Showing Effectiveness of Erelzi in Rheumatic Disease Treatment,2019-11-12 04:26:00-05:00,NVS,neutral
934496.0,Novartis Announces New PREVENT Data Show Cosentyx Delivers Early Relief in Axial Spondyloarthritis,2019-11-12 04:24:00-05:00,NVS,positive
934497.0,Novartis Unit Sandoz Announces Agreement to Acquire Aspen's Japanese Operations and Associated Assets for €300M in Cash,2019-11-11 04:15:00-05:00,NVS,positive
934498.0,"The Week Ahead In Biotech: Adcom Test For Amarin's Fish Oil Pill, Agile Awaits FDA Verdict",2019-11-10 16:08:00-05:00,NVS,positive
934499.0,10 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-11-08 07:48:00-05:00,NVS,neutral
934500.0,AstraZeneca Named The Most Innovative Global Pharma Company,2019-11-06 11:20:00-05:00,NVS,positive
934501.0,Sandoz Receives US FDA Approval for Long-acting Oncology Supportive Care Biosimilar Ziextenzo,2019-11-05 04:28:00-05:00,NVS,positive
934502.0,Novartis Says Cosentyx Shows Encouraging Results vs Humira from Frst-of-its-kind Head-to-head trial in Psoriatic Arthritis,2019-11-01 04:02:00-04:00,NVS,positive
934503.0,13 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-10-30 07:32:00-04:00,NVS,neutral
934504.0,"The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings",2019-10-30 07:01:00-04:00,NVS,negative
934505.0,Novartis Says FDA Placed Partial Hold On Avxs-101 Intrathecal Trials For SMA Patients,2019-10-30 03:46:00-04:00,NVS,neutral
934506.0,"The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study",2019-10-29 07:32:00-04:00,NVS,positive
934507.0,"The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise",2019-10-24 07:36:00-04:00,NVS,neutral
934508.0,Novartis Receives Approval for Cosentyx Label Update in Europe to Include Dosing Flexibility in Ankylosing Spondylitis,2019-10-24 04:20:00-04:00,NVS,positive
934509.0,"The Daily Biotech Pulse: Biogen Alzheimer's Program Back On Track, Novartis Reports Strong Quarter, Takeda In-Licenses Autoimmune Disorder Drug",2019-10-22 07:51:00-04:00,NVS,positive
934510.0,"Earnings Scheduled For October 22, 2019",2019-10-22 05:40:00-04:00,NVS,neutral
934511.0,Novartis Reports Q3 Sales of $12.2B vs $11.7B Reuters Est,2019-10-22 03:36:00-04:00,NVS,neutral
934512.0,Earnings Season Kicks Into Full Gear In Round 3 Of The WeTrader Competition,2019-10-21 11:16:00-04:00,NVS,neutral
934513.0,Novartis Reports Jakavi Phase 3 Trial Met Primary Endpoint,2019-10-16 07:57:00-04:00,NVS,neutral
934514.0,"The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings",2019-10-13 16:33:00-04:00,NVS,neutral
934515.0,Shares of several healthcare companies are trading higher after President Trump made positive remarks on the U.S.-China trade talks as traders grew more optimistic over the possibility of a limited trade deal. Trump is scheduled to meet with Chinese Vice Premier Liu He at the White House today.,2019-10-11 11:19:00-04:00,NVS,positive
934516.0,Shares of several healthcare companies are trading lower with the broader market after the US expanded its trade blacklist to include China's top AI firms. The US also will increase its tariffs on $250 billion worth of goods from 25% to 30% on Oct 15.,2019-10-08 10:36:00-04:00,NVS,positive
934517.0,Novartis Data Show More Patients Are Completely Symptom-free From Chronic Spontaneous Urticaria With Ligelizumab (QGE031) than Xolair® 300 mg,2019-10-08 05:00:00-04:00,NVS,neutral
934518.0,Novartis Receives FDA Approval for Beovu,2019-10-08 04:59:00-04:00,NVS,positive
934519.0,"The Week Ahead In Biotech: Pfenex And Clinuvel On The Radar Ahead of FDA Decisions, 2 IPOs On Deck",2019-10-06 17:15:00-04:00,NVS,neutral
934520.0,"Conatus Pharmaceuticals And Novartis Mutually Agree To Terminate Collaboration Agreement Dated December 19, 2016",2019-10-04 16:13:00-04:00,NVS,positive
934521.0,Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar,2019-10-03 15:49:00-04:00,NVS,positive
934522.0,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued fears of a recession amid a weak ADP jobs report. There is also uncertainty in the market over the upcoming U.S.-China meeting next week.,2019-10-02 10:33:00-04:00,NVS,negative
934523.0,"The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data",2019-10-02 07:17:00-04:00,NVS,positive
934524.0,Novartis Says Positive 52-week PREVENT Data Confirm Cosentyx Efficacy in Addressing Entire axSpA Spectrum,2019-10-02 04:34:00-04:00,NVS,positive
934525.0,"Novartis And Microsoft Announce Medical/Artificial Intelligence Collaboration; Joint Research Activities To Include Personalized Therapies For Macular Degeneration, Cell & Gene Therapy, Drug Design",2019-10-01 10:13:00-04:00,NVS,positive
934526.0,Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates,2019-09-30 16:32:00-04:00,NVS,neutral
934527.0,"The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave",2019-09-27 07:56:00-04:00,NVS,positive
934528.0,XOMA Acquires Royalty Interest Position in Six Clinical-Stage Assets For $10M,2019-09-26 16:08:00-04:00,NVS,positive
934529.0,"Biotech Stock On The Radar: Anavex, A Neurology-Focused Precision Medicine Company",2019-09-25 17:32:00-04:00,NVS,neutral
934530.0,"The Daily Biotech Pulse: Sandoz Recalls Ulcer Drug, Anchiano Strikes Agreement With ADT Pharma, Proteon Announces Reverse Merger",2019-09-24 08:12:00-04:00,NVS,positive
934531.0,The Week Ahead In Biotech: Spotlight On ESMO Conference,2019-09-22 16:22:00-04:00,NVS,neutral
934532.0,15 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-09-20 08:24:00-04:00,NVS,neutral
934533.0,"The Daily Biotech Pulse: China Biologics Receives Buyout Offer, Provention Bio Offering, Exagen IPO",2019-09-19 07:39:00-04:00,NVS,neutral
934534.0,Novartis Announces its Avexis Unit Presents New Data at Epns Continuing to Show Significant Therapeutic Benefit of Zolgensma  in Prolonging Event-free Survival Now Up to 5 Years of Age in Patients With Spinal Muscular Atrophy Type 1,2019-09-19 04:56:00-04:00,NVS,positive
934535.0,9 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-09-17 08:13:00-04:00,NVS,neutral
934536.0,"The Daily Biotech Pulse: Acceleron Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage Study",2019-09-17 07:23:00-04:00,NVS,neutral
934537.0,Novartis Announces Cosentyx Positive 16-week Prevent Results Advance Potential New Indication for Patients With Axial Spondyloarthritis,2019-09-17 04:06:00-04:00,NVS,positive
934538.0,Novartis AG shares are trading lower after a test in Canutillo High School revealed 4 confirmed Tuberculosis cases among students and staff.,2019-09-13 10:17:00-04:00,NVS,neutral
934539.0,"Novartis Reports OMB157 Was Superior to Aubagio, 2 Studies Met Primary Endpoints",2019-09-13 08:17:00-04:00,NVS,positive
934540.0,"The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans",2019-09-13 07:40:00-04:00,NVS,neutral
934541.0,"Novartis Says New Data Show That Neuronal and Glial Filaments, Biomarkers of Disease Activity, Have the Potential to Support Decision Making in the Management of MS Patient",2019-09-13 04:01:00-04:00,NVS,positive
934542.0,"Four TB Cases Confirmed at El Paso, TX High School",2019-09-12 18:46:00-04:00,NVS,positive
934543.0,Novartis Announces New Data at ECTRIMS Showing Mayzent Can Help Preserve Mobility for Longer in Patients With Secondary Progressive Multiple Sclerosis,2019-09-12 04:29:00-04:00,NVS,positive
934544.0,Shares of several drugmakers are trading lower on news of a drug pricing bill being developed by House Democrats. The proposed bill would set US drug prices based on prices in other wealthy countries.,2019-09-10 10:30:00-04:00,NVS,positive
934545.0,Novartis Data at ECTRIMS  to Highlight Innovative Approach to Reimagining Care for People Living With MS,2019-09-10 04:37:00-04:00,NVS,positive
934546.0,"The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight",2019-09-08 11:01:00-04:00,NVS,neutral
934547.0,Novartis Investigational Lung Cancer Therapy Capmatinib (Inc280) Granted FDA Breakthrough Therapy Designation for Patients With Met-mutated Advanced Non-small Cell Lung Cancer,2019-09-06 05:00:00-04:00,NVS,negative
934548.0,"Sandoz Announces Global Deal to Commercialize Proposed Biosimilar Natalizumab, a Key MS Medicine",2019-09-04 03:57:00-04:00,NVS,neutral
934549.0,"Sandoz Announces Global Deal to Commercialize Proposed Biosimilar Natalizumab, a Key Multiple Sclerosis Medicine",2019-09-03 03:49:00-04:00,NVS,neutral
934550.0,Novartis Says Entresto Improved Measures of Heart Structure and Function in HFrEF Patients in New Study,2019-09-02 08:32:00-04:00,NVS,positive
934551.0,18 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-08-30 08:43:00-04:00,NVS,neutral
934552.0,"The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation",2019-08-30 08:28:00-04:00,NVS,neutral
934553.0,Novartis Announces Ofatumumab Demonstrates Superiority vs Aubagio in Two Head-to-head Phase III MS Studies,2019-08-30 03:34:00-04:00,NVS,positive
934554.0,Genmab Acknowledges Novartis Announcement that Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III MS Studies,2019-08-30 03:31:00-04:00,NVS,positive
934555.0,10 Biopharmaceutical Companies Trying To Cure Cancer,2019-08-24 13:46:00-04:00,NVS,negative
934556.0,Novartis Says will Answer U.S. Senate Demand for Data Manipulation Details,2019-08-19 04:16:00-04:00,NVS,negative
934557.0,"Unnamed Novartis Executive Sold $946,000 Worth of Shares Less Than Three Weeks Prior to FDA Announcement that Data From Tests of Its Gene Therapy Zolgensma Had Been Manipulated",2019-08-18 20:59:00-04:00,NVS,positive
934558.0,"Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.",2019-08-16 13:27:00-04:00,NVS,negative
934559.0,'Novartis ousted top scientists over manipulation of data for gene therapy' -STAT,2019-08-14 12:28:00-04:00,NVS,negative
934560.0,Biotech Stock On The Radar: Is Vanda A Buy Ahead Of Its PDUFA Date?,2019-08-13 15:23:00-04:00,NVS,neutral
934561.0,ovartis Benefits from Faster China Drug Approvals,2019-08-12 04:13:00-04:00,NVS,positive
934562.0,"The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO",2019-08-11 15:46:00-04:00,NVS,positive
934563.0,Novartis AG shares are trading higher on seemingly no company specific news.,2019-08-08 13:44:00-04:00,NVS,neutral
934564.0,FDA Investigates Data Manipulation Issue With Newly Approved Novartis Drug Zolgensma,2019-08-07 10:40:00-04:00,NVS,positive
934565.0,From Novartis Call: CEO Sees Zolgensma Data Manipulation As An Isolated Incident Related To Single Set Of Labs,2019-08-07 08:40:00-04:00,NVS,negative
934566.0,"The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout",2019-08-07 07:34:00-04:00,NVS,neutral
934567.0,Novartis Says Stands Behind Zolgensma for the Treatment of Children Less Than 2 Years of Age With Spinal Muscular Atrophy,2019-08-07 04:36:00-04:00,NVS,neutral
934568.0,FDA's Center for Biologics Evaluation And Research Makes Statement On Data Accuracy Issues With AveXis's Zolgensma,2019-08-06 13:04:00-04:00,NVS,neutral
934569.0,Novartis Says Phase III PARAGON-HF Trial  Narrowly Missed Statistical Significance for Its Composite Primary Endpoint of Reducing Cardiovascular Death and Total Heart Failure Hospitalizations,2019-07-29 03:52:00-04:00,NVS,negative
934570.0,"European CHMP Says Has Recommended Novartis' Gilenya Must Not Be Used In Pregnant Women, Women Able To Have Children Who Are Not Using Effective Contraceptive",2019-07-26 10:09:00-04:00,NVS,negative
934571.0,STAT News Article Highlights CAR-T Therapy Innovations,2019-07-22 11:17:00-04:00,NVS,neutral
934572.0,Novartis Unit Sandoz Announces First Patient Enrolled in Clinical Study for Proposed Biosimilar Denosumab in Osteoporosis,2019-07-22 03:54:00-04:00,NVS,neutral
934573.0,"Gilead Will Buy Exclusive Global Rights To Develop, Commercialize Novel Small Molecules Against 3 Undisclosed Targets From Novartis, Novartis Will Receive Upfront Payment, Eligible For Added $291M",2019-07-19 08:31:00-04:00,NVS,positive
934574.0,58 Biggest Movers From Yesterday,2019-07-19 05:02:00-04:00,NVS,neutral
934575.0,Novartis' Key MS Product Gilenya Approved in China,2019-07-19 04:14:00-04:00,NVS,positive
934576.0,42 Stocks Moving In Thursday's Mid-Day Session,2019-07-18 12:57:00-04:00,NVS,neutral
934577.0,Novartis CEO Says US Government Policy Environment 'Very Fluid' Regarding Drug Pricing After Trump Administration Drops Rebate Rule,2019-07-18 08:53:00-04:00,NVS,neutral
934578.0,"Novartis Trades Higher On Q2 Earnings, Guidance Raise",2019-07-18 08:21:00-04:00,NVS,neutral
934579.0,28 Stocks Moving In Thursday's Pre-Market Session,2019-07-18 08:05:00-04:00,NVS,neutral
934580.0,Novartis shares are trading higher after the company reported Q2 EPS and sales results higher from last year. The company also raised its Q3 sales guidance.,2019-07-18 07:39:00-04:00,NVS,positive
934581.0,"Earnings Scheduled For July 18, 2019",2019-07-18 04:28:00-04:00,NVS,neutral
934582.0,Novartis  Announces FDA Accepts File and Accelerates Review of Sickle cell Disease Medicine Crizanlizumab (SEG101),2019-07-16 04:04:00-04:00,NVS,positive
934583.0,Recordati To Acquire Worldwide Rights To Signifor And Osilodrostat; Upon Completion Of Transaction A Consideration Of $390M Will Be Due To Novartis,2019-07-12 14:35:00-04:00,NVS,neutral
934584.0,"Novartis, Amgen Scrap Pivotal Study Of Alzheimer's Prevention Drug",2019-07-12 10:19:00-04:00,NVS,neutral
934585.0,"Shares of several drug manufacturing companies are trading lower, potentially on continued weakness after the Trump Administration on Thursday rolled back a proposal to eliminate rebates from government drug plans.",2019-07-12 09:53:00-04:00,NVS,negative
934586.0,"The Daily Biotech Pulse: Hookipa Leaps, Illumina Dims On Q2 Warning, Novartis-Amgen Halt Alzheimer's Study",2019-07-12 07:24:00-04:00,NVS,negative
934587.0,"Amgen, Novartis And Banner Alzheimer's Institute Discontinue Clinical Research Program With BACE Inhibitor CNP520 For Alzheimer's Prevention",2019-07-11 16:30:00-04:00,NVS,negative
934588.0,"The Daily Biotech Pulse: Jazz Buys Tumor Drug Program, Sanofi's BLA For Multiple Myeloma Drug Accepted, Positive Results For ViiV",2019-07-10 07:17:00-04:00,NVS,positive
934589.0,"Novartis Shares Closed Up ~0.4%, Did Not Appear To Be Impacted By Tues. Morning Report 'Novartis to sell epinephrine shot in U.S. pharmacies amid EpiPen shortage'",2019-07-09 16:30:00-04:00,NVS,positive
934590.0,"The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight",2019-07-05 08:55:00-04:00,NVS,negative
934591.0,Novartis to Launch Generic Iressa When Patent Expires in Europe,2019-07-02 04:31:00-04:00,NVS,neutral
934592.0,"Amazon, Sears Veteran Joins Cresco Labs As Chief Information Officer",2019-07-01 12:29:00-04:00,NVS,positive
934593.0,Lonza to Acquire Sterile Fill and Finish Facility from Novartis; Financial Terms Not Disclosed,2019-07-01 04:51:00-04:00,NVS,neutral
934594.0,Novartis Announces Data Show Aimovig Cuts Acute Migraine Medication Days By Half in Patients Who Failed Prior Preventive Therapies at #EAN2019,2019-07-01 04:32:00-04:00,NVS,negative
934595.0,PeptiDream Announces New Peptide Drug Conjugate  Collaboration Agreement with Novartis,2019-06-28 04:27:00-04:00,NVS,positive
934596.0,NASH Disappointment Forces Conatus To Explore Strategic Alternatives,2019-06-25 11:32:00-04:00,NVS,negative
934597.0,Glenmark Pharmaceuticals To Partner With Novartis In Brazil on Three Respiratory Products,2019-06-24 03:42:00-04:00,NVS,neutral
934598.0,The 5 Most Expensive Drugs In US: What You Should Know,2019-06-23 16:56:00-04:00,NVS,neutral
934599.0,"Top 10 Most Overbought Stocks Via Benzinga Pro's Radar Tool For Thur., June 20, 2019",2019-06-20 14:26:00-04:00,NVS,positive
934600.0,"Amphastar Pharmaceuticals, Inc. Announces Settlement in Litigation with Momenta and Sandoz, Momenta, Sandoz to Pay Amphastar $59.9M",2019-06-19 06:03:00-04:00,NVS,negative
934601.0,Novartis Said Combining its Asciminib with Tyrosine Kinase Inhibitors in Treatment for Leukemia Showed Promising Results,2019-06-14 08:29:00-04:00,NVS,positive
934602.0,"The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana",2019-06-12 07:34:00-04:00,NVS,neutral
934603.0,Novartis Announces Cosentyx Provides Long-lasting Inhibition of Radiographic Progression in Psoriatic Arthritis,2019-06-12 04:31:00-04:00,NVS,negative
934604.0,Sanofi's Leadership Transition: What You Need To Know,2019-06-07 12:25:00-04:00,NVS,neutral
934605.0,"The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix",2019-06-07 07:24:00-04:00,NVS,positive
934606.0,Sanofi CEO Brandicourt to Leave Company from September 1; Paul Hudson to become New Sanofi CEO Effective September 1,2019-06-06 18:07:00-04:00,NVS,positive
934607.0,"The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering",2019-06-06 07:37:00-04:00,NVS,neutral
934608.0,"Novartis Announced New Early Stage Histology Data in Kidney Transplantation, Suggesting That With Investigational Compound Iscalimab it May Be Possible to Prolong Durability of Transplanted Kidneys",2019-06-06 04:34:00-04:00,NVS,neutral
934609.0,Novartis Says Long-Term Survival Benefit Shown For Metastatic Melanoma Patients Treated With Novartis Tafinlar + Mekinist,2019-06-04 13:02:00-04:00,NVS,positive
934610.0,"Aduro Biotech, Novartis Present Results from Ongoing Phase 1b Study of STING Agonist ADU-S100 (MIW815) in Combination with Anti-PD-1 Monoclonal Antibody Spartalizumab (PDR001) in Patients with Advanced Solid Tumors or Lymphomas at #ASCO19",2019-06-02 19:48:00-04:00,NVS,positive
934611.0,The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace,2019-06-01 11:37:00-04:00,NVS,neutral
934612.0,Novartis Announces Kisqali Significantly Extends Life in Women with HR+/HER2- Advanced Breast Cancer in MONALEESA-7 Trial at #ASCO19,2019-06-01 07:37:00-04:00,NVS,negative
934613.0,Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates,2019-05-31 13:45:00-04:00,NVS,neutral
934614.0,"Top 10 Most Overbought Stocks Via Benzinga Pro's Radar Tool For Thur., May 30, 2019",2019-05-30 14:43:00-04:00,NVS,positive
934615.0,"The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug",2019-05-30 07:33:00-04:00,NVS,positive
934616.0,"Novartis' Phase III QUARTZ Study of New Investigational Inhaled Combination Treatment QMF149 Meets Primary, Key Secondary Endpoints in Patients With Inadequately Controlled Asthma",2019-05-30 03:36:00-04:00,NVS,negative
934617.0,BioLife Solutions Joint Venture Partner SAVSU Technologies Selected by Novartis To Supply Advanced Cold Chain Management Platform For Newly Approved Gene Therapy,2019-05-29 08:07:00-04:00,NVS,positive
934618.0,The Week Ahead In Biotech: ASCO Presentations In The Spotlight,2019-05-26 17:03:00-04:00,NVS,neutral
934619.0,"Barron's Picks And Pans: Boston Beer, MGM, Target, Visa And More",2019-05-25 15:42:00-04:00,NVS,neutral
934620.0,FDA Approves Zolgensma Gene Therapy To Treat Children Less Than Two Years Of Age With Spinal Muscular Atrophy,2019-05-24 12:36:00-04:00,NVS,positive
934621.0,"Novartis shares are trading higher after the company's valid Marketing Authorisation Application was accepted by the EU Regulatory Authorities for the approval of QVM149, a potential new inhaled combination therapy for inadequately controlled asthma.",2019-05-24 10:13:00-04:00,NVS,positive
934622.0,"The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice",2019-05-24 07:44:00-04:00,NVS,neutral
934623.0,Vectura Group to Receive $2.5M Milestone Payment Under Exclusive Licence Agreement With Novartis Ag,2019-05-24 04:12:00-04:00,NVS,positive
934624.0,Ideaya Biosciences IPO: What You Need To Know,2019-05-22 17:08:00-04:00,NVS,neutral
934625.0,"The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study",2019-05-22 07:34:00-04:00,NVS,neutral
934626.0,"Jim Cramer Weighs In On Nektar, L Brands And More",2019-05-22 07:29:00-04:00,NVS,neutral
934627.0,Novartis Announces Phase II Data for New Inhaled Combination Treatment Demonstrates Significant Improvements Over Current Standard-of-care Inhaled Treatment,2019-05-22 04:23:00-04:00,NVS,positive
934628.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs",2019-05-18 09:50:00-04:00,NVS,neutral
934629.0,"ACCC Says GSK, Novartis Misled Consumers With Voltaren Osteo Gel Claims",2019-05-17 04:46:00-04:00,NVS,neutral
934630.0,"Japan Government Panel Approves $305,800 Price for Novartis' Cancer Treatment Kymriah",2019-05-15 04:16:00-04:00,NVS,negative
934631.0,Shares of several drug manufacturers are trading lower after the United States filed a lawsuit against Teva alleging price fixing.,2019-05-13 09:53:00-04:00,NVS,positive
934632.0,Teva Plummets Amid Massive Price Fixing Accusations; Other Generic Drugmakers Also Fall,2019-05-13 08:40:00-04:00,NVS,negative
934633.0,Novartis in Talks With Insurers Regarding Price Discounts on Gene Therapy for Spinal Muscular Atrophy,2019-05-13 04:24:00-04:00,NVS,neutral
934634.0,"UPDATE: Novartis Is In Advanced Talks With Health Insurers, Expecting 'Major' Contracts Soon After US Approval Of Zolgensma",2019-05-10 13:35:00-04:00,NVS,positive
934635.0,"Novartis Exec Has Discussed Discounts On Zolgensma To Secure US Insurer Coverage, Seeking Insurer Support For Newborn Screening, Quick Authorization",2019-05-10 13:35:00-04:00,NVS,positive
934636.0,Novartis Data at #AAN2019 Show Gilenya Is the First and Only Disease-modifying Therapy With Proven Superiority vs Glatiramer Acetate in Relapsing Remitting MS,2019-05-10 04:32:00-04:00,NVS,positive
934637.0,"The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut",2019-05-09 07:56:00-04:00,NVS,neutral
934638.0,"Novartis to Acquire Xiidra from Takeda for $3.4B Upfront, Up to $1.9B in Potential Milestones",2019-05-09 04:48:00-04:00,NVS,neutral
934639.0,"Novartis Announces Sandoz Demonstrates Strategic Focus on China, With First-of-a-kind Generic Approval Under Quality Consistency Evaluation System",2019-05-09 04:42:00-04:00,NVS,positive
934640.0,'NovartisConsiders Offer for Takeda Eye-Disease Assets' -Bloomberg Earlier Reported,2019-05-08 12:26:00-04:00,NVS,positive
934641.0,"Novartis Data at AAN Show Mayzent's Positive Impact on Cognitive Processing Speed, a Core Element of Cognitive Function, in People Living With Secondary Progressive MS",2019-05-08 04:05:00-04:00,NVS,positive
934642.0,Novartis Highlights New AveXis Data Showed Long-Term Durability For Zolgensma As Treatment for Spinal Muscular Atrophy Type 1,2019-05-07 13:59:00-04:00,NVS,neutral
934643.0,"In The Search For Safety, Don't Miss The Swiss",2019-05-07 12:22:00-04:00,NVS,positive
934644.0,Shares of several healthcare companies are trading lower after several companies in the space reported weak earnings with Mylan leading the selloff.,2019-05-07 10:25:00-04:00,NVS,negative
934645.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs",2019-05-04 16:56:00-04:00,NVS,neutral
934646.0,What's The Buzz Around Novartis' Gene Therapy Zolgensma?,2019-05-02 09:22:00-04:00,NVS,neutral
934647.0,Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates,2019-04-30 13:00:00-04:00,NVS,neutral
934648.0,Shares of several pharmaceutical companies are trading higher in sympathy with Pfizer and Merck after the companies reported strong Q1 earnings.,2019-04-30 09:34:00-04:00,NVS,positive
934649.0,"The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering",2019-04-30 08:06:00-04:00,NVS,positive
934650.0,"Sandoz Announces Agreement for Proposed Trastuzumab Biosimilar, Currently in Phase III Development, to Treat Selected HER2-positive Cancer Tumors",2019-04-30 03:27:00-04:00,NVS,positive
934651.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs",2019-04-27 11:44:00-04:00,NVS,neutral
934652.0,"Benzinga's Top Upgrades, Downgrades For April 25, 2019",2019-04-25 09:01:00-04:00,NVS,positive
934653.0,Guggenheim Upgrades Novartis AG Common Stock to Buy,2019-04-25 08:21:00-04:00,NVS,neutral
934654.0,"Novartis Earlier Reported Q1 EPS $1.21 Beats $1.2 Estimate, Sales $11.1B Miss $11.78B Estimate",2019-04-24 09:20:00-04:00,NVS,negative
934655.0,24 Stocks Moving In Wednesday's Pre-Market Session,2019-04-24 08:13:00-04:00,NVS,neutral
934656.0,"The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova",2019-04-24 08:09:00-04:00,NVS,neutral
934657.0,Novartis Reports Core Operating Income Grew 18%; Says Catalyst Rich 2019 with Potential Blockbuster Launches on Track,2019-04-24 04:23:00-04:00,NVS,positive
934658.0,"Novartis Starts 2019 With Strong Sales And Double Digit Core Operating Income Growth, Mayzent Launch And Alcon Spin-off; Profit Guidance Upgraded",2019-04-24 04:21:00-04:00,NVS,positive
934659.0,"Earnings Scheduled For April 24, 2019",2019-04-24 04:18:00-04:00,NVS,neutral
934660.0,"Shares of several healthcare-related stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'.",2019-04-23 14:30:00-04:00,NVS,positive
934661.0,Novartis Says Baby's Death May Be Tied to Gene Therapy,2019-04-23 05:05:00-04:00,NVS,negative
934662.0,Novartis Option Alert: May 17 $77.5 Calls Sweep (33) near the Ask: 500 @ $0.95 vs 247 OI; Earnings 4/24 Before Open Ref=$75.49,2019-04-22 13:23:00-04:00,NVS,positive
934663.0,Novartis Says Investigation Underway into Death of 6-Month Old Patient in Trial of Experimental Gene Therapy for Spinal Muscular Atrophy,2019-04-20 13:20:00-04:00,NVS,negative
934664.0,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,2019-04-18 10:51:00-04:00,NVS,negative
934665.0,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,2019-04-17 10:31:00-04:00,NVS,negative
934666.0,"The Daily Biotech Pulse: Zolgensma Data, Roche Q1 Results, Brainsway IPO",2019-04-17 07:48:00-04:00,NVS,neutral
934667.0,"Novartis' AveXis Highlights Interim Data From Phase 3 STRIVE Trial Of Zolgensma In Spinal Muscular Atrophy Type-1 'showed prolonged event-free survival, an early and rapid increase in CHOP-INTEND scores and significant milestone achievement'",2019-04-16 16:51:00-04:00,NVS,positive
934668.0,Shares of several drug companies are trading lower. Weakness may be tied to uncertainty over healthcare policy going into the 2020 primaries and Washington's recent efforts to curb prescription drug prices.,2019-04-16 15:34:00-04:00,NVS,negative
934669.0,"The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives",2019-04-16 08:10:00-04:00,NVS,neutral
934670.0,Novartis Announces FDA Filing Acceptance And Priority Review Of Brolucizumab (RTH258) For Patients With Wet AMD,2019-04-15 16:05:00-04:00,NVS,positive
934671.0,"The Daily Biotech Pulse: Merck's Keytruda Clinches Another FDA Win, KemPharm Close To NDA Filing For ADHD Drug",2019-04-12 07:47:00-04:00,NVS,positive
934672.0,"The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug",2019-04-11 07:48:00-04:00,NVS,positive
934673.0,Novartis' Sandoz Announces Deal with Shionogi for Commercialization of Opioid Induced Constipation Treatment,2019-04-11 03:57:00-04:00,NVS,neutral
934674.0,"Raymond James: Biogen's Business Appears Fragile, Faces Many Headwinds",2019-04-10 09:59:00-04:00,NVS,neutral
934675.0,Second Time's The Charm For Amgen As FDA OKs Bone-Building Osteoporosis Drug,2019-04-10 09:44:00-04:00,NVS,positive
934676.0,"Benzinga's Top Upgrades, Downgrades For April 10, 2019",2019-04-10 09:04:00-04:00,NVS,positive
934677.0,"Q1 Cannabis Wholesale Report: Best-Selling Brands And Products, Pharma, CBD And Interstate Commerce",2019-04-10 07:52:00-04:00,NVS,neutral
934678.0,Morgan Stanley Downgrades Novartis to Underweight,2019-04-10 07:01:00-04:00,NVS,neutral
934679.0,46 Biggest Movers From Yesterday,2019-04-10 06:27:00-04:00,NVS,neutral
934680.0,Morgan Stanley Downgrades Novartis to Underweight from Equal Weight; Lowers Price Target to SFR 80 from SFR 88,2019-04-10 03:59:00-04:00,NVS,negative
934681.0,38 Stocks Moving In Tuesday's Mid-Day Session,2019-04-09 12:52:00-04:00,NVS,neutral
934682.0,"The Daily Biotech Pulse: PhaseBio Gets Breakthrough Therapy Designation, FDA Shoots Down Zogenix Epilepsy Regulatory Filing",2019-04-09 08:10:00-04:00,NVS,neutral
934683.0,28 Stocks Moving In Tuesday's Pre-Market Session,2019-04-09 07:59:00-04:00,NVS,neutral
934684.0,Novartis shares are trading lower after the company spun off Alcon into an independent publicly traded company.,2019-04-09 07:41:00-04:00,NVS,neutral
934685.0,"Alcon Begins Trading as Independent, Publicly Traded Company",2019-04-09 04:10:00-04:00,NVS,neutral
934686.0,"The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership",2019-04-05 07:48:00-04:00,NVS,positive
934687.0,Novartis Announces That There Is A Legal Dispute With Amgen Regarding Collaboration Agreements In Field Of Migraine,2019-04-04 16:02:00-04:00,NVS,neutral
934688.0,"The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings",2019-04-03 08:19:00-04:00,NVS,positive
934689.0,Sandoz Resubmits Biosimilar Pegfilgrastim Application to FDA,2019-04-03 05:00:00-04:00,NVS,neutral
934690.0,Bank Of America Reiterates Buy On Novartis As Firm Forsees 'expansion driven by Novartis's continued metamorphosis into a focused innovative biopharma story with a strong new product cycle and multiple pipeline catalysts in 19E',2019-04-02 10:36:00-04:00,NVS,positive
934691.0,"The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial",2019-04-02 07:30:00-04:00,NVS,neutral
934692.0,Novartis Cosentyx Approved in China for Psoriasis Patients,2019-04-02 05:54:00-04:00,NVS,positive
934693.0,Novartis Announces $1.575B Acquisition Of IFM Tre,2019-04-01 15:59:00-04:00,NVS,neutral
934694.0,"For Cannabis Industry Investment, 2018 Was Terrific But 2019 Looks Even Better",2019-04-01 10:34:00-04:00,NVS,positive
934695.0,"5 Stocks To Watch For April 1, 2019",2019-04-01 04:28:00-04:00,NVS,neutral
934696.0,Novartis Adds Clinical and Preclinical Anti-inflammatory Programs to Portfolio with Acquisition of IFM Tre,2019-04-01 04:27:00-04:00,NVS,neutral
934697.0,Novartis to Acquire IFM Therapeutics for $310M Upfront; Up to $1.265B in Milestone Payments,2019-04-01 04:25:00-04:00,NVS,neutral
934698.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs",2019-03-30 09:32:00-04:00,NVS,neutral
934699.0,"The Daily Biotech Pulse: Safety Board Clears Eisai's Alzheimer's Study, Positive Trial Results For Galapagos-Gilead",2019-03-29 07:42:00-04:00,NVS,positive
934700.0,"The Daily Biotech Pulse: Blueprint Medicine Expedites Clinical Programs, Eyepoint Offering, Precision Biosciences IPO",2019-03-28 07:54:00-04:00,NVS,neutral
934701.0,6 Gene Therapy M&A Targets On The Radar,2019-03-27 12:45:00-04:00,NVS,neutral
934702.0,FDA Approves Novartis Drug To Treat More Severe Form Of Multiple Sclerosis,2019-03-27 09:15:00-04:00,NVS,positive
934703.0,"The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO",2019-03-27 07:52:00-04:00,NVS,positive
934704.0,Novartis Announces FDA Approval for Mayzent to Treat Secondary Progressive MS with Active Disease,2019-03-27 04:15:00-04:00,NVS,positive
934705.0,"The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs",2019-03-26 07:36:00-04:00,NVS,positive
934706.0,Novartis Announces Kymriah Gets Approval as First Car-T therapy in Japan,2019-03-26 04:02:00-04:00,NVS,positive
934707.0,"Sandoz Has Exclusively Launched Generic Version Of United Therapeutics Remodulin, Treprostinil",2019-03-25 16:10:00-04:00,NVS,positive
934708.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs",2019-03-23 12:20:00-04:00,NVS,neutral
934709.0,Analysts Digest Biogen's Alzheimer's Disappointment: 'There Isn't Much To Be Excited About',2019-03-22 13:30:00-04:00,NVS,negative
934710.0,Conatus Shares Fall By More Than 50% After Midstage Study Shows NASH Candidate Lagged Placebo,2019-03-22 10:49:00-04:00,NVS,neutral
934711.0,"The Daily Biotech Pulse: Immutep Gets US Patent, Conatus NASH Disappointment, Eisai Moves On After Aducanumab Setback",2019-03-22 08:16:00-04:00,NVS,negative
934712.0,"Novartis Plans For Alcon Spin-off On April 9, 2019",2019-03-22 04:05:00-04:00,NVS,neutral
934713.0,Novartis Unit Alcon Announces Acquisition of PowerVision for $285M Plus Potential Milestones,2019-03-18 03:41:00-04:00,NVS,neutral
934714.0,"The Daily Biotech Pulse: KaryoPharm's Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA",2019-03-15 07:39:00-04:00,NVS,positive
934715.0,Tilray Adds Former Goldman Sachs Managing Director To Senior Management Team,2019-03-14 14:03:00-04:00,NVS,neutral
934716.0,"Top 15 Most-Volatile Stocks For Wed., Mar. 6, 2019 Via Benzinga's Securities Lending Volatility Index Powered By Tidal Markets",2019-03-06 12:31:00-05:00,NVS,positive
934717.0,"Tilray Harvests Medical Cannabis In Portugal, Ramps European Business",2019-03-06 10:31:00-05:00,NVS,neutral
934718.0,"Piper Jaffray: Tilray, GW Pharma Are Early Leaders In Medical Cannabis",2019-03-05 14:13:00-05:00,NVS,neutral
934719.0,"Novartis Chairman Says 33% Stake In Roche Is Strategic, Says Expects To Double Sales In China Over Next 5 Years",2019-03-05 10:50:00-05:00,NVS,neutral
934720.0,"Novartis Chair Says Cell, Gene Therapy Could Make Up 10-15% Of Overall Portfolio In 10 Years",2019-03-05 10:48:00-05:00,NVS,neutral
934721.0,Novartis Chair Does Not 'Rule Out Anything On Sandoz',2019-03-05 10:37:00-05:00,NVS,neutral
934722.0,"The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings",2019-03-05 07:24:00-05:00,NVS,positive
934723.0,Novartis Cosentyx Shows Superior Improvements In Psoriasis Patients' Quality Of Life vs Janssen's Il-23 Stelara,2019-03-05 04:02:00-05:00,NVS,positive
934724.0,Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates,2019-03-04 11:50:00-05:00,NVS,neutral
934725.0,Novartis Data Confirm Rapid Response And High Efficacy Of Cosentyx In Psoriasis Patients For First Time In China; 87% of Patients Who Received Cosentyx 300mg Achieved Clear Or Almost Clear Skin During  First 16 Weeks Of Treatment,2019-03-04 04:19:00-05:00,NVS,positive
934726.0,Barron's On: Pharma's Big Hope,2019-03-03 10:47:00-05:00,NVS,positive
934727.0,Cohen Says Drugmaker Novartis Wanted Cohen To Lobby For Them But He Refused,2019-02-27 11:45:00-05:00,NVS,negative
934728.0,"Blackstone Life Sciences, Novartis Launch Anthos Therapeutics to Develop Innovative Medicines for Cardiovascular Disease",2019-02-27 04:02:00-05:00,NVS,positive
934729.0,"The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote",2019-02-26 07:56:00-05:00,NVS,positive
934730.0,Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal,2019-02-25 15:12:00-05:00,NVS,positive
934731.0,"Akcea Announces Novartis Exercised Option to License AKCEA-APO(a)-LRx; Axcea, Ionis to Equally Split $150M License Fee",2019-02-25 03:57:00-05:00,NVS,neutral
934732.0,Amarin Shares Spike ~5% Over Last Min. Amid Unconfirmed Takeover Chatter In Name,2019-02-22 10:01:00-05:00,NVS,positive
934733.0,"The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering",2019-02-20 07:34:00-05:00,NVS,negative
934734.0,Mitsubishi Tanabe Pharma Says Novartis Pharma Has Filed Request For Arbitration Against It,2019-02-20 04:05:00-05:00,NVS,neutral
934735.0,"The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings",2019-02-15 14:00:00-05:00,NVS,neutral
934736.0,"The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial",2019-02-14 07:50:00-05:00,NVS,negative
934737.0,"A Peek Into The Markets: US Stock Futures Gain Ahead Of Earnings, Inflation Data",2019-02-13 06:39:00-05:00,NVS,positive
934738.0,Clinigen to Acquire US Rights to Novartis' Cancer Drug Proleukin for $210M,2019-02-13 04:39:00-05:00,NVS,negative
934739.0,"Novartis Ag CEO Says Trying To Limit Our Net Price Increases To Medical Inflation, Or Less",2019-02-06 11:00:00-05:00,NVS,neutral
934740.0,"The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs",2019-02-03 10:09:00-05:00,NVS,neutral
934741.0,Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates,2019-02-01 13:30:00-05:00,NVS,neutral
934742.0,"The Daily Biotech Pulse: Roche Scraps Alzheimer's Disease Trials, Amgen Issues Weak Guidance",2019-01-30 08:12:00-05:00,NVS,negative
934743.0,25 Stocks Moving In Wednesday's Pre-Market Session,2019-01-30 08:12:00-05:00,NVS,neutral
934744.0,"Earnings Scheduled For January 30, 2019",2019-01-30 04:06:00-05:00,NVS,neutral
934745.0,Novartis Data Show Psoriasis Patients Treated With Cosentyx Reported Improvements In Quality Of Life Measures As Early As Week 4,2019-01-28 09:09:00-05:00,NVS,positive
934746.0,Novartis UK Says Building Increased Inventories Across Portfolio Of Medicines In UK Ahead Of Brexit,2019-01-25 06:23:00-05:00,NVS,positive
934747.0,Philogen S.p.a. Entered Collaboration And License Agreement With Novartis; No Financial Details Of Agreement Were Released,2019-01-23 10:07:00-05:00,NVS,positive
934748.0,"The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US",2019-01-17 08:06:00-05:00,NVS,positive
934749.0,"Novartiz Division, Sandoz, Announces Launch Of SYMJEPI Epinephrine Injection In US; Sandoz Is A Partner Of Adamiz Pharmaceuticals",2019-01-16 16:09:00-05:00,NVS,neutral
934750.0,Novartis Response To Nice Appraisal Consultation Document For Aimovig For The Prevention Of Migraine,2019-01-10 04:18:00-05:00,NVS,positive
934751.0,"The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase",2019-01-08 08:15:00-05:00,NVS,negative
934752.0,Novartis Investigational Therapy Crizanlizumab Receives FDA Breakthrough Therapy Designation For The Prevention Of Vaso-occlusive Crises In Sickle Cell Disease,2019-01-08 04:35:00-05:00,NVS,neutral
934753.0,"UPDATE: Cellular Biomedicine Says Novartis Seeks To Entrust Co.'s China Unit To Perform Certain Processing, Supply, Managerial Aspects Of Certain Products In China Region",2018-12-28 16:20:00-05:00,NVS,positive
934754.0,"Cellular Biomedicine 8-K Shows Toll Manufacturing, Supply Deal With Beijing Novartis Pharma",2018-12-28 16:18:00-05:00,NVS,neutral
934755.0,"Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week",2018-12-21 16:53:00-05:00,NVS,positive
934756.0,A Peek Into The Markets: US Stock Futures Down Ahead Of GDP Report,2018-12-21 06:59:00-05:00,NVS,neutral
934757.0,Novartis Receives EC Approval for Expanded Indication for Kisqali,2018-12-21 05:25:00-05:00,NVS,positive
934758.0,"Novartis Reports Offer To Purchase CellforCure, No terms Disclosed",2018-12-20 11:01:00-05:00,NVS,negative
934759.0,Endocyte Stockholders Approve Merger Agreement With Novartis AG; Novartis Will Acquire Co. For $24/Share,2018-12-20 09:26:00-05:00,NVS,positive
934760.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,NVS,positive
934761.0,"Nearly 30 Drug Companies, Including Novartis, Bayer, Amgen, Biogen Notified Payers In California Of Plans To Raise Prices In January",2018-12-19 19:29:00-05:00,NVS,neutral
934762.0,Intec Pharma Sends Letter To Shareholders,2018-12-19 09:32:00-05:00,NVS,neutral
934763.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,NVS,positive
934764.0,"UPDATE: AVEO/Novartis Deal Provides Novartis Will Make 1-Time $2.3M Payment To AVEO On Or Before Jan. 2, 2019, Provide AV380 Drug Supply To Co. At No Charge",2018-12-19 06:14:00-05:00,NVS,negative
934765.0,"UPDATE: AVEO AV380 Agreement With Novartis Provides For Continued Transfer To AVEO Of Preclinical, Technical, Manufacturing, Other Data, Materials Developed By Novartis For Program",2018-12-19 06:13:00-05:00,NVS,positive
934766.0,AVEO Pharma 8-K Shows Deal With Novartis For AVEO's AV380 Program,2018-12-19 06:12:00-05:00,NVS,neutral
934767.0,Novartis Unit Sandoz Enters Commercialization and Supply Agreement for Insulin Biosimilars,2018-12-19 04:50:00-05:00,NVS,positive
934768.0,Novartis Announces Alcon Acquires Tear Film Innovations; Financial Terms Not Disclosed,2018-12-19 04:49:00-05:00,NVS,neutral
934769.0,Anji Pharmaceuticals Licenses Regional Rights to a Clinical Asset from Novartis for $2M,2018-12-19 04:28:00-05:00,NVS,positive
934770.0,Cowen: What The Sandoz Deal Means For Tilray Investors,2018-12-18 13:38:00-05:00,NVS,neutral
934771.0,Tilray Shares Jump On The Back Of Novartis Partnership,2018-12-18 10:30:00-05:00,NVS,positive
934772.0,Tilray shares are trading higher after the company announced a partnership with German pharmaceutical company Sandoz to distribute non-smokable medical cannabis products.,2018-12-18 09:11:00-05:00,NVS,positive
934773.0,Tilray Signs Global Collaboration Agreement With Generic Pharmaceutical Company Sandoz AG,2018-12-18 08:31:00-05:00,NVS,positive
934774.0,Endocyte's Previously Announced Merger With Novartis Cleared by the Committee on Foreign Investment in the United States,2018-12-17 06:42:00-05:00,NVS,positive
934775.0,Fund Flow Data Suggests Traders Are Betting On Emerging Markets Heading Into 2019,2018-12-14 15:50:00-05:00,NVS,neutral
934776.0,"The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen",2018-12-13 07:56:00-05:00,NVS,positive
934777.0,Novartis Receives EC Approval for Self-administration of Xolair Across All Indications,2018-12-13 04:45:00-05:00,NVS,positive
934778.0,Novartis Exec On J&J Call To Discuss TREMFYA Says 'We believe data from ECLIPSE trial...will have limited clinical relevance',2018-12-12 10:29:00-05:00,NVS,negative
934779.0,"Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate",2018-12-11 12:42:00-05:00,NVS,positive
934780.0,"Jefferies Assumes Novartis at Buy, Announces Price Target $105",2018-12-11 10:07:00-05:00,NVS,neutral
934781.0,"The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings",2018-12-11 08:22:00-05:00,NVS,neutral
934782.0,5 Biotech Companies To Keep On Your M&A Watchlist For 2019,2018-12-10 12:32:00-05:00,NVS,neutral
934783.0,Novartis Says Data Demonstrates Consistent Efficacy And Tolerability Of Kisqali Combination Therapy In Hr+/her2- Advanced Breast Cancer In Patients With Difficult-to-treat Visceral Diseasese,2018-12-08 08:56:00-05:00,NVS,negative
934784.0,Novartis Shares Tick Lower Over Last Few Mins; Hearing Barclays Downgraded From Equalweight To Underweight,2018-12-07 13:54:00-05:00,NVS,neutral
934785.0,Novartis to Launch Adamis' EpiPen Rival in U.S. in 2019,2018-12-07 04:25:00-05:00,NVS,neutral
934786.0,QIAGEN Reports New Collaboration For Development Of Companion Diagnostics From Novartis Drug Candidate,2018-12-06 11:04:00-05:00,NVS,neutral
934787.0,UPDATE: Intellia To Receive $10M 1-Time Payment Related To Expansion Of Collab Deal With Novartis,2018-12-06 07:37:00-05:00,NVS,neutral
934788.0,"Intellia Therapeutics, Novartis Expand Existing Cell Therapy Collab To Include Ex Vivo Development Of Cell Therapies Using Certain Ocular Stem Cells",2018-12-06 07:36:00-05:00,NVS,positive
934789.0,"Intec Pharma Reports Accordion Pill To Continue To Clinical PK Study Under Feasibility, Option Deal With Novartis",2018-12-06 07:17:00-05:00,NVS,neutral
934790.0,Novartis Advances Ligelizumab in Urticaria to Phase III on Basis of Strong Phase II Head-to-head Data,2018-12-04 05:08:00-05:00,NVS,positive
934791.0,Novartis Announces FDA Filing Acceptance and Priority Review of AVXS-101 One-time Treatment Designed to Address Genetic Root Cause of SMA Type 1,2018-12-03 04:35:00-05:00,NVS,positive
934792.0,Novartis' Advanced Accelerator Applications Signs Exclusive Option and License Agreement with FUJIFILM Toyama Chemical to Develop and Commercialize Radiolabeled FF-10158 for Oncology Indications,2018-12-03 04:03:00-05:00,NVS,positive
934793.0,Novartis Announces Real-world Data Show Promacta Improves Outcomes for ITP Patients vs Other Second-line Therapies,2018-12-02 21:15:00-05:00,NVS,positive
934794.0,Novartis Announces Real-world Data Show Revolade Improves Outcomes For Itp Patients Compared To Other Second-line Therapies at ASH 2018,2018-12-02 21:09:00-05:00,NVS,positive
934795.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs",2018-12-02 17:51:00-05:00,NVS,neutral
934796.0,"Novartis Announces EU Approval of Gilenya for Children, Adolescents with MS",2018-11-29 04:18:00-05:00,NVS,positive
934797.0,Novartis Announces Sandoz Receives Eighth EC Approval for Biosimilar with Ziextenzo,2018-11-27 04:24:00-05:00,NVS,positive
934798.0,Novartis Announces First Capital Markets Day Ahead of Spinoff of Alcon,2018-11-27 04:23:00-05:00,NVS,neutral
934799.0,"Benzinga's Top Upgrades, Downgrades For November 26, 2018",2018-11-26 09:01:00-05:00,NVS,positive
934800.0,"Cowen & Co. Upgrades Novartis to Outperform, Announces $100 Price Target",2018-11-26 08:44:00-05:00,NVS,neutral
934801.0,Express Scripts' CMO Says $4M for Novartis' Gene Therapy is Too Much,2018-11-23 04:16:00-05:00,NVS,neutral
934802.0,Novartis Announces Landmark EU Approval For One-time Gene Therapy Luxturna® To Restore Vision In People With Rare Inherited Retinal Disease,2018-11-23 04:12:00-05:00,NVS,positive
934803.0,FDA Warns About Severe Worsening Of Multiple Sclerosis After Stopping GILENYA,2018-11-20 13:24:00-05:00,NVS,negative
934804.0,"The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings",2018-11-20 08:29:00-05:00,NVS,negative
934805.0,"Sandoz, Pear Therapeutics Announce Launch of reSET for Treatment of Patients with Substance Use Disorder",2018-11-20 04:37:00-05:00,NVS,negative
934806.0,"Novartis Is Set For 'Higher Returns And Growth,' Goldman Sachs Says In Upgrade",2018-11-19 10:14:00-05:00,NVS,neutral
934807.0,"Benzinga's Top Upgrades, Downgrades For November 19, 2018",2018-11-19 09:14:00-05:00,NVS,positive
934808.0,Goldman Sachs Upgrades Novartis to Conviction Buy,2018-11-19 07:00:00-05:00,NVS,neutral
934809.0,Goldman Sachs Upgrades Novartis to Buy from Neutral;,2018-11-19 04:36:00-05:00,NVS,neutral
934810.0,"Novartis Reports FDA Approved Promacta For First-Line SAA, Granted Breakthrough Therapy Designation For Added New Indication For Low Platelet Counts In People Exposed To Radiation",2018-11-16 16:42:00-05:00,NVS,positive
934811.0,"Novartis Reports Receive Positive CHMP Opinion For Expansion Of Kisqali Combo Therapy For Women With HR+/HER2-Locally Advance, Metastatic Breast Cancer",2018-11-16 08:12:00-05:00,NVS,negative
934812.0,Novartis Says Not Planning Split-off of Sandoz,2018-11-15 04:35:00-05:00,NVS,neutral
934813.0,Hearing Novartis AG Has Approached Horizon Pharma With $31/Share Takeover Bid; Unconfirmed,2018-11-14 09:51:00-05:00,NVS,negative
934814.0,Novartis Says Study Supports Entresto as Foundational HFrEF Therapy and in-hospital Initiation in Appropriate Stabilized Heart Failure Patients,2018-11-11 16:39:00-05:00,NVS,negative
934815.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-11 09:10:00-05:00,NVS,neutral
934816.0,"The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall",2018-11-09 07:32:00-05:00,NVS,neutral
934817.0,Novartis Option Alert: Dec 21 $90 Calls Sweep (2) above Ask!: 650 @ $1.875 vs 7748 OI; Ref=$88.85,2018-11-05 13:46:00-05:00,NVS,positive
934818.0,Novartis Provides R&D Update; Says Cosentyx Expected to Be Co' Largest Drug Next Year; Mayzent Expected to Launch in Q1 2019,2018-11-05 04:05:00-05:00,NVS,neutral
934819.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,NVS,neutral
934820.0,Novartis Receives Health Canada Approval For The Combination Therapy Of TAFINLAR Plus MEKINIST For Adjuvent Treatment Of Patients With BRAF V600 Mutation Melanoma,2018-11-01 10:48:00-04:00,NVS,positive
934821.0,Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates,2018-11-01 09:26:00-04:00,NVS,neutral
934822.0,Novartis Has Applied To Appeals Court Following Judicial Review On Clinical Commissioning Group Policy Related To Routine Use Of Unlicensed Medicine On National Health Service,2018-11-01 06:53:00-04:00,NVS,neutral
934823.0,"Novartis, Pfizer Announce Clinical Collaboration to Advance Treatment of NASH",2018-10-29 04:08:00-04:00,NVS,neutral
934824.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-10-27 10:23:00-04:00,NVS,neutral
934825.0,"The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default",2018-10-26 08:17:00-04:00,NVS,negative
934826.0,Novartis Receives Approval for Cosentyx Label Update in Europe to Include Dosing Flexibility in Psoriatic Arthritis,2018-10-26 05:06:00-04:00,NVS,positive
934827.0,Compact Imaging Collaborates With Global Pharma To Accelerate Development Of Home Monitor For Age-Related Macular Degeneration And Diabetic Retinopathy,2018-10-25 08:25:00-04:00,NVS,neutral
934828.0,11 Stocks That Moved From ESMO 2018,2018-10-22 13:39:00-04:00,NVS,neutral
934829.0,Novartis Announces COMBI-AD Study of Tafinlar + Mekinist Continues to Demonstrate Relapse Free Survival Benefit in Patients with BRAF V600-mutant Stage III Melanoma at ESMO 2018,2018-10-22 04:25:00-04:00,NVS,positive
934830.0,"Novartis Reports Phase 2 GEOMETRY Mono-1 Trial Of Investigational INC280 Showed 'overall response rate of 72%, 39.1%, respectively, in treatment-naive, previously treated patients with advanced MET exon-14 skipping mutated non-small cell lung cancer'",2018-10-19 10:02:00-04:00,NVS,negative
934831.0,"The Daily Biotech Pulse: Novartis Positive Liver Drug Trials, Krytstal Prices Offering, LogicBio To Debut",2018-10-19 08:28:00-04:00,NVS,positive
934832.0,50 Biggest Movers From Yesterday,2018-10-19 05:50:00-04:00,NVS,neutral
934833.0,Novartis Announces Presentation of New Lutathera Netter-1 Data at ESMO Demonstrating Significant Improvement in PFS Regardless of Baseline Liver Tumor Burden,2018-10-19 03:59:00-04:00,NVS,negative
934834.0,Mid-Afternoon Market Update: NASDAQ Down 2.3%; Textron Shares Fall After Q3 Results,2018-10-18 14:37:00-04:00,NVS,positive
934835.0,41 Stocks Moving In Thursday's Mid-Day Session,2018-10-18 12:49:00-04:00,NVS,neutral
934836.0,Mid-Day Market Update: Down Down Over 300 Points; Endocyte Shares Spike Higher,2018-10-18 12:01:00-04:00,NVS,positive
934837.0,Mid-Morning Market Update: Markets Open Lower; Philip Morris Profit Beats Estimates,2018-10-18 10:28:00-04:00,NVS,positive
934838.0,Novartis To Buy Endocyte In $2.1B Deal,2018-10-18 09:06:00-04:00,NVS,neutral
934839.0,25 Stocks Moving In Thursday's Pre-Market Session,2018-10-18 08:10:00-04:00,NVS,neutral
934840.0,"The Daily Biotech Pulse: Novartis Buys Endocyte, Proteostasis Positive Cystic Fibrosis Trial, 2 IPOs",2018-10-18 07:56:00-04:00,NVS,positive
934841.0,Endocyte shares are trading higher after Novartis announced it would buy Endocyte for $24/Share.,2018-10-18 07:44:00-04:00,NVS,positive
934842.0,"Earnings Scheduled For October 18, 2018",2018-10-18 04:17:00-04:00,NVS,neutral
934843.0,Endocyte Enters Into Agreement to be Acquired by Novartis for $24/Share,2018-10-18 03:39:00-04:00,NVS,positive
934844.0,Novartis Q3 Earnings Preview,2018-10-17 14:31:00-04:00,NVS,neutral
934845.0,Benchmark Out Bullish On 'Well-Positioned' Tilray Ahead of Canada's Cannabis Legalization,2018-10-16 10:26:00-04:00,NVS,neutral
934846.0,Novartis Announces 5-year Data in Psoriatic Arthritis and Ankylosing Spondylitis Reinforces Cosentyx Leadership in Spondyloarthritis,2018-10-16 04:53:00-04:00,NVS,neutral
934847.0,4 Major Market Opportunities For The Cannabis Industry,2018-10-14 13:26:00-04:00,NVS,positive
934848.0,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs",2018-10-14 13:21:00-04:00,NVS,neutral
934849.0,"The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program",2018-10-12 07:34:00-04:00,NVS,negative
934850.0,Novartis Highlights New Data From First Direct Head-To-Head Trial Showing Superior Efficacy Of Gilenya Over Cpaxone In Patients With Relapsing Remitting Multiple Sclerosis,2018-10-10 16:36:00-04:00,NVS,positive
934851.0,"The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares",2018-10-10 07:56:00-04:00,NVS,positive
934852.0,Novartis Highlights Data Published In American Journal Of Hematology On SEG101 For Sickle Cell Pain Crises: Data Showed 'more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis...',2018-10-09 16:35:00-04:00,NVS,negative
934853.0,Novartis Announces FDA and EMA Filing Acceptance of Siponimod,2018-10-08 04:11:00-04:00,NVS,positive
934854.0,"The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares",2018-10-03 07:54:00-04:00,NVS,positive
934855.0,Novartis Licenses Three Novel Anti-infective Programs to Boston Pharmaceuticals,2018-10-03 04:22:00-04:00,NVS,positive
934856.0,"Novartis Sees Exiting Its Grimsby, UK Site By End Of 2020, Sees 395 Employees Impacted",2018-09-25 06:56:00-04:00,NVS,neutral
934857.0,"Novartis CEO Says Up to 400 Jobs to be Cut in UK, Unrelated to Brexit",2018-09-25 04:28:00-04:00,NVS,negative
934858.0,"Novartis Announces New Analysis of Phase Iii Brolucizumab Data Reinforces Superior Reduction of Retinal Fluid, a Key Marker of Disease Activity in nAMD",2018-09-22 10:41:00-04:00,NVS,positive
934859.0,Novartis to File for New Lucentis Indication in Retinopathy of Prematurity; Says Rainbow Phase III Study Marginally Missed Statistical Significance for Primary Endpoint,2018-09-22 10:38:00-04:00,NVS,neutral
934860.0,"Novartis Reports Positive CHMP Opinion For 1-Time Gene Therapy Luxturna For Treatment Of Children, Adults With Multiple Sclerosis",2018-09-21 07:26:00-04:00,NVS,positive
934861.0,"Surface Oncology Offers 'Robust Pipeline,' Baird Says In Bullish Initiation",2018-09-19 15:43:00-04:00,NVS,positive
934862.0,"Credit Suisse Lifts Teva Price Target, Says Execution Is Key For Migraine Drug",2018-09-17 15:07:00-04:00,NVS,positive
934863.0,Teva's Preventive Migraine Treatment Approved By FDA,2018-09-17 09:08:00-04:00,NVS,positive
934864.0,"The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx",2018-09-13 08:42:00-04:00,NVS,neutral
934865.0,"Benzinga's Top Upgrades, Downgrades For September 11, 2018",2018-09-11 09:13:00-04:00,NVS,positive
934866.0,Citigroup Upgrades Novartis to Buy,2018-09-11 07:35:00-04:00,NVS,neutral
934867.0,Alcon Confirms Commitment to Switzerland Ahead of Proposed Spinoff from Novartis,2018-09-11 04:34:00-04:00,NVS,positive
934868.0,Bank of America Upgrades Novartis to Buy,2018-09-10 09:41:00-04:00,NVS,neutral
934869.0,New Class of Migraine Drug Creates Four-Way Pharma Development Race,2018-09-06 15:58:00-04:00,NVS,positive
934870.0,"Novartis Says They Face $70M Impairment Related To Sale Of Assets To India's Aurobindo, Will Confirm At Q3 Earnings Report On Oct. 18th",2018-09-06 13:29:00-04:00,NVS,positive
934871.0,Benzinga Pro's 5 Stocks To Watch Today,2018-09-06 09:10:00-04:00,NVS,neutral
934872.0,"The Daily Biotech Pulse: Novartis Divestment, Eyepoint's Drug Gets Coverage, Spectrum's Robust Data",2018-09-06 08:28:00-04:00,NVS,positive
934873.0,"Novartis Receives Health Canada Approval of its CAR-T Cell Therapy, Kymriah",2018-09-06 07:20:00-04:00,NVS,positive
934874.0,"Aurobindo Pharma Unit to Buy Commercial Operations, 3 Manufacturing Facilities in U.S. from Novartis' Sandoz Unit",2018-09-06 04:34:00-04:00,NVS,neutral
934875.0,UK's NHS  Makes Novartis Cancer Cell Therapy Available to Children  with Aggressive Leukaemia,2018-09-05 04:34:00-04:00,NVS,negative
934876.0,Novartis Chairman Says Co to Streamline Production in Response to Falling Drug Prices in U.S.,2018-09-01 16:00:00-04:00,NVS,negative
934877.0,"Midatech Announces Interim Results From Proof Of Concept Exploratory Study For Oncology Candidate MTD201; Co. Says Interim Data For Establishes Favorable Clinical Profile Compared To Reference Product, Novatris' SLAR",2018-08-31 07:03:00-04:00,NVS,positive
934878.0,"The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent",2018-08-29 07:54:00-04:00,NVS,positive
934879.0,Novartis Publishes A Media Release Saying Alcon Announces Voluntary Global Market Withdrawal Of CyPass Micro-Stent For Surgical Glaucoma,2018-08-29 07:50:00-04:00,NVS,neutral
934880.0,EC Approves Novartis Combination Therapy Tafinlar + Mekinist for Adjuvant Treatment of BRAF V600 Mutation-Positive Melanoma,2018-08-29 04:16:00-04:00,NVS,positive
934881.0,"The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero",2018-08-23 08:23:00-04:00,NVS,negative
934882.0,SOLAR-1 trial of Novartis Investigational Alpha-specific PI3K Inhibitor BYL719 (alpelisib) Meets Primary Endpoint in HR+/HER2- Advanced Breast Cancer with PIK3CA Mutation,2018-08-23 04:33:00-04:00,NVS,negative
934883.0,Healint Announces Research Showing Increase in Anxiety and Depression with Higher Migraine Frequency Among Tens of Thousands of US Migraine Patients,2018-08-20 04:31:00-04:00,NVS,negative
934884.0,Mixed Reviews For Allakos As Sell-Side Starts Coverage Of Biotech,2018-08-13 14:52:00-04:00,NVS,neutral
934885.0,Laekna Acquires Exclusive Worldwide Rights to Two Clinical Stage Oncology Assets; Terms Not Disclosed,2018-08-01 04:11:00-04:00,NVS,positive
934886.0,European Commission Has Approved Novartis' Aimovig For Prevention In Migraine In Adults Experiencing Migraines 4+ Times/Day,2018-07-30 16:34:00-04:00,NVS,positive
934887.0,Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus,2018-07-21 08:44:00-04:00,NVS,neutral
934888.0,"Benzinga's Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To Offer Shares, Intuitive Surgical's Strong Q2",2018-07-20 07:53:00-04:00,NVS,positive
934889.0,"Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut",2018-07-19 09:14:00-04:00,NVS,neutral
934890.0,Barclays Upgrades Novartis to Equal-Weight,2018-07-19 09:05:00-04:00,NVS,neutral
934891.0,"'Thank you to Novartis for not increasing your prices on prescription drugs. Likewise to Pfizer. We are making a big push to actually reduce the prices, maybe substantially, on prescription drugs.' -Tweet From Pres Trump",2018-07-19 06:30:00-04:00,NVS,positive
934892.0,"MorphoSys, Galapagos Sign Global License Agreement for MOR106 with Novartis",2018-07-19 04:11:00-04:00,NVS,positive
934893.0,"Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares",2018-07-18 08:42:00-04:00,NVS,positive
934894.0,"Novartis Shares Up 1.7% Premarket Following Q2 Earnings: GAAP EPS $0.84, After-Tax Profit $7.77B, Sales $13.16B vs $12.94B Estimate",2018-07-18 07:40:00-04:00,NVS,positive
934895.0,Novartis Says It Will Not Hike Drug Prices In The U.S.,2018-07-18 06:47:00-04:00,NVS,neutral
934896.0,"Earnings Scheduled For July 18, 2018",2018-07-18 05:44:00-04:00,NVS,neutral
934897.0,Earnings Outlook For Novartis,2018-07-17 16:04:00-04:00,NVS,neutral
934898.0,"Novartis Says it Disagrees With U.S. Senators Conclusion That Co. Issued A Misleading Public Statement About Contract With Cohen, Says It Only Had One Meeting With Cohen March 1, 2017",2018-07-13 08:16:00-04:00,NVS,negative
934899.0,"Novartis to Shut Antibacterial, Antiviral Research Operations in San Francisco Area, Cut 140 Job",2018-07-12 04:16:00-04:00,NVS,negative
934900.0,"Novartis, Roche, Gilead Have Cancelled Some Drug Price Increases",2018-07-10 14:46:00-04:00,NVS,negative
934901.0,Health Care Sector Outlook: Checking In Ahead Of Q2 Earnings Reports,2018-07-09 14:39:00-04:00,NVS,positive
934902.0,A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year,2018-07-05 12:25:00-04:00,NVS,neutral
934903.0,44 Biggest Movers From Yesterday,2018-07-03 05:54:00-04:00,NVS,neutral
934904.0,38 Stocks Moving In Monday's Mid-Day Session,2018-07-02 12:29:00-04:00,NVS,neutral
934905.0,Adamis Pharma Soars 60% Amid New Partnership With Novartis To Commercialize Symjepi,2018-07-02 10:14:00-04:00,NVS,neutral
934906.0,Adamis Pharmaceuticals Announces Distribution and Commercialization Agreement with Sandoz for Symjepi,2018-07-01 20:03:00-04:00,NVS,positive
934907.0,The Week Ahead In Biotech: Delayed Clinical Trial Releases In Focus,2018-06-30 17:32:00-04:00,NVS,negative
934908.0,"Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos",2018-06-29 08:11:00-04:00,NVS,positive
934909.0,"EU Recommends Approval Of Novartis Kymriah, Recommends Approval Of Utlragenyx Drug For Treatment Of Sly Syndrome, Recommends Approval Of Yescarta",2018-06-29 07:50:00-04:00,NVS,positive
934910.0,EMA Has Recommended Approval For Novartis's Kymriah,2018-06-29 07:47:00-04:00,NVS,positive
934911.0,Novartis CEO Says Alcon will be 100% Spinoff to Shareholders; Will Take 9 Months to Complete Spinoff,2018-06-29 04:18:00-04:00,NVS,neutral
934912.0,"Amgen And Novartis Present New Data Demonstrating Long-Term Efficacy, Safety And Tolerability Of Aimovig, Results From a One-Year Study of Efficacy and Safety of Aimovig in Chronic Migraine and Data From a Three-Year Analysis",2018-06-28 16:31:00-04:00,NVS,positive
934913.0,"Piper Jaffray, Stifel Defend Array Biopharma As Stock Falls On Profit-Taking",2018-06-28 11:42:00-04:00,NVS,neutral
934914.0,"Benzinga's Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut",2018-06-28 08:26:00-04:00,NVS,positive
934915.0,"Everest Medicines Unit Entered Licensing Agreement to Develop Novartis' Novel FGFR4 Kinase Inhibitor, FGF401",2018-06-25 20:26:00-04:00,NVS,positive
934916.0,"Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anika's Flunked Trial, Eidos To Commence Trading",2018-06-20 08:36:00-04:00,NVS,negative
934917.0,Novartis Reports FDA Approval For Inclusion Of New Evidence Cosentyx Inhibits Progression Of Joint Structural Damage At Week 24 vs Placebo,2018-06-19 16:04:00-04:00,NVS,negative
934918.0,Novartis Reports Interim Results From I-WISh Study Showed '36% of patients said that having ITP had a high impact on their emotional well-being while 28% of patients had disease symptoms that caused them to miss work',2018-06-15 07:09:00-04:00,NVS,neutral
934919.0,"Rovi Reports Deal With Novartis Unit Sandoz For Distribution, Marketing Of Enoxaparin Biosimilar",2018-06-12 07:27:00-04:00,NVS,neutral
934920.0,REGENXBIO Reports Received $100M Accelerated License Payment Due To Purchase Of AveXis By Novartis,2018-06-11 16:05:00-04:00,NVS,neutral
934921.0,Crispr Therapeutics Falls As Studies Suggest Possible Cancerous Side Effect,2018-06-11 13:58:00-04:00,NVS,neutral
934922.0,"Pharma Stock Roundup: Merck, Eli Lilly, AbbVie And More",2018-06-08 16:33:00-04:00,NVS,neutral
934923.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,NVS,negative
934924.0,Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO,2018-06-01 08:16:00-04:00,NVS,neutral
934925.0,"EMA Has Recommended Approval Of Amgen, Novartis Migraine Drug Erenumab",2018-06-01 07:28:00-04:00,NVS,positive
934926.0,"Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immutep Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA",2018-05-30 08:14:00-04:00,NVS,positive
934927.0,Novartis Announces FDA Expedites Review of Promacta for First-line Severe Aplastic Anemia,2018-05-30 04:30:00-04:00,NVS,negative
934928.0,"Benzinga's Top Upgrades, Downgrades For May 29, 2018",2018-05-29 09:19:00-04:00,NVS,positive
934929.0,"The Market In 5 Minutes: Italy, ASCO, Roku And More",2018-05-29 09:06:00-04:00,NVS,neutral
934930.0,A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street,2018-05-29 06:57:00-04:00,NVS,negative
934931.0,HSBC Downgrades Novartis to Hold,2018-05-29 06:11:00-04:00,NVS,neutral
934932.0,Novartis Gets Approval For Remicade Biosimilar In Europe,2018-05-25 13:51:00-04:00,NVS,positive
934933.0,"Benzinga's Top Upgrades, Downgrades For May 25, 2018",2018-05-25 09:44:00-04:00,NVS,positive
934934.0,Credit Suisse Upgrades Novartis to Neutral,2018-05-25 06:22:00-04:00,NVS,positive
934935.0,"Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings",2018-05-24 08:37:00-04:00,NVS,neutral
934936.0,"UPDATE: Amgen Shares Up 1.7%, Novartis Up 0.3%; Cos. Late Thurs. Disclosed FDA Approval Of Aimovig For Migraine Treatment",2018-05-18 08:08:00-04:00,NVS,positive
934937.0,"Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved",2018-05-18 08:00:00-04:00,NVS,positive
934938.0,"UPDATE: FDA Offers Guidelines, Background For Reference Listed Drug Access Inquiries, Related To Claim Of Blocking Generic Rivals",2018-05-17 12:38:00-04:00,NVS,negative
934939.0,"Hearing FDA Names Drugmakers Accused Of Blocking Generic Rivals Including Gilead, Celgene, Novartis",2018-05-17 09:21:00-04:00,NVS,negative
934940.0,"Novartis Reports Data Which Will Be Presented At ASCO, EHA",2018-05-17 09:02:00-04:00,NVS,neutral
934941.0,"Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More",2018-05-17 08:27:00-04:00,NVS,neutral
934942.0,REMINDER: Novartis Has FDA PDUFA Date Today for Erenumab,2018-05-17 07:16:00-04:00,NVS,neutral
934943.0,Ex-Novartis CEO Jimenez Tells Reuters A Novartis Search For Consultants Following The 2016 U.S. Election Resulted In 3rd-Party Referral To Trump's Lawyer Cohen,2018-05-16 07:05:00-04:00,NVS,neutral
934944.0,'JUST IN: Novartis top lawyer quits over Cohen payment'-CNN Money,2018-05-16 06:32:00-04:00,NVS,positive
934945.0,Novartis Completes Tender Offer for All Outstanding Shares of AveXis,2018-05-15 03:47:00-04:00,NVS,positive
934946.0,"The Week Ahead: Coindesk Conference, Walmart And Retailers Close Out Earnings Season",2018-05-14 12:46:00-04:00,NVS,neutral
934947.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-13 10:06:00-04:00,NVS,neutral
934948.0,FDA Announces Approval of Novartis' Gilenya,2018-05-11 16:29:00-04:00,NVS,positive
934949.0,3 Companies Tied Up With Cohen's Shell Company — And What They Need From Trump,2018-05-09 17:03:00-04:00,NVS,neutral
934950.0,'Trump's lawyer pitched himself as a fixer to Novartis and got paid $1.2 million',2018-05-09 14:14:00-04:00,NVS,neutral
934952.0,"DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR, Co. Is Now eligible For Up To $30M In Milestone Payments, Down From $43M In Payments Before",2018-05-09 08:04:00-04:00,NVS,positive
934953.0,Esperion Shares Plunge After Cholesterol-Lowering Drug's Phase 3 Results Stir Safety Concerns,2018-05-02 11:56:00-04:00,NVS,positive
934954.0,"Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings",2018-05-02 07:41:00-04:00,NVS,neutral
934955.0,Novartis Reports Kymriah Received Second FDA Approval To Treat Appropriate r/r Patients With Large B-Cell Lymphoma,2018-05-01 16:27:00-04:00,NVS,positive
934956.0,Attention Biotech Investors: Mark Your Calendar For These May PDUFA Action Dates,2018-05-01 15:39:00-04:00,NVS,neutral
934957.0,"Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings",2018-05-01 07:51:00-04:00,NVS,neutral
934958.0,Novartis Provides Update on Proposed Acquisition of AveXis,2018-05-01 04:25:00-04:00,NVS,neutral
934959.0,Novartis Reports Received FDA Approval For Tafinlar + Mekinist For Adjuvant Treatment Of BRAF V600-Mutant,2018-04-30 16:11:00-04:00,NVS,positive
934960.0,Novartis Reports Phase III Data For Brolucizumab Showed Reliability Of 12-Week Treatment Interval,2018-04-30 16:11:00-04:00,NVS,neutral
934961.0,Endpoints Reports 'Novartis poaches Bristol-Myers/Amgen vet John Tsai for top drug development post in a $9B organization',2018-04-19 15:03:00-04:00,NVS,positive
934962.0,"Novartis Shares Indicated Higher Premarket; Co. Early Thurs. Reported Q1 Operating Profit $2.4B, Sales $12.7B Beats $12.57B Est.",2018-04-19 06:26:00-04:00,NVS,positive
934963.0,"10 Stocks To Watch For April 19, 2018",2018-04-19 04:17:00-04:00,NVS,neutral
934964.0,"Earnings Scheduled For April 19, 2018",2018-04-19 04:08:00-04:00,NVS,neutral
934965.0,Novartis Commences Tender Offer for AveXis,2018-04-17 03:56:00-04:00,NVS,neutral
934966.0,Jefferies On Novartis: Co. Could Use ~$4B Of Proceeds From Sale Of Consumer JV To Fund A Buyback Plan,2018-04-13 06:28:00-04:00,NVS,neutral
934967.0,"Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis To Merge With Novartis And More",2018-04-11 14:31:00-04:00,NVS,neutral
934968.0,Novartis Afinitor DISPERZ Receives FDA Approval to Treat TSC-associated Partial-onset Seizures,2018-04-10 19:53:00-04:00,NVS,positive
934969.0,40 Biggest Movers From Yesterday,2018-04-10 04:21:00-04:00,NVS,neutral
934970.0,Mid-Afternoon Market Update: Crude Oil Up Over 2%; Therapix Biosciences Shares Spike Higher,2018-04-09 14:32:00-04:00,NVS,negative
934971.0,Analyst: AveXis M&A Could Support Interest In Regenxbio,2018-04-09 13:36:00-04:00,NVS,positive
934972.0,31 Stocks Moving In Monday's Mid-Day Session,2018-04-09 12:32:00-04:00,NVS,neutral
934973.0,Mid-Day Market Update: Dow Rises 250 Points; Menlo Therapeutics Shares Slide,2018-04-09 12:09:00-04:00,NVS,positive
934974.0,"Chardan Raised Its REGENXBIO Price Target From $85 to $90 On News Co.'s Partner, AveXis, Was Bought By Novartis, Believing This Could Support M&A Interest in RGNX & Suggesting 'Consensus is underestimating the impact of AVXS-101 royalites on REGENXBIO'",2018-04-09 10:48:00-04:00,NVS,positive
934975.0,Mid-Morning Market Update: Markets Open Higher; Novartis To Acquire AveXis For $8.7B,2018-04-09 10:15:00-04:00,NVS,neutral
934976.0,Regenxbio Inc To Receive $180M From Novartis Takeover Of AveXis Per 2014 Agreement,2018-04-09 09:13:00-04:00,NVS,positive
934977.0,Why The Novartis-AveXis Deal Is Good News For The Gene Therapy Space,2018-04-09 09:11:00-04:00,NVS,positive
934978.0,20 Stocks Moving In Monday's Pre-Market Session,2018-04-09 08:06:00-04:00,NVS,neutral
934979.0,A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street,2018-04-09 07:11:00-04:00,NVS,neutral
934980.0,AveXis Announces Agreement to be Acquired by Novartis for $8.7B; $218/Share,2018-04-09 04:06:00-04:00,NVS,positive
934981.0,"The Week Ahead In Biotech: PDUFA Dates, IPOs And More",2018-04-06 12:55:00-04:00,NVS,neutral
934982.0,8 Biotech Stocks With Clinical Trial Outcomes In April,2018-04-05 15:30:00-04:00,NVS,neutral
934983.0,Novartis Announces JAMA Cardiology Publication of Data Showing Entresto improves Physical and Social Activity in HFrEF patients versus enalapril,2018-04-04 11:04:00-04:00,NVS,positive
934984.0,Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates,2018-04-03 08:14:00-04:00,NVS,neutral
934985.0,"On World Autism Awareness Day, A Look At Biotech Firms With Potential Treatments In The Pipeline",2018-04-02 12:31:00-04:00,NVS,neutral
934986.0,"The Week Ahead In Biotech: PDUFA Dates, Clinical Trials And Conferences",2018-03-30 09:46:00-04:00,NVS,neutral
934987.0,Hearing Dealreporter Said Novartis Is Weighing A Bid For Incyte,2018-03-28 09:36:00-04:00,NVS,neutral
934988.0,GlaxoSmithKline To Buy Novartis' Stake in Consumer Health Care JV For $13 Billion,2018-03-27 10:53:00-04:00,NVS,positive
934989.0,Novartis to Sell Stake in Consumer Healthcare JV to GSK for $13B,2018-03-27 04:20:00-04:00,NVS,neutral
934990.0,Novartis Announces Tasigna Approved By FDA As Treatment For Children With Rare Form Of Leukemia,2018-03-22 12:31:00-04:00,NVS,positive
934991.0,Biotech Winners And Losers From Congress' Latest Funding Bill,2018-03-22 11:46:00-04:00,NVS,negative
934992.0,Novartis Expands Alliance with Science 37 to Advance Virtual Clinical Trials Program,2018-03-07 03:53:00-05:00,NVS,positive
934993.0,"Novartis, Pear Therapeutics to Develop Digital Therapeutics for Patients with Schizophrenia, MS",2018-03-01 04:40:00-05:00,NVS,neutral
934994.0,"Regulatory Concern For Celgene's Ozanimod Could Be Big For Arena Pharma, Novartis",2018-02-28 08:26:00-05:00,NVS,neutral
934995.0,"Canaccord Slices Regeneron Price Target 32% On Eylea, Dupixent Challenges",2018-02-21 11:07:00-05:00,NVS,positive
934996.0,Wedbush: Restorbio's Therapy For Aging-Related Diseases Has Best-In-Class Potential,2018-02-20 14:39:00-05:00,NVS,neutral
934997.0,Novartis CEO Says Drugmaker to become Focused Medicines Company Powered by Data Science and Digital Technologies -Wall Street Journal,2018-02-19 16:13:00-05:00,NVS,positive
934998.0,Analyst: Regeneron Is Undervalued By The Street,2018-02-09 10:46:00-05:00,NVS,neutral
934999.0,The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease,2018-02-08 09:41:00-05:00,NVS,negative
935000.0,U.S. Regulators Delayed Approval of Generic Version of GSK's Advair by Novartis's Sandoz Unit,2018-02-08 04:43:00-05:00,NVS,positive
935001.0,Novartis Receives FDA Approval for Cosentyx Label Update to Include Moderate-to-severe Scalp Psoriasis,2018-02-08 04:10:00-05:00,NVS,positive
935002.0,Array's Melanoma Combo Shows Positive Overall Survival Data,2018-02-07 11:31:00-05:00,NVS,positive
935003.0,Novartis Reports Advanced Accelerator Applications Received US FDA Approval Of NDA For Lutathera For Treatment Of Somatostatin Receptor Positive GEP-NETs,2018-01-26 13:08:00-05:00,NVS,positive
935004.0,"Earnings Scheduled For January 24, 2018",2018-01-24 05:25:00-05:00,NVS,neutral
935005.0,"Novartis Incoming CEO Sees No Change to Co's Position on GSK JV, Roche Stake -Reuters",2018-01-24 05:10:00-05:00,NVS,negative
935006.0,Pharma M&A Picks Up Momentum,2018-01-23 13:56:00-05:00,NVS,neutral
935007.0,Teva's Asthma Therapy Reslizumab Fails In Late-Stage Studies,2018-01-23 10:59:00-05:00,NVS,negative
935008.0,Novartis completes tender offer for Advanced Accelerator Applications,2018-01-22 04:11:00-05:00,NVS,positive
935009.0,Novartis Granted FDA Priority Review for Kymriah for Adults with r/r DLBCL,2018-01-17 04:29:00-05:00,NVS,positive
935010.0,Novartis Reprots Sandoz Regulatory Submission for Proposed Biosimilar Adalimumab Accepted by FDA,2018-01-16 04:17:00-05:00,NVS,positive
935011.0,Novartis Announces New Data Reinforces Superiority of Cosentyx vs Stelara in Achieving Skin Clearance for Psoriasis Patients,2018-01-16 03:58:00-05:00,NVS,positive
935012.0,Novartis Kisqali Received FDA Breakthrough Therapy Designation for Initial Endocrine-Based Treatment in Premenopausal Women With HR+/HER2- Advanced Breast Cancer,2018-01-03 04:45:00-05:00,NVS,negative
935013.0,Attention Biotech Investors: Brace For These January PDUFA Events,2017-12-30 10:19:00-05:00,NVS,neutral
935014.0,Novartis's TASIGNA Approved By FDA,2017-12-22 16:46:00-05:00,NVS,positive
935015.0,Novartis' Tasigna Label is Updated to Include How to Stop Treatment,2017-12-22 15:45:00-05:00,NVS,negative
935016.0,The Companies That Led 2017's Biotech Rally,2017-12-22 09:50:00-05:00,NVS,neutral
935017.0,3 Biotech Pipeline Areas To Keep An Eye On In 2018,2017-12-20 12:37:00-05:00,NVS,neutral
935018.0,Ultragenyx Sells Priority Review Voucher To Novartis for $130M,2017-12-18 08:31:00-05:00,NVS,neutral
935019.0,"ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More",2017-12-13 12:31:00-05:00,NVS,neutral
935020.0,"Novartis Says Is Optimizing Its US Portfolio, Including Sale Or Closure Of Non-Core Products, Refers To Sandoz Generics Unit",2017-12-13 09:31:00-05:00,NVS,positive
935021.0,Omeros' OMIDRIA Eye Drop OK'ed For Pediatric Use,2017-12-12 10:12:00-05:00,NVS,negative
935022.0,Novartis' Crizanlizumab Shows Prolonging Of Time To Patients' First Sickle Cell Pain Crisis In Subgroup Analysis Of SUSTAIN Study,2017-12-11 10:52:00-05:00,NVS,negative
935023.0,Novartis Says Kisqali Benefited For Longer Time Until Health-Related QOL Deterioration Vs Those Taking Endocrine Therapy Alon,2017-12-06 13:26:00-05:00,NVS,neutral
935024.0,Reuters Reporting ACCC Institured Proceedings Against GlaxoSmithKline and Novartis Consumer Health In Australia,2017-12-05 17:33:00-05:00,NVS,neutral
935025.0,Advanced Accelerator Application Recommends the $82/ADS Takeover by Novartis,2017-12-05 16:01:00-05:00,NVS,positive
935026.0,Advanced Accelerator Applications Board of Directors Recommends $3.B All Cash Tender Offer by Novartis,2017-12-05 16:01:00-05:00,NVS,positive
935027.0,Medigene Sells U.S. Rights For Veregen To Novartis Group's Fougera Pharmaceuticals,2017-12-05 10:35:00-05:00,NVS,neutral
935028.0,Novartis Canada Announces Rydapt has Been Approved Following Priority Review by Health Canada​,2017-12-05 06:03:00-05:00,NVS,positive
935029.0,Eli Lilly's Taltz Gets Approval For Label Expansion in US,2017-12-04 12:39:00-05:00,NVS,positive
935030.0,"Citi Downgrades Regeneron, Citing 'Underappreciated' Risk",2017-12-01 09:57:00-05:00,NVS,negative
935031.0,Novartis Highlights Phase 3 STRIVE Data Showing 'significant and sustained efficacy of erenumab in migraine prevention' Will Be Published In NEJM,2017-11-29 17:03:00-05:00,NVS,positive
935032.0,Novartis' Ultibro Breezhaler Significantly Improved COPD Patients' Lung Function after Direct Switch from Seretide,2017-11-27 04:20:00-05:00,NVS,positive
935033.0,Novartis Announces Positive Results from Phase III Trial of Kisqali Combination Therapy in Premenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer,2017-11-08 04:20:00-05:00,NVS,positive
935034.0,9 Notable Biotechs Presenting At This Year's ASH Meeting,2017-11-06 16:31:00-05:00,NVS,neutral
935035.0,"Pharma Stock Roundup: Pfizer, Teva, Novartis, And More",2017-11-06 12:19:00-05:00,NVS,neutral
935036.0,Reuters Reports Novartis Could Receive $1.5B from Sale of Dermatology Portfolio; Hires Centerview as Advisor,2017-11-02 15:41:00-04:00,NVS,neutral
935037.0,"Wall Street's M&A Chatter From November 1: Dunkin Brands, Novartis, Owens & Minor-Halyard Health",2017-11-02 07:43:00-04:00,NVS,neutral
935038.0,Novartis Buys French Radiopharmaceutical Company,2017-11-01 12:50:00-04:00,NVS,neutral
935039.0,Novartis Considering Sale Of Its Dermatology Generics Unit,2017-11-01 06:09:00-04:00,NVS,neutral
935040.0,Novartis Submits Application to FDA for Kymriah in Adult Patients with r/r DLBCL,2017-10-31 04:09:00-04:00,NVS,neutral
935041.0,"Jim Cramer Shares His Thoughts On CSX Corporation, Baozun And More",2017-10-30 08:41:00-04:00,NVS,positive
935042.0,"Novartis to Acquire Advanced Accelerator Applications for $41/Share, $82/ADS",2017-10-30 04:09:00-04:00,NVS,positive
935043.0,"Novartis Reports PARADIGMS Data show Children, Adolescents with MS had 82% Lower Relapse Rate with Gilenya vs interferon beta-1a",2017-10-28 16:43:00-04:00,NVS,negative
935044.0,"Novartis/Sandoz Proposed Biosimilar to Neulasta, Pegfilgrastim, Accepted by EMA for Regulatory Review",2017-10-27 04:32:00-04:00,NVS,positive
935045.0,"Benzinga's Top Upgrades, Downgrades For October 25, 2017",2017-10-25 09:12:00-04:00,NVS,positive
935046.0,Barclays Downgrades Novartis AG Common Stock to Underweight,2017-10-25 07:42:00-04:00,NVS,neutral
935047.0,"Earnings Scheduled For October 24, 2017",2017-10-24 04:09:00-04:00,NVS,neutral
935048.0,8 Firms To Debut On The Markets This Week,2017-10-23 08:55:00-04:00,NVS,neutral
935049.0,Novartis Combination Adjuvant Therapy Tafinlar + Mekinist Receives FDA Breakthrough Therapy Designation for Stage III BRAF V600 Mutation-positive Melanoma Patients,2017-10-23 04:06:00-04:00,NVS,neutral
935050.0,"Gilead's Yescarta Cancer Treatment Approved, Some Analysts Shrug",2017-10-19 12:22:00-04:00,NVS,negative
935051.0,What's In The Cards For Novartis This Earnings Season?,2017-10-18 12:12:00-04:00,NVS,neutral
935052.0,Novartis Decides Not Sell 33% Roche Stake -HandelsZeitung,2017-10-11 12:52:00-04:00,NVS,neutral
935053.0,5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings,2017-10-10 12:52:00-04:00,NVS,positive
935054.0,Novartis Announces Alcon Receives CE Mark for First-of-its-kind AutonoMe Reloaded Intraocular Lens Delivery System with Clareon IOL,2017-10-06 04:32:00-04:00,NVS,neutral
935055.0,Novartis Shares Unaffected Following Report Argentum Pharma Has Said It Succeeded In Starting Patent Cancellation Trial Against Co.'s Afinitor,2017-09-29 13:48:00-04:00,NVS,positive
935056.0,This Analyst Predicts Bullish Growth Outlook For Incyte,2017-09-12 09:28:00-04:00,NVS,positive
935057.0,Novartis' Sandoz Division Announces FDA Accepted BLA for Proposed Biosimilar Rituximab,2017-09-12 05:40:00-04:00,NVS,positive
935058.0,Novartis Announces Phase III Study Found Adjuvant Tafinlar + Mekinist Reduced Risk of Disease Recurrence by 53% in patients with Resected BRAF V600 Mutation-positive Melanoma,2017-09-10 18:43:00-04:00,NVS,negative
935059.0,What Pharmaceuticals Spend On Lobbying To Influence Trump,2017-09-09 16:28:00-04:00,NVS,negative
935060.0,Novartis Reports 6.6% Passive Stake in Xoma in 13G,2017-09-05 17:24:00-04:00,NVS,positive
935061.0,Novartis Lower Despite FDA Approval For Treatment Of Leukemia,2017-08-30 12:29:00-04:00,NVS,negative
935062.0,Novartis Reportedly Sets U.S. Price For KYMRIAH Gene Therapy At $475K,2017-08-30 12:24:00-04:00,NVS,neutral
935063.0,FDA Issues Release Highlighting Approval Of Novartis' Kymriah For Form Of ALL,2017-08-30 11:37:00-04:00,NVS,positive
935064.0,"Novartis Shares Spike Higher Off Session Lows Following Circulation Of FDA.gov Approval For CAR T-Cell Therapy To Treat Certain Children, Young Adults With B-Cell Acute Lymphoblastic Leukemia",2017-08-30 10:57:00-04:00,NVS,positive
935065.0,GlaxoSmithKline Recent Pullback Delivers A Healthy Opportunity To Buy,2017-08-30 09:55:00-04:00,NVS,positive
935066.0,Adam Feuerstein Tweets: $GILD should be more worried about $NVS undercutting CAR-T pricing than any NIH-loving ninny.,2017-08-28 13:23:00-04:00,NVS,negative
935067.0,Novartis Annpunces Phase III CANTOS Study Shows Targeting Inflammation with ACZ885 Reduces Cardiovascular Risk,2017-08-28 06:15:00-04:00,NVS,negative
935068.0,Novartis Announces Lancet Report Shows ACZ885 Reduced Lung Cancer Mortality by 77% in CANTOS Study,2017-08-27 08:46:00-04:00,NVS,negative
935069.0,U.S. Files Claims Lawsuit Against U.S. Bioservices Over Kickback Relationship With Novartis Which Previously Settled Related Case,2017-08-22 09:32:00-04:00,NVS,negative
935070.0,"Novartis, Medicines for Malaria Venture Launch Patient Trial in Africa for KAF156 in Multidrug-resistant Malaria",2017-08-21 04:03:00-04:00,NVS,neutral
935071.0,"Lightning Round: Jim Cramer Weighs In On Juno Therapeutics, Halliburton And More",2017-08-18 07:54:00-04:00,NVS,neutral
935072.0,"Democrats On House Committe On Oversight & Govt. Reform Say Launching Into MS Drug Pricing, Committee Send Letters To Biogen, Teva, Sanofi, Roche, Novartis, And Bayer",2017-08-17 11:17:00-04:00,NVS,neutral
935073.0,"Wall Street's M&A Chatter From August 4-7: Acadia Pharma, United Technologies-Rockwell Collins, United Therapeutics",2017-08-07 07:19:00-04:00,NVS,positive
935074.0,"United Therapeutics Shares Up 7.7% On M&A Chatter; GSK, Gilead, Novartis Said To Be Possibly Considering Deal For Co.",2017-08-04 09:40:00-04:00,NVS,positive
935075.0,"UK Evening Standard Reports GSK, Gilead, Novartis Could Pay Up to $200/Share for United Therapeutics",2017-08-04 08:00:00-04:00,NVS,positive
935076.0,"Reduced Risk, Upcoming Pipeline Inspire Bull Case For Novartis",2017-07-26 15:52:00-04:00,NVS,positive
935077.0,"Benzinga's Top Upgrades, Downgrades For July 26, 2017",2017-07-26 09:25:00-04:00,NVS,positive
935078.0,Morgan Stanley Upgrades Novartis AG Common Stock to Overweight,2017-07-26 07:47:00-04:00,NVS,negative
935079.0,Cryoport Announces a 3 Year Contract with Novartis for Logistics Support,2017-07-25 07:17:00-04:00,NVS,positive
935080.0,"Novartis Reports Received CHMP Opinion For Rydapt For Newly-Diagnosed FLT3-Mutated Acute Myeloid Leukemia, 3 Types Of Advanced Systemic Mastocytosis",2017-07-21 07:35:00-04:00,NVS,positive
935081.0,Watching Novartis Shares As FDA Accepted BLA For AMG-334,2017-07-20 16:49:00-04:00,NVS,positive
935082.0,Amgen Reports FDA Accepts Biologics License Application For Aimovig,2017-07-20 16:30:00-04:00,NVS,positive
935083.0,"Hearing Novartis CEO Joseph Jimenez Said Does Not Know Timing Of Trump Admin.'s Action On Outcomes-Based Pricing Model, Sees Proposal 'This Summer'",2017-07-18 09:16:00-04:00,NVS,neutral
935084.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-07-18 08:08:00-04:00,NVS,neutral
935085.0,"Earnings Scheduled For July 18, 2017",2017-07-18 04:29:00-04:00,NVS,neutral
935086.0,4 Sell-Ranked Drug Stocks To Avoid Ahead Of Q2 Earnings,2017-07-17 14:21:00-04:00,NVS,negative
935087.0,Prima BioMed Announces Second Milestone Payment for IMP701 Program; Payment Amount from Novartis Not Disclosed,2017-07-16 21:10:00-04:00,NVS,neutral
935088.0,Novartis Confirms 5-Year data For CoSentyx,2017-07-14 15:52:00-04:00,NVS,neutral
935089.0,"Novartis Shares Spike to $84 High Following Panel Approval, Now Relatively Unaffected; Shares Of Bristol Myers Fell 1.8%",2017-07-12 15:34:00-04:00,NVS,positive
935090.0,FDA Advisory Panel Backs Approval Of Novartis' Pioneering Gene Therapy,2017-07-12 15:25:00-04:00,NVS,positive
935091.0,Adam Feuerstein Tweets: The $NVS CTL019 PDUFA date is Oct. 3. Did we know this? I thought $NVS was always cagey about exact date. It's in briefing document.,2017-07-11 14:22:00-04:00,NVS,neutral
935092.0,Novartis Gene Therapy Leukemia Drug Raises Concern To FDA Staff In Review Over Potential To Cause New Malignancies,2017-07-10 08:07:00-04:00,NVS,neutral
935093.0,"Adam Feuerstein Tweets: FDA on $NVS CAR-T: ""The overall effectiveness of this product is not the primary issue forconsideration by this Committee.",2017-07-10 08:02:00-04:00,NVS,neutral
935094.0,"Adam Feuerstein Tweets: FDA discussion points for $NVS CAR-T adcomm center on manufacturing, safety, risk mitigation. One voting question — benefit-risk.",2017-07-10 08:01:00-04:00,NVS,positive
935095.0,Adam Feuerstein Tweets: $NVS — CAR-T briefing documents posted —> fda.gov/AdvisoryCommit…,2017-07-10 07:58:00-04:00,NVS,neutral
935096.0,"Benzinga's Top Upgrades, Downgrades For July 5, 2017",2017-07-05 09:25:00-04:00,NVS,positive
935097.0,The Market In 5 Minutes,2017-07-05 09:00:00-04:00,NVS,neutral
935098.0,Credit Suisse Downgrades Novartis AG Common Stock to Underperform,2017-07-05 06:39:00-04:00,NVS,positive
935100.0,Adam Feuerstein Tweets: '$NVS 'A huge win for biology': Trial shows anti-inflammatory drugs may reduce heart disease',2017-06-27 15:13:00-04:00,NVS,positive
935103.0,Attention To Details: Neos' ADHD Portfolio,2017-06-26 09:05:00-04:00,NVS,neutral
935108.0,How Altimmune Is Trying To Get Ahead Of A Potentially Fatal 'Flu Pandemic',2017-06-23 08:15:00-04:00,NVS,negative
935110.0,Novartis Kisqali Receives Positive CHMP Opinion as First-Line Treatment for HR+/HER2- Locally Advanced or Metastatic Breast Cancer in Combination With Any Aromatase Inhibitor,2017-06-23 04:45:00-04:00,NVS,neutral
935111.0,FDA Approves Novartis Combination Therapy Tafinlar And Mekinist For BRAF V600E Mutant Metastatic Non-small Cell Lung Cancer,2017-06-22 17:44:00-04:00,NVS,negative
935113.0,Regeneron Provides Deal Details On Royalty Agreement With Novartis For ACZ885,2017-06-22 09:01:00-04:00,NVS,positive
935114.0,Novartis Phase III Study Shows ACZ885  Reduces Cardiovascular Risk in People who Survived Heart Attack,2017-06-22 06:27:00-04:00,NVS,negative
935117.0,Novartis +1.4% Premarket @$82.59; Co Said  RTH258 Achieved Primary Efficacy Endpoint of of Non-inferiority to Aflibercept,2017-06-20 06:55:00-04:00,NVS,neutral
935122.0,Hearing FDA Has Accepted Sandoz's Regulatory Submission Related To Generic Version Of Advair Diskus,2017-06-15 14:04:00-04:00,NVS,positive
935124.0,Pegfilgrastim To Help Chemotherapy Patients Fails To Clear Regulatory Hurdle; Coherus Receives CRL,2017-06-12 10:08:00-04:00,NVS,positive
935127.0,The Only Bullish Scenario For Juno Therapeutics: Its CEO May Get Fired,2017-06-08 10:05:00-04:00,NVS,negative
935128.0,Key Reasons BTIG Just Upgraded Kite Pharma,2017-06-08 09:20:00-04:00,NVS,neutral
935129.0,"Novartis Exec Says Latest Data For CTL019 Similar To Results From Rivals' Blood Cancer Trials, Showed Overall Response Rate At 3 Months In Adults Was 45%, 37% Complete Responses",2017-06-07 12:02:00-04:00,NVS,negative
935131.0,Adam Feuerstein Tweets: Full response from $NVS spox on CTL019 manufacturing in JULIET trial. $KITE,2017-06-07 10:51:00-04:00,NVS,neutral
935132.0,"Kite Pharma Shares Dip Lower Over Last Few Mins, Pullback from Session High As Traders Circulating Word Novartis Has Said Co.'s Manufacturing Improved To 97% In The Last 30 Patients",2017-06-07 10:41:00-04:00,NVS,positive
935133.0,Novartis Says FDA Panel Meeting for CTL019 CAR-T Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia Set for Jul. 12,2017-06-06 10:23:00-04:00,NVS,neutral
935134.0,Novartis Announces Study of Tafinla + Mekinis Demonstrates Durable Survival BenefitaAt Five Years in Patients With Braf Mutation-Positive Metastatic Melanoma #ASCO17,2017-06-04 09:15:00-04:00,NVS,neutral
935135.0,"Jim Cramer Gives His Opinion On Exxon Mobil, Allegiant Travel Company And Novartis AG",2017-06-02 08:33:00-04:00,NVS,neutral
935136.0,"Novartis Presents Updated Data That Reinforce Efficacy, Safety of Kisqal + Letrozole as First-Line Option for HR+/HER2- Advanced or Metastatic Breast Cancer",2017-06-02 04:49:00-04:00,NVS,negative
935137.0,From Novartis Investor Event: CEO Jimenez Says There's Been No Change to Plans for Roche Stake,2017-05-31 08:54:00-04:00,NVS,negative
935138.0,From Novartis Investor Event: CEO Joseph Jimenez Says Sees Trump Suggesting Proposals on Addressing Drug Prices Within 3 Months,2017-05-31 08:44:00-04:00,NVS,neutral
935139.0,Monday's Market In 5 Minutes,2017-05-30 08:31:00-04:00,NVS,neutral
935140.0,"5 Stocks To Watch For May 30, 2017",2017-05-30 05:44:00-04:00,NVS,neutral
935141.0,Novartis Receives FDA Approval For Expanded Use Of Zykadia In Metastatic NSCLC,2017-05-26 15:48:00-04:00,NVS,positive
935142.0,Novartis Reports Received FDA Approval for Expanded Use of Zykadia,2017-05-26 15:33:00-04:00,NVS,positive
935143.0,The Current State Of The Breast Cancer Treatment Space,2017-05-23 08:59:00-04:00,NVS,negative
935144.0,Novartis Reports Received CHMP Opinion for Zykadia in ALK-Positive Advanced NSCLC,2017-05-19 07:49:00-04:00,NVS,positive
935145.0,A Smart Idea Among Europe ETFs,2017-05-16 08:49:00-04:00,NVS,positive
935146.0,GlaxoSmithKline to Acquire Novartis's 36.5% stake in GSK Consumer Healthcare -UK Sunday Times,2017-05-15 04:03:00-04:00,NVS,neutral
935147.0,"Novartis Reports Received FDA Approval for Kisqali Femara Co-Pack for Initial Treatment of HR+/HER2- Advanced, Metastatic Breast Cancer",2017-05-08 16:54:00-04:00,NVS,negative
935148.0,"Analyst: Kite Pharma's CAR-T Patient Death, Stock Selloff Is A Buying Opportunity",2017-05-08 11:31:00-04:00,NVS,negative
935149.0,"DURECT to get $20M Payment from a Division of Novartis, Up to $43M of Development Milestones, Up to $230M of Sales Milesones",2017-05-08 07:29:00-04:00,NVS,neutral
935150.0,"Barron's Picks And Pans: Amazon, Novartis, Tesla And More",2017-05-07 14:06:00-04:00,NVS,positive
935151.0,Novartis Exercises Exclusive Option Agreement with Conatus for Treatment of NASH,2017-05-04 04:16:00-04:00,NVS,positive
935152.0,Celyad Grants to Novartis a Non-Exclusive License for Its Allogeneic TCR-Deficient CAR-T Cells Patents; Celyad to Receive Payments of Up to $96M,2017-05-02 04:33:00-04:00,NVS,positive
935153.0,"Weed Vs. Opioids: Nontraditional And Traditional Biotech Take On Wall Street, But Who's Winning?",2017-04-30 12:38:00-04:00,NVS,positive
935154.0,Novartis Receives FDA Approval For Rydapt In AML And 3 Types of Systemic Mastocytosis,2017-04-28 11:55:00-04:00,NVS,positive
935155.0,Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates,2017-04-25 13:44:00-04:00,NVS,positive
935156.0,Novartis Shares Up 2+% Premarket as Hearing Report Co. Has Pushed Its M&A Efforts Toward Early-Stage Drugs,2017-04-25 08:43:00-04:00,NVS,positive
935157.0,"Earnings Scheduled For April 25, 2017",2017-04-25 05:03:00-04:00,NVS,neutral
935158.0,Amgen Reports Expanded Commercial Collaboration with Novartis for Erenumab in Migraine,2017-04-24 16:30:00-04:00,NVS,neutral
935159.0,What Would A $5.8 Billion NIH Cut Look Like? Devastation,2017-04-20 13:38:00-04:00,NVS,negative
935160.0,"Parvus Therapeutics Reports Exclusive Global License, Collab Deal with Novartis for Development, Commercialization of Lead Nanomedicine to Treat Type 1 Diabetes",2017-04-19 08:11:00-04:00,NVS,positive
935161.0,"Allergan, Novartis Enter Phase 2b Clinical Trial to Evaluate Use of Allergan's Cenicriviroc, Novartis Lead FXR Agonist to Treat NASH",2017-04-18 04:03:00-04:00,NVS,positive
935162.0,"Cowen Downgrades Novartis, Strengths 'Now Balance Its Risks'",2017-04-05 12:36:00-04:00,NVS,positive
935163.0,TheStreet's Adam Feuerstein Tweets '$NVS Keeps 'JULIET' Study Results Close as Investors and Rival $KITE',2017-04-05 12:24:00-04:00,NVS,neutral
935164.0,5 Biggest Price Target Changes For Wednesday,2017-04-05 09:48:00-04:00,NVS,neutral
935165.0,"Benzinga's Top Upgrades, Downgrades For April 5, 2017",2017-04-05 09:27:00-04:00,NVS,positive
935166.0,The Market In 5 Minutes,2017-04-05 09:15:00-04:00,NVS,neutral
935167.0,"Cowen & Co. Downgrades Novartis AG To Market Perform, Lowers Price Target To $77",2017-04-05 07:12:00-04:00,NVS,negative
935168.0,"Forbes Reporter Matthew Herper Tweets: $NVS spox: ""We are track with our regulatory filings and we will present the data from JULIET at an upcoming medical meeting."" $KITE",2017-04-03 14:01:00-04:00,NVS,neutral
935169.0,Novartis Drug Combination Tafinlar + Mekinist Receives EU Approval for BRAF V600-positive Advanced NSCLC,2017-04-03 05:59:00-04:00,NVS,positive
935170.0,Galectin Shares Upgraded To Buy; NASH-CX Results In December A 'Major Stock Catalyst',2017-03-30 08:46:00-04:00,NVS,positive
935171.0,Novartis Announces First CAR-T Cell Therapy BLA for Pediatric and Young Adult Patients with R/R B-cell ALL Granted FDA Priority Review,2017-03-29 16:46:00-04:00,NVS,positive
935172.0,UPDATE: Cerulean To Sell Dynamic Tumor Targeting Platform To Novartis For $6M,2017-03-20 08:02:00-04:00,NVS,neutral
935173.0,New Analysis Dhows Novartis' Entresto Improves Glycemic Control in Reduced Ejection Fraction Heart Failure Patients with Diabetes,2017-03-18 15:23:00-04:00,NVS,negative
935174.0,Gilead Looking To Buy Incyte? It Makes Sense,2017-03-14 10:55:00-04:00,NVS,neutral
935175.0,Novartis Kisqali Receives FDA Approval As First-Line Treatment For HR+/HER2 Metastic Breast Cancer,2017-03-13 15:10:00-04:00,NVS,negative
935176.0,How The Ultra-Wealthy Are Helping Advance Health And Life Sciences,2017-03-10 15:58:00-05:00,NVS,positive
935177.0,RBC Hints At Potential M&A For Kite Pharma,2017-03-06 13:10:00-05:00,NVS,neutral
935178.0,"Novartis Division Sandoz Announces Proposed Biosimilar Adalimumab Shown to have Equivalent Efficacy, Similar Safety Profile as Humira",2017-03-06 04:09:00-05:00,NVS,positive
935179.0,"Synergy's Safety Profile Should Boost Trulance Uptake, Takeover Prospects Remain Favorable",2017-03-02 14:53:00-05:00,NVS,positive
935180.0,Carl Icahn's Track Record In Big Pharma,2017-02-24 09:40:00-05:00,NVS,neutral
935181.0,Breaking Down The Multiple Sclerosis 2017 Formularies: 'Stability Fares Well For The Market',2017-02-23 14:06:00-05:00,NVS,positive
935182.0,Novartis' Zykadia Gets FDA Priority Review for First-line Use in Patients with ALK+ Metastatic NSCLC,2017-02-23 04:33:00-05:00,NVS,neutral
935183.0,Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?,2017-02-21 16:48:00-05:00,NVS,neutral
935184.0,"Ionis, Akcea Close on Strategic Collaboration with Novartis to Develop and Commercialize AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx, WIll Pay $75M Uo-Front Payment",2017-02-16 07:09:00-05:00,NVS,negative
935185.0,Deutsche Bank Casts Doubt On Pfizer's Rumored Takeover Approach To Bristol-Myers,2017-02-15 14:26:00-05:00,NVS,negative
935186.0,A District Court's Ruling Against Teva Pharma Opens The Door For Generics,2017-01-31 14:51:00-05:00,NVS,neutral
935187.0,"President Trump Doubles Down On Healthcare Criticism, Says Drug Prices Are 'Astronomical'",2017-01-31 10:57:00-05:00,NVS,negative
935188.0,What We Learned From The Last Avian Flu Outbreak,2017-01-28 14:39:00-05:00,NVS,negative
935189.0,A CEO Who's Who Of Trump's Manufacturing Council,2017-01-27 16:36:00-05:00,NVS,neutral
935190.0,"Novartis Under Investigation By DoJ, SEC Over Greece Payments",2017-01-25 10:59:00-05:00,NVS,neutral
935191.0,Q4 2016 Real-Time Call Brief,2017-01-25 10:50:00-05:00,NVS,neutral
935192.0,"Novartis Says Elevates Cart Therapy CTL019 TO Group Of Drugs It Expects Will Be Blockbuster, With At Least $1B in Sales",2017-01-25 08:42:00-05:00,NVS,positive
935193.0,Novartis Says Initiating Share Buyback of Up to $5B in 2017 Under Existing Shareholder Authority,2017-01-25 06:25:00-05:00,NVS,positive
935194.0,Novartis CEO Says Review of Options for Alcon Could Lead to IPO,2017-01-25 06:23:00-05:00,NVS,neutral
935195.0,"Earnings Scheduled For January 25, 2017",2017-01-25 04:42:00-05:00,NVS,neutral
935196.0,Health Canada Wants Warning Stickers on Prescription Painkillers -Reuters,2017-01-23 04:26:00-05:00,NVS,negative
935197.0,"Hearing Supreme Court Will Agree to Hear Dispute Between Novartis, Amgen Related to Biosimilar Drugs",2017-01-13 14:32:00-05:00,NVS,positive
935198.0,Short Interest In Conatus Pharmaceuticals Surges,2017-01-13 06:45:00-05:00,NVS,positive
935199.0,Credit Suisse Downgrades Novartis AG Common Stock to Neutral,2017-01-11 06:32:00-05:00,NVS,positive
935200.0,The Fentanyl Abuse Epidemic,2017-01-10 07:02:00-05:00,NVS,negative
935201.0,"Novartis CEO At JPM Healthcare Conf. Says Company's Pipeline Is Underappreciated, Too Much Focus Has Been On Alcon",2017-01-09 11:52:00-05:00,NVS,neutral
935202.0,The Year's Biggest Healthcare Conference Commences This Week; Here's What You Need To Know,2017-01-09 06:33:00-05:00,NVS,neutral
935203.0,15 Biggest Mid-Day Gainers For Friday,2017-01-06 12:51:00-05:00,NVS,neutral
935204.0,18 Stocks Moving In Friday's Pre-Market Session,2017-01-06 08:25:00-05:00,NVS,neutral
935205.0,Ionis Pharmaceuticals +5.8% Premarket @$49.85; Co Announced Licensing Deal With Novartis,2017-01-06 06:23:00-05:00,NVS,neutral
935206.0,"UPDATE: Ionis, Akcea are Eligible to Receive $225M in Near-term Payments, Including Immediate $75M Up-front Option Payment, $100M Equity Investment Which Equates to 1,631,435 Shares at $61.30/Share",2017-01-06 04:32:00-05:00,NVS,positive
935207.0,"Ionis, Akcea Enter into Strategic Collaboration with Novartis Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx",2017-01-06 04:25:00-05:00,NVS,neutral
935208.0,Novartis Shares Turn Negative as Hearing JP Morgan Issued Mid-Day Downgrade to Neutral,2017-01-03 11:48:00-05:00,NVS,neutral
935209.0,Barron's Best Income Ideas For 2017,2017-01-02 17:26:00-05:00,NVS,positive
935210.0,Wall Street's M&A Chatter From December 28,2016-12-29 07:04:00-05:00,NVS,neutral
935211.0,Intercept Shares Higher After It Requests To Keep Piece Of Q3 Info Secret Until 2020,2016-12-28 12:50:00-05:00,NVS,positive
935212.0,6 Worst Biotech Stocks Of 2016,2016-12-23 11:50:00-05:00,NVS,negative
935213.0,Novartis To File Annulment Action In Colombia Challenging Ministry Of health Decision To Enforce A Declaration Of Public Interest On Cancer Medicine Glivec,2016-12-21 10:47:00-05:00,NVS,negative
935214.0,Mid-Afternoon Market Update: Worthington Drops On Earnings Miss; Fred's Shares Spike Higher,2016-12-20 14:34:00-05:00,NVS,positive
935215.0,15 Biggest Mid-Day Gainers For Tuesday,2016-12-20 12:43:00-05:00,NVS,neutral
935216.0,Mid-Day Market Update: Conatus Jumps Following Announcement of Licensing Deal With Novartis; Sucampo Shares Slide,2016-12-20 12:04:00-05:00,NVS,positive
935217.0,Mid-Morning Market Update: Markets Open Higher; BlackBerry Earnings Beat Views,2016-12-20 09:50:00-05:00,NVS,neutral
935218.0,18 Stocks Moving In Tuesday's Pre-Market Session,2016-12-20 08:32:00-05:00,NVS,neutral
935219.0,Novartis to Acquire Encore Vision; Terms Not Disclosed,2016-12-20 05:43:00-05:00,NVS,positive
935220.0,Conatus Shares Rise as High as $5.90 After-Hours Following Announcement of Licensing Deal with Licensing Deal With Novartis,2016-12-19 17:10:00-05:00,NVS,positive
935221.0,Jefferies' 2017 Global Pharma Outlook,2016-12-19 10:56:00-05:00,NVS,neutral
935222.0,Novartis AG Receives Positive CHMP For Ilaris To Treat Rare Disease In Adults & Children Called Periodic Fever Syndromes,2016-12-16 07:28:00-05:00,NVS,positive
935223.0,"Novartis, Biomarin, Alexion Shares All Moving Higher On AstraZeneca Halt",2016-12-09 09:57:00-05:00,NVS,positive
935224.0,What If Trump Keeps Badmouthing Drug Pricing?,2016-12-07 13:38:00-05:00,NVS,neutral
935225.0,8 Of The Biggest Biotech Announcements Out Of The 2016 ASH Meeting,2016-12-06 16:09:00-05:00,NVS,neutral
935226.0,Novartis Tells Benzinga On Intereconomia Report It Expressed Takeover Interest In Depomed 'We Don't Comment On Rumors And Speculation',2016-12-06 14:23:00-05:00,NVS,positive
935227.0,Intereconomia Reporting That Novartis Is Interesting In Buying Depomed,2016-12-06 09:47:00-05:00,NVS,positive
935228.0,Novartis To Put Some Older Neuroscience Drugs Up For Sale In Possible $500M Deal,2016-12-06 08:22:00-05:00,NVS,neutral
935229.0,Novartis Announces Zykadia First-line Study Results Showing 16.6 Month Progression-free Survival in Patients with ALK+ Advanced NSCLC,2016-12-06 05:08:00-05:00,NVS,positive
935230.0,Novartis Announces Data Showing SEG101 Significantly Reduces Frequency of Sickle Cell Pain Crises in Phase II Study at ASH 2016,2016-12-03 14:36:00-05:00,NVS,negative
935231.0,"Forbes Healthcare Summit Begins Today, Day 1 Of 2; Presenters Include Novartis, Walgreens",2016-11-30 08:29:00-05:00,NVS,neutral
935232.0,"Martin Shkreli Tweets: $NVS slightly undervalued, no surprise--market is good at arbitraging large cos. Moving to penny stock trash $IMNP. hitbox.tv/martinshkrelil…",2016-11-29 17:46:00-05:00,NVS,positive
935233.0,Eli Lilly's Solanezumab Failure: Alzheimer's Treatment Space Feels Aftershock,2016-11-23 13:22:00-05:00,NVS,negative
935234.0,Stocks Hitting 52-Week Lows,2016-11-22 12:49:00-05:00,NVS,negative
935235.0,"The Market In 5 Minutes: Symantec To Buy LifeLock, New Netflix Buy Rating",2016-11-21 09:09:00-05:00,NVS,neutral
935236.0,A Peek Into The Markets: U.S. Stock Futures Edge Higher; Symantec To Acquire Lifelock,2016-11-21 07:36:00-05:00,NVS,neutral
935237.0,"Novartis Acquires Selexys Pharmaceuticals Corporation for Up to $665M Upfront, Plus Milestone Payments",2016-11-21 04:36:00-05:00,NVS,neutral
935238.0,Novartis Announces New Cosentyx Data Showing Long-lasting Efficacy In Psoriatic Arthritis Over 3 Years Including Patient-reported Pain,2016-11-14 04:41:00-05:00,NVS,negative
935239.0,Novartis Chairman Considering Sale of Alcon - SonntagsZeitung,2016-11-14 04:35:00-05:00,NVS,neutral
935240.0,Novartis Said to Hold Talks to Buy Generics Maker Amneal for as Much as $8B -Bloomberg,2016-11-14 04:25:00-05:00,NVS,neutral
935241.0,Novartis PKC412 Granted FDA Priority Review for Newly-diagnosed FLT3-mutated AML and Advanced Systemic Mastocytosis,2016-11-14 04:21:00-05:00,NVS,positive
935242.0,Novartis Tells Benzinga On Intereconomia Article Suggesting Deal With AstraZeneca 'Novartis Doesn't Comment On Market Rumor Or Speculation',2016-11-11 12:02:00-05:00,NVS,neutral
935243.0,Why The Time Has Come To Buy Novartis,2016-11-10 10:57:00-05:00,NVS,neutral
935244.0,Benzinga's Top Upgrades,2016-11-10 08:54:00-05:00,NVS,positive
935245.0,Argus Research Upgrades Novartis AG Common Stock to Buy,2016-11-10 07:28:00-05:00,NVS,neutral
935246.0,"Pharma Stocks Up Post Election: Ariad 16%, Infinity Up 13%, Allergan, Progenics, Endo 10%, Pfizer, Regeneron 8%, AbbVie 7%, Mylan, Medicines Co. 6%, Perrigo, Merck 5%, Bristol-Myers, Eli Lilly, Sanofi, Novartis 3.5%",2016-11-09 09:41:00-05:00,NVS,neutral
935247.0,Biotech Is Getting A Big Boost Following Clinton's Loss,2016-11-09 08:38:00-05:00,NVS,positive
935248.0,Novartis Bioventures Reports 11.8% Passive Stake in RA Pharmaceuticals in 13G,2016-10-31 16:56:00-04:00,NVS,positive
935249.0,6 Big Pharma Companies Left To Report September Quarterly Figures,2016-10-25 13:45:00-04:00,NVS,neutral
935250.0,Novartis Reports Q3 EPS $1.23 vs $1.19 Est; Revenue $12.126B vs $12.23B Est,2016-10-25 05:05:00-04:00,NVS,neutral
935251.0,"Earnings Scheduled For October 25, 2016",2016-10-25 04:15:00-04:00,NVS,neutral
935252.0,Roche Holding Says Still Expects MS Drug Ocrevus to be Approved in US This Year; Says Expects Aphinity Trial Readout in Q1 2017;  Roche CEO Declines Comment on Novartis Stake in Roche -Reuters,2016-10-20 04:26:00-04:00,NVS,positive
935253.0,Mid-Afternoon Market Update: Imperva Tumbles Amid Sale Concerns; Banc of California Shares Surge,2016-10-19 14:58:00-04:00,NVS,positive
935254.0,15 Biggest  Mid-Day Gainers For Wednesday,2016-10-19 12:26:00-04:00,NVS,neutral
935255.0,Mid-Day Market Update: Crude Oil Up 2.75%; Cerulean Pharma Shares Surge On News Of Novartis Collaboration,2016-10-19 12:02:00-04:00,NVS,negative
935256.0,Cerulean Stock Shoots Higher On News Of Novartis Collaboration,2016-10-19 11:11:00-04:00,NVS,neutral
935257.0,Shares of AstraZeneca Trading Higher Over Past Few Minutes On Rumor Of Potential Roche Acquisition of AstraZeneca,2016-10-17 10:01:00-04:00,NVS,positive
935258.0,Juno Therapeutics Viewed As A Sympathy Play On Kite Pharma's KTE-C19,2016-09-27 09:42:00-04:00,NVS,positive
935259.0,"vTv Therapeutics Shares Initiated With Buy Rating, $13 Target",2016-09-26 11:46:00-04:00,NVS,positive
935260.0,"The Market In 5 Minutes: Oil, Debates And Epidiolex",2016-09-26 09:04:00-04:00,NVS,neutral
935261.0,Can You Guess This Chart?,2016-09-26 07:29:00-04:00,NVS,neutral
935262.0,Glaukos Way Ahead Of The Glaucoma Competition,2016-09-23 13:53:00-04:00,NVS,neutral
935263.0,Novartis Reports Three New FDA Approvals for Expanded Use of Ilaris Treating Rare Periodic Fever Syndrome Conditions,2016-09-23 11:53:00-04:00,NVS,neutral
935264.0,"Hearing Novartis M&A Chatter For Celgene, Unoconfirmed",2016-09-22 10:30:00-04:00,NVS,neutral
935265.0,Novartis A Buy At Chardan,2016-09-20 10:15:00-04:00,NVS,neutral
935266.0,"Chardan Capital Initiates Coverage on Novartis at Buy, Announces $95.00 PT",2016-09-20 03:19:00-04:00,NVS,neutral
935267.0,Novartis Earlier Announced Data Presented at ECTRIMS Showed Benefit of Gilenya on Patient Disability Progression at 10 Years,2016-09-16 08:03:00-04:00,NVS,positive
935268.0,"Reads For The Weed-Kend: Marijuana Roadside Testing, Pregnancy And Depression",2016-09-11 17:09:00-04:00,NVS,negative
935269.0,Gretchen Carlson's $20 Million And Some Of The Biggest Sexual Harassment Payouts Ever,2016-09-06 12:23:00-04:00,NVS,negative
935270.0,"Out With The Old, In With The New: State Agencies Seem To Prefer Marijuana Over Opioids",2016-09-06 10:26:00-04:00,NVS,neutral
935271.0,GenVec Says Novartis Remains Engaged on CGF166 Program,2016-09-01 06:48:00-04:00,NVS,positive
935272.0,BTIG Is 'Generally Skeptical' On Kite Pharma Expectations,2016-08-31 09:17:00-04:00,NVS,negative
935273.0,FDA Approves Novartis Drug Sandoz Erelzi To Treat Multiple Inflammatory Diseases,2016-08-30 16:02:00-04:00,NVS,positive
935274.0,Almost The Whole World In This ETF's Hands,2016-08-29 13:30:00-04:00,NVS,neutral
935275.0,"Waiting For Growth, Or A Better Valuation, Argus Stays Sidelined On Novartis Shares",2016-08-24 15:30:00-04:00,NVS,positive
935276.0,Hearing Handelszeitung Reporting Novartis Preparing Sale of Stake in Roche,2016-08-24 09:18:00-04:00,NVS,neutral
935277.0,Novartis Enters License Agreement With Cyon Therapeutics For LGT-209 Worldwide Rights,2016-08-23 11:01:00-04:00,NVS,positive
935278.0,"Barron's Picks And Pans: Trump Stocks, Hillary Stocks, Safe European Yields And More",2016-08-14 10:12:00-04:00,NVS,positive
935279.0,Canada's Plan To Fight Opioid Addiction Might Hurt Its Weakest Patients,2016-08-08 16:59:00-04:00,NVS,negative
935280.0,Generics Keeping The Pressure On Big Pharma,2016-08-03 17:13:00-04:00,NVS,negative
935281.0,"Watch Potential Buyers of Generic Assets Following Report FTC Will Require Teva to Divest Generic Drugs: Valeant, Mylan, Akorn, Novartis",2016-07-27 14:35:00-04:00,NVS,positive
935282.0,FDA Lifts Clinical Hold On CGF166,2016-07-25 07:59:00-04:00,NVS,neutral
935283.0,GenVec Reports FDA Lifts Clinical Hold On CGF166,2016-07-25 07:30:00-04:00,NVS,neutral
935284.0,"Opioid Addiction: What To Do When A Loved One Is Hooked, According To Science",2016-07-21 08:40:00-04:00,NVS,positive
935285.0,"Earnings Scheduled For July 19, 2016",2016-07-19 04:09:00-04:00,NVS,neutral
935286.0,Hearing FDA Staff Review Has Shown Novartis's Biosimilar is 'Highly' Similar to Amgen's Enbrel,2016-07-11 08:05:00-04:00,NVS,neutral
935287.0,"Novartis Says Health Canada Approves Afinitor Tablets for Progressive, Non-Functional GI and Lung Neuroendocrine Tumors",2016-07-11 06:06:00-04:00,NVS,positive
935288.0,Novartis Reports FDA Approval Of Xolair For Pediatric Asthma Allergy,2016-07-07 16:48:00-04:00,NVS,positive
935289.0,Novartis Announces New Data Show Sandoz Biosimilar Etanercept Candidate has Equivalent Efficacy to Originator Product,2016-07-07 04:55:00-04:00,NVS,neutral
935290.0,Regeneron Is 'One Of The Stronger Growers In Biotech',2016-06-29 15:04:00-04:00,NVS,positive
935291.0,Mid-Afternoon Market Update: Crude Oil Up 2.5%; Xencor Shares Surge Following Deal With Novartis,2016-06-28 14:30:00-04:00,NVS,negative
935292.0,Xencor Up 36% After Deal With Novartis,2016-06-28 13:02:00-04:00,NVS,neutral
935293.0,10 Biggest Mid-Day Gainers For Tuesday,2016-06-28 12:33:00-04:00,NVS,neutral
935294.0,Mid-Day Market Update: Dow Surges 150 Points; Regulus Therapeutics Shares Tumble,2016-06-28 12:15:00-04:00,NVS,positive
935295.0,Benzinga's Volume Movers,2016-06-28 11:12:00-04:00,NVS,neutral
935296.0,Mid-Morning Market Update: Markets Open Higher; Gannett To Acquire ReachLocal,2016-06-28 10:12:00-04:00,NVS,neutral
935297.0,Xencor Announces Strategic Collaboration With Novartis,2016-06-28 04:03:00-04:00,NVS,neutral
935298.0,Jefferies Shares Pharma Stock Catalyst Outlook,2016-06-14 16:33:00-04:00,NVS,positive
935299.0,"Has Cancer Research Become Cancerous? Same Cancer Strategy Targeted By 'Too Many Drugmakers,' Say Regulators",2016-06-13 09:37:00-04:00,NVS,negative
935300.0,Novartis Presents Data Showing Jakavi is Superior to Best Available Therapy in Patients with Less Advanced Polycythemia Vera at EHA,2016-06-10 05:07:00-04:00,NVS,positive
935301.0,Novartis Announces Long-Term Safety Data of Revolade in Adults With Chronic Immune Thrombocytopenia at EHA,2016-06-10 05:05:00-04:00,NVS,positive
935302.0,Bernstein Lists Active Buyers Of Ophthalmology Companies,2016-06-09 14:12:00-04:00,NVS,positive
935303.0,Spectrum Pharmaceuticals Subsidiary Enters into Patent Litigation Settlement Agreement with Sandoz,2016-06-09 06:07:00-04:00,NVS,positive
935304.0,"UPDATE: Amgen Meets Erenumab Phase 2 Primary Endpoint, Erenumab Co-Developed By Novartis",2016-06-08 16:33:00-04:00,NVS,neutral
935305.0,Novartis Reports AMG334 Significant Reduced Patients' Monthly Migraine Days in Phase II Study of CMP,2016-06-08 16:31:00-04:00,NVS,positive
935306.0,4 Key Takeaways From ASCO,2016-06-06 17:32:00-04:00,NVS,neutral
935307.0,Novartis Announces Tafinlar + Mekinist Combo Therapy Showed Overall Survival Benefit at Three Year Follow Up in Patients with Advanced Melanoma,2016-06-06 14:43:00-04:00,NVS,positive
935308.0,UPDATE: Novartis Release Shows Median Duration of Response for BRAF V600E-Mutant NSCLC Patients Treated with Tafinlar + Mekinist Combo Was 9 Mos.,2016-06-06 10:56:00-04:00,NVS,neutral
935309.0,Novartis Offers Pivotal Data for Tafinlar + Mekinist Which Showed 63% Overall Response Rate in Treating Rare Form of Lung Cancer,2016-06-06 10:55:00-04:00,NVS,negative
935310.0,Novartis Announces Data Show 50%+ of Eligible Ph+ CML Patients Maintain Treatment-free Remission after Stopping Tasigna; Data Presented at #ASCO16,2016-06-04 21:38:00-04:00,NVS,negative
935311.0,"Ouch! Jobs Report Miss Sends Rate Hike Odds Down, Raises Questions",2016-06-03 13:49:00-04:00,NVS,negative
935312.0,Novartis Bioventures Ltd. Reports 13.6% Passive Stake in Merus in 13G,2016-06-03 08:04:00-04:00,NVS,positive
935313.0,"Eisai, Novartis Report Deal to Collaborate on Commercial, Medical Affairs Activities for LENVIMA Caps in Combo with Everolimus in US",2016-06-02 16:18:00-04:00,NVS,neutral
935314.0,"Novartis' Afinitor Receives EU Approval to Treat Certain Types of Advanced Gastrointestinal, Lung Neuroendocrine Tumors",2016-06-02 05:19:00-04:00,NVS,positive
935315.0,Novartis' CEO Says Company Open To Selling Its $14 Billion Stake In Roche 'If The Opportunity Were Right',2016-05-25 09:41:00-04:00,NVS,positive
935316.0,Novartis Holds Third Annual Meet Novartis Management Event,2016-05-25 05:23:00-04:00,NVS,neutral
935317.0,"Novartis CEO Says Would Potentially Sell Roche Stake Without a Premium, if Opportunity Were Right -Reuters",2016-05-25 05:21:00-04:00,NVS,negative
935318.0,How Big Pharma Uses Charity Programs To Cover Drug Price Hikes,2016-05-20 15:46:00-04:00,NVS,positive
935319.0,"Novartis Announces The Establishment Of FortiHFy, But What Is It?",2016-05-19 10:04:00-04:00,NVS,neutral
935320.0,Novartis Announces investment in FortiHFy Clinical Program of Entresto and Heart Failure,2016-05-19 05:04:00-04:00,NVS,negative
935321.0,UPDATE: Novartis Says They Expect 'No Big Costs' From Pharma Reorganization,2016-05-17 11:40:00-04:00,NVS,negative
935322.0,"UPDATE: Novartis Announces Novartis Pharmaceuticals, Novartis Oncology Units",2016-05-17 11:35:00-04:00,NVS,neutral
935323.0,"Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology",2016-05-17 11:31:00-04:00,NVS,positive
935324.0,"Benzinga's M&A Chatter for Monday May 16, 2016",2016-05-16 20:09:00-04:00,NVS,neutral
935325.0,Shares of Anacor Spike Higher as Hearing JMP Has Said Expects a Competing $130/Share Bid from Novartis,2016-05-16 14:22:00-04:00,NVS,positive
935326.0,Novartis Announces Major Study Published in NEJM Confirms Ultibro Breezhaler Superiority vs Seretide in Preventing COPD Exacerbations,2016-05-16 05:37:00-04:00,NVS,positive
935327.0,"Teva, Mylan, Novartis Shares Largely Unaffected Following Bloomberg Report Teva's European Unit Has Drawn Interest from Mylan, Novartis",2016-05-13 11:03:00-04:00,NVS,positive
935328.0,"Jefferies Updates Price Targets In Global Pharma, Sees 'Rich Catalyst Environment' Ahead",2016-05-11 13:05:00-04:00,NVS,positive
935329.0,"Benzinga's M&A Chatter for Thursday May 5, 2016",2016-05-05 20:02:00-04:00,NVS,neutral
935330.0,"Benzinga's M&A Chatter for Tuesday May 3, 2016",2016-05-03 18:52:00-04:00,NVS,neutral
935331.0,Benzinga's Weekend M&A Chatter,2016-05-01 20:36:00-04:00,NVS,neutral
935332.0,UPDATE: Novartis Also Said to be Considering Options with Advisors for Potential Medivation Bid,2016-04-29 12:33:00-04:00,NVS,neutral
935333.0,"Pfizer Shares Also Spiked Slightly Higher with Medivation, Novartis Moves",2016-04-29 12:31:00-04:00,NVS,positive
935334.0,Novartis Shares Tick Slightly Higher as Medivation Spikes Sharply Higher,2016-04-29 12:29:00-04:00,NVS,positive
935335.0,Novartis Announces Three FDA Breakthrough Therapy Designations for Ilaris to Treat Rare Types of Periodic Fever Syndromes,2016-04-27 05:42:00-04:00,NVS,positive
935336.0,The Market In 5 Minutes: Sometimes It Snows In April,2016-04-22 10:07:00-04:00,NVS,neutral
935337.0,Benzinga's Top Upgrades,2016-04-22 09:27:00-04:00,NVS,positive
935338.0,"Novartis CEO Says Sees Lack of Urgency Among U.S. Doctors to Switch Patients to Entresto, Says Still Bullish on Heart Drug -Reuters",2016-04-21 06:39:00-04:00,NVS,negative
935339.0,"Earnings Scheduled For April 21, 2016",2016-04-21 04:14:00-04:00,NVS,neutral
935340.0,Hearing Negative Comments On Novartis From A Boutique Firm,2016-04-18 08:00:00-04:00,NVS,negative
935341.0,Morgan Stanley Downgrades Novartis to Underperform,2016-04-12 09:37:00-04:00,NVS,neutral
935342.0,"Switzerland ETF Sort Of Stable, But Currency Is An Issue",2016-04-11 09:11:00-04:00,NVS,positive
935343.0,Ligand Partner Novartis Gets Key E.U. Approval: Roth Capital Likes It,2016-04-07 09:46:00-04:00,NVS,positive
935344.0,"Incyte Acquires Rights To Devlop and Commercialize Ruxolitinib From Lilly, Will Make $35M Upfront Payment As Well As Additional Potential Payments Contingent On Certain Regulatory Milestones; Novartis Granted Right To Develop & Commercialize Ruxolitinib",2016-04-06 07:31:00-04:00,NVS,positive
935345.0,"Argus Initiates Novartis With A Hold, Highlights Underperformance Vs. S&P 500",2016-04-05 08:27:00-04:00,NVS,neutral
935346.0,Stocks Hitting 52-Week Lows,2016-04-01 10:14:00-04:00,NVS,negative
935347.0,"UBS Downgrades Novartis To Neutral, Sees 'No Meaningful Earnings Growth Expected Before '18'",2016-04-01 09:30:00-04:00,NVS,positive
935348.0,"UBS Downgrades Novartis, Says 'no meaningful earnings growth before 2018'",2016-04-01 07:48:00-04:00,NVS,positive
935349.0,UBS Downgrades Novartis to Neutral,2016-04-01 07:45:00-04:00,NVS,neutral
935350.0,"Novartis -2.7% Premarket @$70.49, UBS Downgrade from Buy to Neutral",2016-04-01 05:15:00-04:00,NVS,neutral
935351.0,Office of Ankara's Chief Prosecutor has Launched Investigation into Novartis' Turkish Unit,2016-04-01 05:12:00-04:00,NVS,positive
935352.0,"Novartis Is Under SEC Investigation, Probes Reporter Says",2016-03-31 16:33:00-04:00,NVS,neutral
935353.0,Probes Reporter Tells Benzinga Novartis Has 'Stealth Disclosure' Of SEC Probe,2016-03-31 13:09:00-04:00,NVS,negative
935354.0,Turkish Health Ministry Launches Investigation Into Bribery Allegations Involving Novartis; Co Says Allegations are Unfounded -Reuters,2016-03-31 06:50:00-04:00,NVS,neutral
935355.0,Citi Downgrades Novartis Following SAG Investigation,2016-03-29 10:10:00-04:00,NVS,neutral
935356.0,Citigroup Downgrades Novartis to Neutral,2016-03-29 04:40:00-04:00,NVS,neutral
935357.0,SEC Says Novartis To Pay $1.47M Interest To Settle Bribery Case Without Admitting Or Denying Its Finding-Reuters,2016-03-23 16:12:00-04:00,NVS,positive
935358.0,"Novartis Shares Downgraded, Leerink Says 'Consensus Still Way Too High'",2016-03-23 09:32:00-04:00,NVS,positive
935359.0,Benzinga's Top Downgrades,2016-03-23 09:22:00-04:00,NVS,positive
935360.0,"Leerink Swann Downgrades Novartis to Market Perform, Lowers PT to $85.00",2016-03-23 06:30:00-04:00,NVS,negative
935361.0,Novartis Reports Cosentyx Superior to Stelara in Delivering Long-lasting Skin Clearance for Psoriasis Patients at 52 Weeks,2016-03-05 17:50:00-05:00,NVS,positive
935362.0,"Bernstein Cuts LLY FY 2017 EPS From $4.23 To $4.07, Cuts NVS FY 2017 EPS From $5.21 To %5.17",2016-03-03 07:35:00-05:00,NVS,negative
935363.0,"FDA Approves New Indication for Novartis Drug Afinitor for Progressive, Nonfunctional GI and Lung Neuroendocrine Tumors",2016-02-26 14:46:00-05:00,NVS,positive
935364.0,Report Says Novartis Office in S. Korea Raided Over Bribery Issues,2016-02-22 11:58:00-05:00,NVS,neutral
935365.0,Novartis Reports PKC412 Received Breakthrough Therapy Designation from FDA Related to FLT3-AML,2016-02-19 07:25:00-05:00,NVS,neutral
935366.0,Novartis PKC412 Receives Breakthrough Therapy Designation from FDA for Newly-diagnosed FLT3-mutated AML,2016-02-19 04:31:00-05:00,NVS,positive
935367.0,Novartis Announces Health Canada Has Approved PrJakavi for Polycythemia,2016-02-18 06:05:00-05:00,NVS,positive
935368.0,Earnings Recap For January 27,2016-01-27 17:17:00-05:00,NVS,neutral
935369.0,"Radius Health, Novartis Pharma. Partner To Evaluate RAD1901 Combo In Advanced Breast Cancer Regimens",2016-01-27 16:32:00-05:00,NVS,negative
935370.0,Novartis Reports Q4 EPS 1.14 vs 1.18 Est; Revenue $12.52B vs 12.64B Est,2016-01-27 05:02:00-05:00,NVS,neutral
935371.0,Novartis CEO Sees More Consolidation in Drug Sector in 2016; Says Seeking Bolt-On Assets for Three Divisions -Reuters,2016-01-27 04:54:00-05:00,NVS,positive
935372.0,"Earnings Scheduled For January 27, 2016",2016-01-27 04:05:00-05:00,NVS,neutral
935373.0,Regeneron Is Now A Sell For Chardan,2016-01-25 08:40:00-05:00,NVS,neutral
935374.0,"Bloomberg: GlaxoSmithKline, Qualcomm To Jointly Develop Medical Technology",2016-01-20 13:34:00-05:00,NVS,neutral
935375.0,Hearing FDA Has Approved Novartis' Ofatumumab,2016-01-19 14:53:00-05:00,NVS,positive
935376.0,"On January 8, Novartis Notified Genvec That It Was Pausing Enrollment In The Clinical Trial Of Cgf166 To Conduct A Safety Review Of Patient Data",2016-01-11 08:28:00-05:00,NVS,positive
935377.0,Novartis Announces Collaboration and Licensing Agreement with Surface Oncology,2016-01-11 04:19:00-05:00,NVS,positive
935378.0,A New ETF Avenue To Europe,2015-12-31 09:31:00-05:00,NVS,neutral
935379.0,Watch Stocks of Co.'s with Flu-Related Solutions; Macquarie Note Earlier Highlighted 'Early Flu Results Lagging,2015-12-22 12:06:00-05:00,NVS,negative
935380.0,Novartis Issues Release Highlighting New CTL019 Phase 2 Data Shows 93% Complete Remission in Pediatric Patients with r/r ALL,2015-12-07 15:08:00-05:00,NVS,neutral
935381.0,"Novartis Issues Release Reporting Phase 3 Data Shows Sandoz' Proposed Biosimilar Pegfilgrastim Has Similar Safety, Efficacy as Reference Product",2015-12-07 10:49:00-05:00,NVS,positive
935382.0,Novartis Announces New CTL019 Study Data Demonstrating Overall Response in Adults with Certain Types of Lymphoma at #ASH2015,2015-12-06 08:43:00-05:00,NVS,positive
935383.0,Novartis Announces Phase III Studies of Jakavi Show Disease Improvement in Patients with Myelofibrosis and Polycythemia Vera,2015-12-05 10:18:00-05:00,NVS,positive
935384.0,"Hearing Charterhouse Considering Sale of Doc Generici for ~€600M, PE Suitors Could Be Blackstone, CVC",2015-12-02 09:47:00-05:00,NVS,neutral
935385.0,Seqirus Receives Fda Approval for Fluad Flu Vaccine for Adults Aged 65 Years+,2015-11-25 10:46:00-05:00,NVS,positive
935386.0,"Novartis Announces EC Approvals for Cosentyx to Treat Patients with Ankylosing Spondylitis, Psoriatic Arthritis",2015-11-23 04:12:00-05:00,NVS,positive
935387.0,DOJ Says Novartis Agrees to $370M Settlement in Kickback Case -DJ,2015-11-20 14:45:00-05:00,NVS,positive
935388.0,Hearing Novartis Will Pay $390M to Settle with US Gov't Related to Kickbacks Paid to Specialty Pharmacies,2015-11-20 13:41:00-05:00,NVS,negative
935389.0,Ophthotech Shares Up 7-8% Following Earlier News Roche's Genentech Has Elected to Exercise Right to Opt-In to Novartis Portion of Ophthotech/Novartis Excluding US Deal for Fovista,2015-11-17 10:12:00-05:00,NVS,positive
935390.0,"Novartis Heart Failure Medicine Entresto Substantially Cuts Hospital Re-admissions, New Post-Hoc Analysis Shows",2015-11-10 17:32:00-05:00,NVS,negative
935391.0,Novartis Presents New Two-year Data for Cosentyx Showing No Progression in Joint Damage in 84% of Psoriatic Arthritis Patients,2015-11-07 20:03:00-05:00,NVS,negative
935392.0,Novartis Announces FDA Approval of New Dual Combo Bronchodilator Utibron Neohaler,2015-10-29 16:53:00-04:00,NVS,positive
935393.0,FDA Approves New Novartis Dual Combination Bronchodilator Utibron Neohaler for Patients With Chronic Obstructive Pulmonary Disease,2015-10-29 16:51:00-04:00,NVS,positive
935394.0,"Earnings Scheduled For October 27, 2015",2015-10-27 04:14:00-04:00,NVS,neutral
935395.0,"Novartis Receives Positive CHMP Opinion for First Il-17A Inhibitor Cosentyx to Treat Ankylosing Spondylitis, Psoriatic Arthritis",2015-10-23 07:27:00-04:00,NVS,positive
935396.0,Xoma +11% Premarket Following Announcement of Licensing Deal With Novartis,2015-10-21 07:44:00-04:00,NVS,neutral
935397.0,Credit Suisse: 12 U.S.-Listed European Stocks To Buy Now,2015-10-16 16:26:00-04:00,NVS,positive
935398.0,Elbit Imaging Announces Novartis to Invest $5M in Gamida for ~2.5% Stake,2015-10-12 10:35:00-04:00,NVS,neutral
935399.0,Novartis Division Alcon Receives FDA Approval for AcrySof®IQ Aspheric IOL with UltraSert Pre-loaded Delivery System,2015-10-05 04:14:00-04:00,NVS,positive
935400.0,US Stock Futures Up; All Eyes On Jobs Report,2015-10-02 07:37:00-04:00,NVS,neutral
935401.0,FDA Accepts Novartis/Sandoz Regulatory Submission for Proposed Biosimilar to Enbrel,2015-10-02 04:19:00-04:00,NVS,positive
935402.0,Xoma +86% Premarket After Resumption of Trading,2015-10-01 08:11:00-04:00,NVS,neutral
935403.0,Novartis Announces NEJM Publication Of Secukinumab Phase III Data Confirming Significant Efficacy In Patients With Psoriatic Arthritis,2015-09-30 17:02:00-04:00,NVS,positive
935404.0,Novartis Reports Patients with Aggressive Form of Melanoma Lived Average of Two+ Years When Taking Tafinlar + Mekinist,2015-09-27 18:23:00-04:00,NVS,negative
935405.0,Novartis' Afinito Significantly Improves Progression-Free Survival In Advanced Nonfunctional GI and Lung NET,2015-09-27 06:48:00-04:00,NVS,positive
935406.0,Novartis' New Heart Failure Medicine Entresto Receives CHMP Recommendation for EU Approval,2015-09-25 04:31:00-04:00,NVS,negative
935407.0,"Novartis CEO, Speaking on CNBC, Says Still Looking at Possible Acquisitions, But Assets are Expensive",2015-09-18 05:13:00-04:00,NVS,positive
935408.0,FIPB Approves Proposal from Elanco India to Acquire Novartis' Animal Health Division -Reuters,2015-09-16 06:53:00-04:00,NVS,positive
935409.0,A Portfolio To Support Cancer Treatments In Time For Prostate Cancer Awareness Month,2015-09-08 16:05:00-04:00,NVS,negative
935410.0,US Stock Futures Tumble; Jobs Report In Focus,2015-09-04 07:09:00-04:00,NVS,neutral
935411.0,Novartis Announces EU approval for Farydak,2015-09-04 04:45:00-04:00,NVS,positive
935412.0,Novartis Receives EU Approval for Tafinlar and Mekinist for Patients with Aggressive Form of Melanoma,2015-09-01 04:53:00-04:00,NVS,positive
935413.0,"Swiss Miss: Switzerland Skirts Recession, But ETFs Struggle",2015-08-28 14:32:00-04:00,NVS,negative
935414.0,Novartis Announces FDA Expansion of Uses for Co.'s Promacta to Include Treatment of Children Ages 1+ with Chronic Immune Thrombocytopenia,2015-08-24 12:12:00-04:00,NVS,positive
935415.0,"US Stock Futures Slide Ahead Of Deere, Foot Locker Earnings",2015-08-21 07:06:00-04:00,NVS,neutral
935416.0,"Novartis Acquires Rremaining Rghts to GSK's Ofatumumab to Develop Treatments for MS, Other Autoimmune Indications",2015-08-21 04:34:00-04:00,NVS,neutral
935417.0,Novartis Receives EU Approval for Skin Cancer Treatment Odomzo,2015-08-20 05:50:00-04:00,NVS,negative
935418.0,O'Leary's O'Shares Triples The Size Of Its ETF Stable,2015-08-19 15:22:00-04:00,NVS,positive
935419.0,Morning Market Gainers,2015-08-17 09:45:00-04:00,NVS,neutral
935420.0,Benzinga's Top #PreMarket Gainers,2015-08-17 08:08:00-04:00,NVS,positive
935421.0,UPDATE: AVEO +107% Premarket Following Announcement of Licensing Deal With Novartis,2015-08-17 06:53:00-04:00,NVS,neutral
935422.0,Aveo Shares Rise 28% Premaket Following Announcement of Licensing Agreement With Novartis,2015-08-17 06:07:00-04:00,NVS,positive
935423.0,"UPDATE: AVEO to Receive $15M Upfront Payment from Novatis, Up to $311M in Milestone Payments",2015-08-17 06:06:00-04:00,NVS,neutral
935424.0,"AVEO Announces Exclusive Worldwide License Agreement for, Development, Commercialization of AV-380 and Related Antibodies",2015-08-17 06:02:00-04:00,NVS,positive
935425.0,Morning Market Gainers,2015-08-14 09:44:00-04:00,NVS,neutral
935426.0,Benzinga's Top #PreMarket Gainers,2015-08-14 08:17:00-04:00,NVS,positive
935427.0,US Stock Futures Slip Ahead Of Economic Data,2015-08-14 07:11:00-04:00,NVS,neutral
935428.0,Prima Biomed Shares +50% Following Announcement of Milestone Payment from Novartis,2015-08-14 07:07:00-04:00,NVS,positive
935429.0,Prima Biomed to Receive Undisclosed Milestone Payment from Novartis,2015-08-14 04:34:00-04:00,NVS,neutral
935430.0,Shares of Novartis Volatile Over Last Few Mins Following FDA Warning Related to First Cases of PML Being Reported in Patients Taking Gilenya,2015-08-04 13:44:00-04:00,NVS,negative
935431.0,FDA Warns About Cases of Rare Brain Infection With Ms Drug Gilenya in Two Patients With No Prior Exposure to Immunosuppressant Drugs -Reuters,2015-08-04 13:11:00-04:00,NVS,negative
935432.0,5 Biotechs With Catalysts Coming This Week,2015-08-03 16:59:00-04:00,NVS,neutral
935433.0,Novartis Completes Divestiture of Influenza Vaccines Business to CSL Limited for $275M,2015-08-02 19:55:00-04:00,NVS,negative
935434.0,"Novartis' Sandoz Unit Can't Sell Biosimilar Drug Zarxio Until September 2, 2015, According to Appeals Court Decision -Reuters",2015-07-21 10:29:00-04:00,NVS,neutral
935435.0,Novartis CEOS Says Looking at Offering Extra Health-Care Services With Heart Drug Entresto -DJ,2015-07-10 06:01:00-04:00,NVS,neutral
935436.0,FDA Approves New Drug To Treat Heart Failure,2015-07-07 16:37:00-04:00,NVS,positive
935437.0,Alcon Receives European Approval for Pre-loaded Intraocular Lens Delivery System to Treat Patients Undergoing Cataract Surgery,2015-07-01 04:15:00-04:00,NVS,positive
935438.0,"Must Watch Stocks for June 29, 2015",2015-06-29 05:53:00-04:00,NVS,neutral
935439.0,Novartis Acquires Spinifex Pharmaceuticals,2015-06-29 05:29:00-04:00,NVS,neutral
935440.0,Novartis Announces Publication in The Lancet Showing Positive Results with Secukinumab Over One Year in PsA Patients,2015-06-28 19:23:00-04:00,NVS,positive
935441.0,Bryan Garnier Upgrades Novartis to Buy,2015-06-22 10:02:00-04:00,NVS,neutral
935442.0,The Note Moving Pharma Giants Today,2015-06-17 16:06:00-04:00,NVS,neutral
935443.0,New Report: Abbvie Is Jefferies' Top Global Pharma Stock,2015-06-16 12:15:00-04:00,NVS,positive
935444.0,Novartis Division Alcon Receives CE Mark for CrySof IQ PanOptix Trifocal Intraocular Lens,2015-06-16 04:46:00-04:00,NVS,neutral
935445.0,Novartis Reports European Study Data Reinforce Benefit of First-line Tasigna in Newly-diagnosed Patients with CML,2015-06-13 22:00:00-04:00,NVS,positive
935446.0,Novartis Announces Majority of Patients with Polycythemia Vera Treated with Jakavi Achieved Long-term Disease Control,2015-06-13 07:55:00-04:00,NVS,neutral
935447.0,Novartis Data at EHA Show Increased PFS Benefit of Farydak in New Subgroup of Patients With Previously Treated Multiple Myeloma,2015-06-12 06:06:00-04:00,NVS,positive
935448.0,Hearing Novartis Panobinostat Combo Data Presented at EHA Showed Momre Than Double Median PFS Benefit by 7.8 Months,2015-06-12 06:06:00-04:00,NVS,positive
935449.0,Novartis Considers Delisting Indian Unit -Bloomberg,2015-06-11 07:44:00-04:00,NVS,neutral
935450.0,Novartis Announces New one-year Results Demonstrating Sustained Secukinumab Efficacy in Ankylosing Spondylitis Patients,2015-06-10 04:47:00-04:00,NVS,neutral
935451.0,"Novartis Presents New Positive One-Year Secukinumab Data at EULAR, WCD",2015-06-02 04:26:00-04:00,NVS,positive
935452.0,Novartis Highlights CTL019 Data Showing Potential as Treatment for Specific Types of non-Hodgkin Lymphoma,2015-06-01 16:11:00-04:00,NVS,neutral
935453.0,"Novartis Reports Combination of Tafinlar, Mekinist Shows Significant Survival Benefit in Patients with Metastatic Melanoma",2015-05-31 10:56:00-04:00,NVS,positive
935454.0,Merus Labs Acquires Specialty Product Rights from Novartis for $29.5M,2015-05-22 07:06:00-04:00,NVS,neutral
935455.0,8K Filing: Immunogen Recieves $5M Milestone Payment  From Novartis Institutes,2015-05-21 08:39:00-04:00,NVS,neutral
935456.0,Novartis' Afinitor Extended Progression-free Survival in Phase III Trial,2015-05-21 04:35:00-04:00,NVS,neutral
935457.0,"Novartis Reports Two Positive US Phase III Programs in COPD for QVA149, NVA237",2015-05-20 11:32:00-04:00,NVS,positive
935458.0,Microbix Provides Update on US VIRUSMAX Litigation vs Novartis,2015-05-15 08:31:00-04:00,NVS,negative
935459.0,Novartis Lung Cancer Drug Zykadia Receives EU Approval,2015-05-08 04:24:00-04:00,NVS,negative
935460.0,Novartis Reports Phase III Study of Arzerra Met Primary Endpoint of Improved Progress-Free Survival in Patients with Relapsed CLL,2015-04-27 10:30:00-04:00,NVS,positive
935461.0,Novartis Reports Q1 EPS $1.33 vs $1.10 Est; Revenue $11.935B vs $12.90B Est; Confirms Full-Year Guidance,2015-04-23 05:26:00-04:00,NVS,neutral
935462.0,Novartis Posts Higher Q1 Profit,2015-04-23 05:22:00-04:00,NVS,positive
935463.0,CAR-T Therapy Stocks Hit Hard Following AACR Data,2015-04-20 13:44:00-04:00,NVS,negative
935464.0,It's A Big Weekend For Biotech,2015-04-17 16:31:00-04:00,NVS,neutral
935465.0,Mylan Scores Final Win In Patent Challenge On Inhalation Drug,2015-04-17 14:27:00-04:00,NVS,positive
935466.0,Novartis' Alcon Receives FDA Approval of New Multifocal Intraocular Lens for Cataract Patients in US,2015-04-16 04:49:00-04:00,NVS,positive
935467.0,SocGen Initiates Big Drug/Pharma Names,2015-04-15 12:07:00-04:00,NVS,neutral
935468.0,Gilenya Data at AAN to Highlight How Novartis is Advancing Methods Assessing Impact of RMS,2015-04-13 05:25:00-04:00,NVS,positive
935469.0,FDA Says High-Dose Influenza Vaccine Significantly More Effective Than Standard Dose in Elderly -Reuters,2015-04-08 09:49:00-04:00,NVS,positive
935470.0,"Icon Bioscience Announces Successful Outcomes of Phase 3 Study of IBI-10090, a Novel Sustained Release Drug Being Developed to Treat Inflammation with Cataract Surgery",2015-04-06 09:06:00-04:00,NVS,positive
935471.0,Novartis Reports Approval For Jadenutm For Chronic Iron Overload,2015-03-30 17:46:00-04:00,NVS,positive
935472.0,Advaxis Shares Rise 13% Premarket; May be Attributed to Novartis Deal with Aduro Biotech,2015-03-30 07:23:00-04:00,NVS,positive
935473.0,Novartis Announces Alliance With Aduro Biotech; Includes $250M Upfront Payment,2015-03-30 04:40:00-04:00,NVS,neutral
935474.0,"Amgen to Appeal Rejection of Bid to Block Sale of Novartis Biosimilar form of Neupogen, According to Court Filing -Reuters",2015-03-25 13:44:00-04:00,NVS,negative
935475.0,Novartis Announces Positive Cosentyx Results,2015-03-25 07:09:00-04:00,NVS,positive
935476.0,"Novartis' Cosentyx 2-year Data Shows Sustained Effect, Favorable Safety Profile in Psoriasis Patients",2015-03-23 05:00:00-04:00,NVS,positive
935477.0,Novartis International AG: New Novartis data shows Cosentyx is significantly superior to Stelara and clears skin (PASI 90,2015-03-20 12:46:00-04:00,NVS,positive
935478.0,US Judge Denies Amgen Bid for Preliminary Injunction vs Novartis' Sandoz Unit Regarding Disputed Biologic Products -Reuters,2015-03-19 15:14:00-04:00,NVS,negative
935479.0,Incyte Announces Jakavi Receives EC Approval as First Targeted Therapy for Patients with Polycythemia Vera,2015-03-17 04:38:00-04:00,NVS,positive
935480.0,8 Healthcare Names Cowen & Co Are Talking About,2015-03-10 18:02:00-04:00,NVS,neutral
935481.0,UPDATE: Ophthotech Announces Second $50M Enrollment Milestone under Ex-US Licensing and Commercial Agreement with Novartis for Fovista,2015-03-10 07:06:00-04:00,NVS,positive
935482.0,Analyst: 'Mess Continues' With Amgen Neupogen Competitor,2015-03-09 15:16:00-04:00,NVS,negative
935483.0,Novartis Reports FDA Approval of First Biosimilar ZarxioTM from Sandoz,2015-03-06 09:11:00-05:00,NVS,positive
935484.0,Arrowhead Research Soars After Acquiring Novartis' RNAi Portfolio,2015-03-05 12:54:00-05:00,NVS,neutral
935485.0,Omnicare Announces Specialty Care Group ACS Will Provide Specialty Pharmacy Services for Novartis' Farydak,2015-03-05 07:50:00-05:00,NVS,positive
935486.0,Report: Pharmacyclics Inc. To Be Acquired By Johnson & Johnson,2015-03-04 18:13:00-05:00,NVS,neutral
935487.0,Natixis Upgrades Novartis To  Buy,2015-03-04 09:18:00-05:00,NVS,neutral
935488.0,Benzinga's Top Upgrades,2015-03-04 09:10:00-05:00,NVS,positive
935489.0,Natixis Upgrades Novartis to Buy,2015-03-04 04:59:00-05:00,NVS,neutral
935490.0,Novartis International Reports Phase II Study Of Alcon's RTH258 Meets Primary Endpoint,2015-02-27 11:33:00-05:00,NVS,neutral
935491.0,"Benzinga's M&A Chatter for Wednesday February 25, 2015",2015-02-25 21:26:00-05:00,NVS,neutral
935492.0,Deutsche Bank On Pharmacyclics: 'We Do Not See Much Upside',2015-02-25 17:05:00-05:00,NVS,neutral
935493.0,Novartis Release Confirms FDA Approval of Farydak,2015-02-23 15:20:00-05:00,NVS,positive
935494.0,FDA Reports Approval of Novartis' Farydak for Treatment of Multiple Myeloma,2015-02-23 14:58:00-05:00,NVS,positive
935495.0,Canada Competition Bureau Says Won't Block Glaxosmithkline-Novartis Deal,2015-02-23 11:58:00-05:00,NVS,positive
935496.0,FTC Puts Conditions on Novartis AG's Proposed Acquisition of GlaxoSmithKline's Oncology Drugs,2015-02-23 11:34:00-05:00,NVS,neutral
935497.0,"Novartis, Verastem & Cepheid Making Biotech Headlines On Friday",2015-02-13 15:32:00-05:00,NVS,neutral
935498.0,Novartis' LCZ696 Granted FDA Priority Review,2015-02-13 11:31:00-05:00,NVS,positive
935499.0,Novartis Shares Rise 2% Premarket; Citi Resumes With Buy; Adds to Europe Focus List,2015-02-09 07:50:00-05:00,NVS,positive
935500.0,"After A Blockbuster 2014, What Will 2015 Hold For Pharmaceutical M&A?",2015-02-06 15:28:00-05:00,NVS,positive
935501.0,Credit Suisse Adds 10 Names To European 'Top Picks',2015-02-05 07:48:00-05:00,NVS,positive
935502.0,Pfizer Just Won With This Breast Cancer Drug,2015-02-04 14:37:00-05:00,NVS,negative
935503.0,Novartis Announces Alcon Receives FDA Approval for Pazeo Solution for Oocular Allergy Itch Relief,2015-02-02 05:04:00-05:00,NVS,positive
935504.0,Stocks That Battle Cancer Were The Best-Performing Biotechs In January,2015-01-30 13:03:00-05:00,NVS,negative
935505.0,Morning Market Gainers,2015-01-27 09:47:00-05:00,NVS,neutral
935506.0,Benzinga's Top #PreMarket Gainers,2015-01-27 08:13:00-05:00,NVS,positive
935507.0,Novartis Posts Drop In Q4 Net Profit,2015-01-27 04:58:00-05:00,NVS,positive
935508.0,From Conf Call: Novartis CEO Says Franc Appreciation Won't Have Any Material Effect on Sales,2015-01-27 04:43:00-05:00,NVS,positive
935509.0,"Novartis Reports Q4 EPS of $1.21, Inline; Revenue of $14.63B vs $14.58B Est",2015-01-27 04:42:00-05:00,NVS,neutral
935510.0,"Earnings Scheduled For January 27, 2015",2015-01-27 04:34:00-05:00,NVS,neutral
935511.0,Trio Of Wall Street Firms Up Array BioPharma Price Targets,2015-01-26 10:05:00-05:00,NVS,neutral
935512.0,Benzinga's Weekend M&A Chatter,2015-01-25 18:50:00-05:00,NVS,neutral
935513.0,FDA Approves Second Vaccine to Prevent Serogroup B Meningococcal Disease,2015-01-23 16:07:00-05:00,NVS,positive
935514.0,Adam Feuerstein @adamfeuerstein Tweet: FDA approval PRs coming. $NVS vaccine.,2015-01-23 16:01:00-05:00,NVS,positive
935515.0,Why Shares Of Array Biopharma Are Surging More Than 35%,2015-01-23 11:52:00-05:00,NVS,positive
935516.0,Array BioPharma Shares Rise 47% on Announcement of Deal to Acquire Encorafenib from Novartis,2015-01-23 09:52:00-05:00,NVS,positive
935517.0,Novartis' Jakav Recommended by CHMP for EU Approval for Adults with Rare Blood Cancer polycythemia vera,2015-01-23 07:31:00-05:00,NVS,negative
935518.0,Novartis CEO: Supporting Affordable Care Act Supports Insuring Americans,2015-01-23 06:55:00-05:00,NVS,positive
935519.0,Aspen Pharmacare Acquires Rights to Mono-embolex from Novartis for $142.3M,2015-01-23 04:49:00-05:00,NVS,neutral
935520.0,Novartis Announces FDA Approval for Cosentyx for Moderate-to-Severe Plaque Psoriasis,2015-01-21 12:34:00-05:00,NVS,positive
935521.0,Watchmakers Caught In The #Francogeddon Storm,2015-01-16 14:39:00-05:00,NVS,neutral
935522.0,Benzinga's Volume Movers,2015-01-15 10:40:00-05:00,NVS,neutral
935523.0,Swiss ADRs Gain Big As Swiss National Bank Surprises With Currency Revaluation,2015-01-15 10:07:00-05:00,NVS,positive
935524.0,US Stock Futures Jump Ahead Of Jobless Claims,2015-01-08 07:00:00-05:00,NVS,neutral
935525.0,Novartis Announces Positive Phase III Results for QVA149 and NVA237,2015-01-08 04:57:00-05:00,NVS,positive
935526.0,FDA Panel Gives Unanimous Backing to Novartis Copy of Amgen Cancer Drug Neupogen,2015-01-07 15:54:00-05:00,NVS,negative
935527.0,"Novartis Announces Collaborations With Intellia Therapeutics, Caribou Biosciences Related to CRISPR Genome Editing Technology",2015-01-07 05:32:00-05:00,NVS,neutral
935528.0,Qualcomm Reports Strategic Collaboration with Novartis Related to Optimization of Global Clinical Trials,2015-01-05 16:01:00-05:00,NVS,positive
935529.0,Benzinga's Top Upgrades,2015-01-05 08:34:00-05:00,NVS,positive
935530.0,Cowen Upgrades Novartis To Outperform,2015-01-05 07:01:00-05:00,NVS,neutral
935531.0,"Cowen & Company Upgrades Novartis to Outperform, Raises PT to $105.00",2015-01-05 05:33:00-05:00,NVS,neutral
935532.0,CORRECTION -- Pot Stocks Pay Off: Here's How The Marijuana Sector Fared Last Year,2015-01-04 23:12:00-05:00,NVS,negative
935533.0,Lilly Completes Acquisition of Novartis Animal Health,2015-01-01 08:22:00-05:00,NVS,neutral
935534.0,Novartis Announces Regulatory Approval of Cosentyx in Japan for Psoriasis and Psoriatic Arthritis,2014-12-26 06:21:00-05:00,NVS,positive
935535.0,Benzinga's Volume Movers,2014-12-23 10:47:00-05:00,NVS,neutral
935536.0,Mid-Morning Market Update: Markets Mostly Higher; Walgreen Profit Beats Expectations,2014-12-23 10:40:00-05:00,NVS,positive
935537.0,Morning Market Movers,2014-12-23 09:54:00-05:00,NVS,neutral
935538.0,Benzinga's Top #PreMarket Gainers,2014-12-23 08:11:00-05:00,NVS,positive
935539.0,Vanda Pharmaceuticals And Novartis Settle License Dispute,2014-12-23 08:08:00-05:00,NVS,negative
935540.0,UPDATE: Vanda to Acquire Rights to Phase II Clinical Compound From Novartis,2014-12-22 16:04:00-05:00,NVS,neutral
935541.0,Novartis to Purchase $25M Og Vanda Common Stock,2014-12-22 16:03:00-05:00,NVS,neutral
935542.0,Novartis Reports 12.8% Passive Stake in BioLineRx as of December 16,2014-12-22 06:09:00-05:00,NVS,positive
935543.0,Dr. Reddy's Closes Acquisition of Habitro Brand from Novartis,2014-12-19 05:00:00-05:00,NVS,neutral
935544.0,Novartis Shares Volatile Here as Seeing FDA Has Approved Alcon's Xtoro for Treatment of Swimmer's Ear,2014-12-17 15:20:00-05:00,NVS,positive
935545.0,Morning Market Movers,2014-12-16 09:42:00-05:00,NVS,neutral
935546.0,Benzinga's Top #PreMarket Gainers,2014-12-16 08:05:00-05:00,NVS,positive
935547.0,"UPDATE: Bioline RX Said Novartis Made $10M Initial Investment for ~12.8% of Co., Has Option to Pay $5M Fee, Could Fund 50% of Development Costs",2014-12-16 07:49:00-05:00,NVS,negative
935548.0,UPDATE: BioLine RX Shares Rise 20% Premarket on Announcement of  Strategic Collaboration Agreement With Novartis,2014-12-16 07:47:00-05:00,NVS,positive
935549.0,US Stock Futures Edge Lower; Crude Oil Drops,2014-12-16 07:03:00-05:00,NVS,negative
935550.0,Novartis Announces FDA Approval for Signifor LAR to Treat Patients with Acromegaly,2014-12-16 04:57:00-05:00,NVS,positive
935551.0,Novartis Reports Results of Trial Evaluating Use of Afinitor,2014-12-12 08:34:00-05:00,NVS,neutral
935552.0,Novartis Cosentyx Superior to Stelara in Clearing Skin in Head-to-Head Psoriasis Study,2014-12-12 05:59:00-05:00,NVS,positive
935553.0,"Novartis Announces Positive CTL019 Clinical Data in Children, Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia",2014-12-06 17:28:00-05:00,NVS,positive
935554.0,Morgan Stanley Pair Trade On Novartis And AstraZeneca,2014-12-02 14:01:00-05:00,NVS,neutral
935555.0,Morgan Stanley Upgrades Novartis AG to Equalweight,2014-12-02 11:46:00-05:00,NVS,neutral
935556.0,"Novartis Says Italian Court Has Upheld Decision Related to Lucentis/Avastin, Calls Allegations of Anti-Competitive Behavior 'Unfounded,' Says Can Not Comment on Rationale of Italian Court Decision",2014-12-02 11:30:00-05:00,NVS,neutral
935557.0,Novartis Fingolimod Phase III Trial in Primary Progressive MS did Not Meet Primary Eendpoint,2014-12-01 05:06:00-05:00,NVS,neutral
935558.0,"FTC Places Conditions on JV Between GlaxoSmithKline, Novartis",2014-11-26 13:09:00-05:00,NVS,neutral
935559.0,"US Stock Futures Edge Higher Ahead Of GDP, Housing Data",2014-11-25 07:35:00-05:00,NVS,neutral
935560.0,Novartis Announces FDA Grants Extension to NDA Review Period for Multiple Myeloma Investigational Compound LBH589,2014-11-25 05:22:00-05:00,NVS,positive
935561.0,Novartis' Signifor Approved in EU,2014-11-24 05:17:00-05:00,NVS,positive
935562.0,Novartis Psoriasis Treatment Receives Posiive Opinion from CHMP,2014-11-21 05:54:00-05:00,NVS,neutral
935563.0,Novartis Int'l Reports Nine New Analyses Show Co.'s LCZ696 Could Avert Course of Heart Failure for Patients,2014-11-17 16:47:00-05:00,NVS,negative
935564.0,Novartis First IL-17A Phase III Trial Results Show AIN457 Significantly Improves Psoriatic Arthritis,2014-11-16 15:10:00-05:00,NVS,positive
935565.0,Novartis Says Secukinumab Met Primary Endpoint Demonstrating Statistically Significant Improvements Versus Placebo With AS,2014-11-15 18:32:00-05:00,NVS,positive
935566.0,Novartis Does Not Receive FDA Advisory Committee Recommendation for Panobinostat,2014-11-06 11:52:00-05:00,NVS,neutral
935567.0,"Markets Continue To Rally As The Dow Closes Above 17,000",2014-10-28 16:44:00-04:00,NVS,neutral
935568.0,Novartis Posts Higher Q3 Profit,2014-10-28 06:17:00-04:00,NVS,positive
935569.0,"Earnings Scheduled For October 28, 2014",2014-10-28 05:25:00-04:00,NVS,neutral
935570.0,Novartis AG Reports Q3 EPS of $1.37 vs $1.29 Est; Revenue of $14.70B vs $14.34B Est,2014-10-28 05:23:00-04:00,NVS,neutral
935571.0,Novartis Divests Influenza Vaccines Business to CSL for $275M ,2014-10-26 19:09:00-04:00,NVS,neutral
935572.0,Drug ETFs Attractive Buys On Pullback,2014-10-22 17:10:00-04:00,NVS,positive
935573.0,Novartis Reports FDA AdCom Unanimously Recommended Approval of AIN457 for Patients with Moderate-to-Severe Plaque Psoriasis,2014-10-20 15:02:00-04:00,NVS,positive
935574.0,US Stock Futures Signal Lower Start On Wall Street,2014-10-10 07:20:00-04:00,NVS,negative
935575.0,Novartis Presents Data Showing Consistent Efficacy of AIN457 in Clearing Skin of Psoriasis Patients at EADV,2014-10-10 05:24:00-04:00,NVS,neutral
935576.0,"8-K from Immunogen Shows Has Recorded $25.7M in Current Qtr. Related to Licenses, Novartis Deal, Each License Entitles Co. to Up to $199.5M in Milestone Payments",2014-10-07 08:37:00-04:00,NVS,neutral
935577.0,Novartis Reports Afinitor First Treatment for Advanced Pancreatic NET to Provide Overall Survival of 3.5+ Years in Phase III Trial,2014-09-27 08:58:00-04:00,NVS,positive
935578.0,Novartis Reports CHMP Has Recommended EU Approval for Signifor LAR for Treatment of Patients with Acromegaly,2014-09-26 07:20:00-04:00,NVS,positive
935579.0,Could European Funds Offer An Opportunity Now?,2014-09-23 10:04:00-04:00,NVS,positive
935580.0,3 Companies Investing In Stem Cell Research,2014-09-14 16:34:00-04:00,NVS,neutral
935581.0,PREVIEW: Merus Labs to Resume Trading at 9:00 AM ET,2014-09-08 08:45:00-04:00,NVS,neutral
935582.0,"Merus Labs Reports Purchase of Sintrom(R) from Novartis, No Terms Disclosed",2014-09-08 08:30:00-04:00,NVS,negative
935583.0,"Ophthotech Wins $50M Milestone Under Ex-US Licensing Deal with Novartis, Related to Fovista",2014-09-08 07:31:00-04:00,NVS,positive
935584.0,ECB Decision Boosts ETFs,2014-09-04 16:02:00-04:00,NVS,positive
935585.0,Benzinga's Volume Movers,2014-09-02 10:25:00-04:00,NVS,neutral
935586.0,Novartis' LCZ696 Reduced Cardiovascular Deaths by 20% vs ACE-inhibitor in PARADIGM-HF Trial ,2014-08-30 08:19:00-04:00,NVS,neutral
935587.0,Novartis Reports Xolair Approved in Canada as Licensed Therapy for CIU Patients,2014-08-28 09:02:00-04:00,NVS,positive
935588.0,Elbit Imaging Announces Novartis to Invest $35M in Gamida Cell,2014-08-19 03:46:00-04:00,NVS,neutral
935589.0,Enanta Pharmaceuticals Announces Novartis Advanced EDP-239 into Combination Studies with Alisporivir ,2014-08-07 08:35:00-04:00,NVS,positive
935590.0,"Novartis Announces Investigational Secukinumab Met All Primary, Key Secondary Endpoints at Week 12 ",2014-08-05 09:21:00-04:00,NVS,neutral
935591.0,Alcon's Simbrinza Approved in EU to Treat Patients with Glaucoma,2014-07-28 05:26:00-04:00,NVS,positive
935592.0,FDA Accepts Novartis' Sandoz Application for Biosimilar Filgrastim,2014-07-24 05:44:00-04:00,NVS,positive
935593.0,5 New Medical Technologies For Diabetics,2014-07-18 13:10:00-04:00,NVS,neutral
935594.0,Novartis Joins Google To Develop Contacts For Diabetics,2014-07-18 09:59:00-04:00,NVS,neutral
935595.0,"#PreMarket Primer: Friday, July 18: Tension Between Russia And The West At An All Time High",2014-07-18 07:16:00-04:00,NVS,negative
935596.0,Markets Sell-Off After Malaysian Airline Crash In Ukraine,2014-07-17 16:50:00-04:00,NVS,negative
935597.0,"Alzheimer's Rates Falling, But Pharma's Search For A Cure Yields No Results",2014-07-17 11:12:00-04:00,NVS,negative
935598.0,From Novartis Earnings Conference Call: CEO Says Co. Not Considering Sale of Mature Drugs Right Now But 'Never Say Never' on Possibility of Sale,2014-07-17 09:16:00-04:00,NVS,positive
935599.0,"8-K from Vanda Pharma Shows Novartis is Counter-Claimant in Arbitration Proceeding, Expecting Closing or Proceeding in 12-18 Mos.",2014-07-17 08:26:00-04:00,NVS,neutral
935600.0,"#PreMarket Primer: Thursday, July 17: Russia Hit With New Sanctions",2014-07-17 07:17:00-04:00,NVS,neutral
935601.0,Novartis Reports Q2 EPS of $1.34 vs $1.42 Est; Revenue of $14.60B vs $14.81B Est,2014-07-17 05:38:00-04:00,NVS,neutral
935602.0,Novartis Reconfirms Full Year Outlook ,2014-07-17 05:35:00-04:00,NVS,neutral
935603.0,"Earnings Scheduled For July 17, 2014",2014-07-17 05:08:00-04:00,NVS,neutral
935604.0,"Markets Mixed, NASDAQ Lower As Yellen Suggests Valuations Are Stretched",2014-07-15 16:35:00-04:00,NVS,negative
935605.0,Novartis to License Google Smart Lens Technology ,2014-07-15 05:48:00-04:00,NVS,positive
935606.0,Benzinga Weekly Preview: Earnings Season Kicks Into High Gear,2014-07-11 16:44:00-04:00,NVS,neutral
935607.0,"Incyte Announces $25M Milestone Payment for Approval of Jakavi in Japan, Will Receive Payment from Novartis",2014-07-08 07:34:00-04:00,NVS,positive
935608.0,Novartis Personalized Cell Therapy CTL019 Receives FDA Breakthrough Therapy Designation,2014-07-07 12:41:00-04:00,NVS,neutral
935609.0,Novartis Int'l Reports FDA Breakthrough Designation for Personalized Cell Therapy CTL019 ,2014-07-07 12:31:00-04:00,NVS,neutral
935610.0,Novartis Announces Beginning of Shipment of Seasonal Influenza Vaccines to US Market for '14-'15 Season,2014-07-02 16:33:00-04:00,NVS,neutral
935611.0,Novartis Faces Charges in Japan Regarding Data Manipulation by Former Staff -FT,2014-07-01 06:48:00-04:00,NVS,negative
935612.0,FDA Approves Ranbaxy Laboratories' Generic Version of Novartis Blood Pressure Pill Diovan,2014-06-26 14:46:00-04:00,NVS,positive
935613.0,Shire Announces Vyvanse Patents Found to Be Infringed and Valid by US District Court,2014-06-25 05:42:00-04:00,NVS,neutral
935614.0,Delaware Judge Rules Novartis Pharma Patents Not Infringed by Alvogen,2014-06-24 15:58:00-04:00,NVS,neutral
935615.0,FDA Reports Approved Novartis' Request to Supplement BLA for FluCelVax,2014-06-24 09:58:00-04:00,NVS,positive
935616.0,US Stock Futures Edge Higher Ahead Of Consumer Price Index,2014-06-17 07:30:00-04:00,NVS,neutral
935617.0,Novartis Submits BLA to FDA for Meningitis B Vaccine Candidate Bexsero ,2014-06-17 05:43:00-04:00,NVS,neutral
935618.0,ASCO Meeting Day 1: Preserving Fertility And Reducing Side Effects,2014-06-04 10:11:00-04:00,NVS,neutral
935619.0,UPDATE: Incyte Announces Trial Met Endpoint,2014-06-03 10:48:00-04:00,NVS,neutral
935620.0,Watch Shares of Novartis Following News from Incyte,2014-06-03 10:47:00-04:00,NVS,positive
935621.0,Novartis Reports Study Shows Zykadia(TM) Shrank Tumors in Majority of ALK+ NSCLC Patients,2014-06-02 16:02:00-04:00,NVS,neutral
935622.0,Novartis Data Presented at ASCO Shows LBH589 Significantly Improved Progression-Free Survival in Patients with Multiple Myeloma,2014-06-02 09:04:00-04:00,NVS,positive
935623.0,Novartis' investigational Compound LDE225 Shows Marked Tumor Responses in Advanced Basal Cell Carcinoma ,2014-06-01 10:03:00-04:00,NVS,negative
935624.0,Novartis Names Bruno Strigini as President of Novartis Oncology ,2014-06-01 09:55:00-04:00,NVS,neutral
935625.0,Judge Has Denied Novartis Offer to Throw Out Drug Sales Kickback Lawsuit - Bloomberg,2014-05-29 15:53:00-04:00,NVS,negative
935626.0,US Judge Denies Novartis Motion to Dismiss US Lawsuit Over Alleged Kickback Scheme -Reuters,2014-05-29 15:13:00-04:00,NVS,negative
935627.0,"Italy Health Ministry Asks for €1.2B  of Compensation from Roche, Novartis, €14M Euros from Pfizer Following Anti-Trust Ruling -Reuters",2014-05-28 13:23:00-04:00,NVS,neutral
935628.0,Novartis Alcon Reports Positive CHMP Opinion for Simbrinza,2014-05-23 07:36:00-04:00,NVS,positive
935629.0,Ophthotech Mega Million Deal With Novartis; Oncolytics Biotech Brain Cancer Trial Positive Data; Tarena International Solid Results,2014-05-20 09:40:00-04:00,NVS,negative
935630.0,"Ophthotech Announces Has Entered Into Ex-US Licensing, Commercialization Deal with Novartis, Will Potentially Get Upfront Payment of $200M, Receive Over $1B",2014-05-19 16:06:00-04:00,NVS,neutral
935631.0,"Two New WisdomTree International ETFs (IHDG, EUDG, BHP, NVS)",2014-05-14 07:24:00-04:00,NVS,neutral
935632.0,"UPDATE: Allergan Rumored to Contact Glaxo, Novartis About Possible Interest",2014-05-09 14:04:00-04:00,NVS,positive
935633.0,FDA Approves Xolair for Treatment of Chronic Hives ,2014-05-07 13:23:00-04:00,NVS,positive
935634.0,Novartis' Announces Positive Results in Phase III Trial of Signifor LAR ,2014-05-05 05:38:00-04:00,NVS,positive
935635.0,Jefferies Upgrades Novartis AG to Buy,2014-05-02 07:35:00-04:00,NVS,neutral
935636.0,Novartis Release Confirms FDA Approval for Zykadia to Treat ALK+ NSCLC Previously Treated with ALK Inhibitor Crizotinib,2014-04-29 15:31:00-04:00,NVS,positive
935637.0,FDA Issues Approval for Novartis' Zykadia for Late-Stage Lung Cancer,2014-04-29 15:09:00-04:00,NVS,negative
935638.0,JP Morgan Upgrades Novartis to Overweight - Bloomberg,2014-04-29 11:37:00-04:00,NVS,neutral
935639.0,Novartis' INSTEAD Sudy for Onbrez Breezhaler Meets Primary Objective,2014-04-25 05:38:00-04:00,NVS,neutral
935640.0,Market Wrap For April 24: Apple's Smashing Earnings Overshadowed By Ukraine Concerns,2014-04-24 16:41:00-04:00,NVS,neutral
935641.0,RBC Optimistic on Regeneron Following Lower Sales by Novartis' Lucentis,2014-04-24 16:31:00-04:00,NVS,neutral
935642.0,Natixis Downgrades Novartis AG to Neutral,2014-04-24 07:59:00-04:00,NVS,neutral
935643.0,UPDATE: Novartis Posts Rise In Q1 Profit,2014-04-24 05:38:00-04:00,NVS,positive
935644.0,"Earnings Scheduled For April 24, 2014",2014-04-24 05:33:00-04:00,NVS,neutral
935645.0,"Benzinga's M&A Chatter for Tuesday April 22, 2014",2014-04-22 18:19:00-04:00,NVS,neutral
935646.0,"Market Wrap For April 22: S&P Rises For Sixth Straight Day, Dow & Nasdaq Also Positive",2014-04-22 16:52:00-04:00,NVS,positive
935647.0,"Drug ETFs Surge On M&A Activity (AGN, VRX, IHE, XPH, PPH, AZN)",2014-04-22 13:24:00-04:00,NVS,neutral
935648.0,US Stock Futures Edge Higher Ahead Of McDonald's Earnings,2014-04-22 07:31:00-04:00,NVS,neutral
935649.0,Novartis Acquires GSK Oncology Products Business for $14.5B,2014-04-22 06:03:00-04:00,NVS,neutral
935650.0,Lilly to Acquire Novartis Animal Health for Approximately $5.4B in Cash,2014-04-22 05:40:00-04:00,NVS,neutral
935651.0,"Thrombogenics Says Review is at Prelim. Stage, Does Not Intend to Comment on Market Speculation - Bloomberg",2014-04-14 15:57:00-04:00,NVS,neutral
935652.0,"Novartis, Shire Could Be Weighing Bids for ThromboGenics - Bloomberg",2014-04-14 11:18:00-04:00,NVS,neutral
935653.0,Adam Feuerstein Tweet: '$NVS spokesperson says FDA still reviewing Zykadia. Approval email sent in error by an online health community',2014-04-11 16:15:00-04:00,NVS,positive
935654.0,Novartis Meningitis B Vaccine Bexsero Receives FDA Breakthrough Therapy Designation,2014-04-07 05:37:00-04:00,NVS,neutral
935655.0,Novartis Says Court Has Blocked Biocon from  Making Vildagliptin - Bloomberg,2014-04-03 07:40:00-04:00,NVS,negative
935656.0,Novartis Presenting Data on 19 Compounds at AACR,2014-04-03 06:18:00-04:00,NVS,neutral
935657.0,UPDATE: Novartis Announces PARADIGM-HF Trial of LCZ696 for Chronic Heart Failure Closes Early  on Strength of Interim Results ,2014-03-31 07:44:00-04:00,NVS,neutral
935658.0,"Novartis PARADIGM-HF Trial of LCZ696 for Chronic Heart Failure Closes Early on Strength of Interim Results, Shares Rise 4% in Premarket",2014-03-31 07:35:00-04:00,NVS,positive
935659.0,Market Wrap For March 27: Markets Lower Following Mixed Economic Data,2014-03-27 17:39:00-04:00,NVS,negative
935660.0,FDA Panel Votes 11-0 Novartis' Serelaxin Should Not Be Approved,2014-03-27 15:58:00-04:00,NVS,negative
935661.0,FDA Advisory Panel Recommends Against Approval of Novartis Drug Serelaxin to Treat Acute Heart Failure -Reuters,2014-03-27 15:58:00-04:00,NVS,positive
935662.0,Novartis Announces Study Published in New England Journal of Medicine Showed LDK378 Demonstrated Overall Response Rate of 58% in Patients with ALK+ NSCLC,2014-03-26 17:02:00-04:00,NVS,neutral
935663.0,Market Wrap For March 25: Markets Snap Two-Day Losing Steak On Confidence Data,2014-03-25 16:24:00-04:00,NVS,positive
935664.0,FDA Staff Recommends Rejection of Novartis Heart-Failure Drug Serelaxin,2014-03-25 13:45:00-04:00,NVS,negative
935665.0,Google Honors Activist Dorothy Height & Her Contributions,2014-03-24 14:56:00-04:00,NVS,positive
935666.0,Novartis Announces FDA Has Approved XOLARI for CIU,2014-03-21 14:39:00-04:00,NVS,positive
935667.0,US Stock Futures Signal Higher Start On Wall Street,2014-03-21 07:35:00-04:00,NVS,neutral
935668.0,Novartis Initiates Secukinumab vs Stelara Phase IIIb Head-to-Head Psoriasis Study at AAD 2014 ,2014-03-21 05:37:00-04:00,NVS,neutral
935669.0,UPDATE: Novartis CEO Says Aims to File Cart-19 T-Cell Cancer Therapy for Approval in 2016,2014-03-20 08:59:00-04:00,NVS,negative
935670.0,UPDATE: Novartis CEO Says Co Could Do Bolt-On Buys in Range Of $2B-$5B in Any Year,2014-03-20 08:57:00-04:00,NVS,neutral
935671.0,Novartis CEO Says Co in Talks With Other Companies Interested in Potential Asset Swaps -Reuters Interview,2014-03-20 08:56:00-04:00,NVS,positive
935672.0,Novartis Launches Lucentis in State of the Art Pre-Filled Syringe ,2014-03-20 05:39:00-04:00,NVS,neutral
935673.0,Novartis Offers Data at EBCC-9 Related to Secondary Survial Endpoint of Afinitor Trial in HR+/HER2- Advanced Breast Cancer,2014-03-19 13:28:00-04:00,NVS,negative
935674.0,Market Wrap For March 18: Markets Positive Despite Crimea Concerns,2014-03-18 16:35:00-04:00,NVS,positive
935675.0,"Morgan Stanley Issues Mid-Day Downgrade on Novartis, Shares Turn Well Into Negative Territory",2014-03-13 12:53:00-04:00,NVS,negative
935676.0,Novartis Bexsero Meningitis B Vaccine Receives Clinical Recommendation For Use In Infants And Adolescents In Australia,2014-03-13 06:00:00-04:00,NVS,neutral
935677.0,Market Wrap For March 7: Markets Cap Off Positive Week With Small Gains,2014-03-07 16:31:00-05:00,NVS,positive
935678.0,Novartis Announces Positive Phase III Study for Jakavi in Patients with Polycythemia Vera ,2014-03-07 05:36:00-05:00,NVS,positive
935679.0,Market Wrap For February 26: Markets Slightly Higher On Housing Data,2014-02-26 16:49:00-05:00,NVS,neutral
935680.0,"GenVec Shares Surge Nearly 20% on Very Light Pre-Market Volume, 8-K from This Morning Showed Third Milestone Had Been Achieved Related to Research, Collaboration, License Deal with Novartis",2014-02-26 09:11:00-05:00,NVS,positive
935681.0,European ETFs Flying Under The Radar ,2014-02-25 15:23:00-05:00,NVS,neutral
935682.0,Novartis Announces Lucentis Approval in Japan for Diabetic Macular Edema,2014-02-21 05:55:00-05:00,NVS,positive
935683.0,"Market Wrap For February 19: Stocks Close Lower, Nasdaq Ends Winning Streak",2014-02-19 17:01:00-05:00,NVS,positive
935684.0,Market Wrap For February 4: Investors And Traders Go Bargain Hunting,2014-02-04 16:40:00-05:00,NVS,positive
935685.0,Novartis Shares Nearing Session Lows as Bloomberg Highlighting Unconfirmed Story Vaccines Unit is Drawing Interest ,2014-02-04 13:54:00-05:00,NVS,positive
935686.0,Market Wrap For February 3: Bears In Complete and Absolute Control,2014-02-03 16:45:00-05:00,NVS,neutral
935687.0,"Market Wrap For January 29: Markets Lower on Fed Taper, Emerging Markets Worries",2014-01-29 17:38:00-05:00,NVS,negative
935688.0,Tug Of War In Ariad Pharmaceuticals,2014-01-28 14:36:00-05:00,NVS,negative
935689.0,"Benzinga's M&A Chatter for Monday January 27, 2014",2014-01-27 17:21:00-05:00,NVS,neutral
935690.0,Market Wrap For January 24: Fear Is Back In The Markets,2014-01-24 16:30:00-05:00,NVS,negative
935691.0,Novartis Positive Opinion from CHMP for Xolair in Severe Form of Skin Disease CSU,2014-01-24 05:59:00-05:00,NVS,positive
935692.0,NJ Woman Sues Novartis over Pricing of Similar Excedrin Pain Medicines,2014-01-19 17:53:00-05:00,NVS,negative
935693.0,UPDATE: Allergan Has Won a Ruling Blocking Generics of Lumigan Until 2027,2014-01-14 11:21:00-05:00,NVS,positive
935694.0,Novartis Pharma Canada Receives Health Canada Approval for Ultibro Breezhaler for COPD,2014-01-13 14:37:00-05:00,NVS,positive
935695.0,"Novartis CEO Jimenez at JP Morgan Conference Says Co Will Provide 2014 Outlook on Jan. 29th, Will Return At Least $17B Through Buybacks, Dividends Over Next Two Years",2014-01-13 12:23:00-05:00,NVS,positive
935696.0,Novartis CEO Jimenez Speaking at JP Morgan Healthcare Conference: Says Portfolio Review is Ongoing,2014-01-13 12:16:00-05:00,NVS,positive
935697.0,Cell Therapeutics to Reacquire Rights to Two Anti-Cancer Compounds from Novartis,2014-01-13 06:01:00-05:00,NVS,neutral
935698.0,No Imminent Widespread Outbreak of Human-to-Human Transmitted Avian Flu Expected,2014-01-12 18:48:00-05:00,NVS,negative
935699.0,Jefferies Downgrades Novartis AG to Hold,2014-01-09 08:21:00-05:00,NVS,neutral
935700.0,UPDATE: NY AG Says Pharmacy Will Pay $15M to Settle,2014-01-08 16:50:00-05:00,NVS,negative
935701.0,UPDATE: NY AG Claiming Novartis Paid Kickbacks to Pharmacy Co.,2014-01-08 16:49:00-05:00,NVS,neutral
935702.0,NY AG Reports Suit Against Novartis,2014-01-08 16:48:00-05:00,NVS,neutral
935703.0,"UPDATE: Novartis Could Swap Its Animal-Health, Human Vaccines Units for Merck's OTC Health-Products Unit",2014-01-08 14:54:00-05:00,NVS,neutral
935704.0,Bloomberg Reporting Novartis Said to Be in Talks with Merck on $5B Unit Swap,2014-01-08 14:52:00-05:00,NVS,neutral
935705.0,"Form 8-K from Wright Medical Group Shows Co. Received (on Dec 20th) Notice from Novartis, Biomimetic of Intent to End Manufacturig, Supply Pact",2013-12-27 10:12:00-05:00,NVS,neutral
935706.0,Novartis' Sandoz Receives First Approval for AirFluSal Forspiro,2013-12-18 12:01:00-05:00,NVS,positive
935707.0,Novartis Pharma Reports Health Canada Approval for ILARIS in SJIA,2013-12-17 07:18:00-05:00,NVS,positive
935708.0,"Apricus Expands Exclusive License Agreement With Sandoz Affiliate, Apricus to Receive Up to $63M in Milestone Payments",2013-12-16 07:09:00-05:00,NVS,positive
935709.0,Retrophin Signs US License Agreement for Syntocinon Nasal Spray with Novartis ,2013-12-12 07:23:00-05:00,NVS,positive
935710.0,Novartis Says Jakavi Improved Overall Survival of Patients with Myelofibrosis,2013-12-09 11:32:00-05:00,NVS,positive
935711.0,Novartis to Supply Bexsero to Princeton,2013-12-09 08:09:00-05:00,NVS,neutral
935712.0,US Stock Futures Rise; All Eyes On Jobs Report,2013-12-06 07:11:00-05:00,NVS,neutral
935713.0,Novartis Investigational Compound LBH589 Met Primary Endpoint in Phase III Study,2013-12-06 06:08:00-05:00,NVS,neutral
935714.0,"Bloomberg Reporting Merck, Eli Lilly Rumored to Be Interested in Novartis' Veterinary Unit",2013-12-03 12:20:00-05:00,NVS,positive
935715.0,Novartis Wins Orphan Drug Designation for Polymyositis Treatment,2013-12-03 12:04:00-05:00,NVS,positive
935716.0,Stocks Hitting 52-Week Highs,2013-12-03 10:28:00-05:00,NVS,neutral
935717.0,Morning Market Movers ,2013-12-03 09:52:00-05:00,NVS,neutral
935718.0,Benzinga's Top #PreMarket Gainers,2013-12-03 08:37:00-05:00,NVS,positive
935719.0,"Reuters Reports Novartis Letting Bayer, Other Potential Buyers Look at Animal Health Business Books, According to Sources",2013-12-03 06:33:00-05:00,NVS,neutral
935720.0,Natixis Upgrades Novartis AG to Buy,2013-11-25 07:49:00-05:00,NVS,neutral
935721.0,Market Wrap For November 22: Markets Finish The Week On a Positive Note,2013-11-22 16:57:00-05:00,NVS,positive
935722.0,US Stock Futures Flat After Record Close,2013-11-22 07:09:00-05:00,NVS,neutral
935723.0,Novartis Announces $5B Share Buyback,2013-11-22 06:14:00-05:00,NVS,positive
935724.0,UPDATE: IntelliPharmaCeutics Will Have 180 Days Exclusivity of Generic Sales,2013-11-18 16:41:00-05:00,NVS,neutral
935725.0,"IntelliPharmaCeutics to Make Immediate Commercial Launch of 15, 30mg Generic Focalin XR",2013-11-18 16:36:00-05:00,NVS,neutral
935726.0,Mid-Day Market Update: Gogo Jumps On Upbeat Results; 8x8 Shares Tumble,2013-11-11 12:48:00-05:00,NVS,positive
935727.0,Mid-Morning Market Update: Markets Edge Higher; Shire To Acquire ViroPharma For $4.2B,2013-11-11 10:37:00-05:00,NVS,neutral
935728.0,ImmunoGen Announces License Agreement with Novartis,2013-11-11 06:38:00-05:00,NVS,positive
935729.0,"Grifols to Acquire Transfusion Diagnostics Business of Novartis for $1,675M",2013-11-11 06:11:00-05:00,NVS,neutral
935730.0,Bloomberg Reporting Novartis Said to Explore Sale of Animal-Health Unit,2013-11-04 13:35:00-05:00,NVS,neutral
935731.0,Questcor Says in Process of Transferring Critical Data from Novartis,2013-10-29 16:47:00-04:00,NVS,negative
935732.0,Alcon Receives Positive NICE Recommendation for Jetrea,2013-10-22 19:07:00-04:00,NVS,positive
935733.0,Novartis AG Reports Q3 Core EPS of $1.26 vs $1.31 Est; Revenue of $14.30B vs $14.28B Est,2013-10-22 06:03:00-04:00,NVS,neutral
935734.0,Teva Holders Shrug at FDA Approval of Generic-Version of Novartis' TOBI in US,2013-10-14 09:38:00-04:00,NVS,positive
935735.0,US Stock Futures Up; J.P. Morgan Earnings In Focus,2013-10-11 07:13:00-04:00,NVS,neutral
935736.0,ImmunoGen Announces New License Agreement with Novartis,2013-10-11 06:54:00-04:00,NVS,positive
935737.0,Shares of Vanda Pharma Bouncing Off Session Lows Despite Concern Related to Novartis's Fanapt Winning Paragraph IV Patent Notification from FDA,2013-10-09 09:45:00-04:00,NVS,positive
935738.0,MainFirst Initiates Coverage on Novartis AG at Underperform,2013-10-09 06:56:00-04:00,NVS,neutral
935739.0,JP Morgan Downgrades Novartis AG to Neutral,2013-10-08 06:29:00-04:00,NVS,positive
935740.0,Novartis Reports Evidence Gilenya Reduce MS Relapse Rates More Effectively than Interferons or Glatiramer Acetate ,2013-10-03 06:09:00-04:00,NVS,positive
935741.0,Novartis Shares Higher as Co. Says Newest Lucentis Data Reinforces Efficacy; UBS Removed Stock from 'Most Preferred' List,2013-09-27 07:43:00-04:00,NVS,positive
935742.0,"BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)",2013-09-25 12:52:00-04:00,NVS,positive
935743.0,Barron's Recap: Protecting Your Health and Wealth,2013-09-22 14:54:00-04:00,NVS,positive
935744.0,Novartis Wins FDA Orphan Drug Designation for Cushing's Disease Treatment,2013-09-19 10:06:00-04:00,NVS,positive
935745.0,Write A Prescription For Health Care ETFs,2013-09-19 08:06:00-04:00,NVS,positive
935746.0,Barclays Downgrades Novartis AG to Underweight,2013-09-16 07:48:00-04:00,NVS,neutral
935747.0,Novartis Data Demonstrates Efficacy of Ultibro Breezhaler,2013-09-08 07:26:00-04:00,NVS,neutral
935748.0,FDA Approves Novartis Request to Supplement BLA for Fluvirin at Speke Site,2013-09-06 08:27:00-04:00,NVS,positive
935749.0,"Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, VRTX)",2013-08-27 13:29:00-04:00,NVS,positive
935750.0,Amgen and Onyx Finally Ink Deal Two Months In The Making,2013-08-26 07:27:00-04:00,NVS,neutral
935751.0,US Stock Futures Down Ahead Of Economic Data,2013-08-15 07:32:00-04:00,NVS,neutral
935752.0,Novartis Vaccine Bexsero Approved in Australia,2013-08-15 05:59:00-04:00,NVS,positive
935753.0,"Benzinga's M&A Chatter for Tuesday August 13, 2013",2013-08-13 17:51:00-04:00,NVS,neutral
935754.0,Bloomberg Reporting Novartis Said to Be Out of Running for Onyx,2013-08-13 12:49:00-04:00,NVS,neutral
935755.0,Onyx Not Speculating on Novartis CEO Comments Regarding Potential $10B Acquisition,2013-08-13 12:20:00-04:00,NVS,neutral
935756.0,"UPDATE: Novartis Chair Says Will Review Business Including Animal Health, Vaccines, Calls Bolt-On Acquisitions Attractive",2013-08-13 11:32:00-04:00,NVS,positive
935757.0,Bloomberg Reporting Novartis Chair Reinhardt Speaking in Interview Said $10B Acquisition is Not 'Out of Reach',2013-08-13 11:31:00-04:00,NVS,neutral
935758.0,"Apple, Wal-Mart And Other Companies With Monster Share Buyback (AAPL, WMT)",2013-08-05 13:10:00-04:00,NVS,positive
935759.0,"(ONE) Novartis International AG : FDA Expands Age Indication for Menveo®, First and Only Quadrivalent Meningococcal Vaccine",2013-08-01 17:51:00-04:00,NVS,positive
935760.0,"Benzinga's M&A Chatter for Tuesday July 30, 2013",2013-07-30 17:41:00-04:00,NVS,neutral
935761.0,Hearing Deal Reporter Says Novartis Submits Bid for Onyx,2013-07-30 15:49:00-04:00,NVS,neutral
935762.0,"Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)",2013-07-26 10:46:00-04:00,NVS,positive
935763.0,Bloomberg Reporting a Novartis Spokesperson Has Said the Co. Has Not Been contacted by Chinese Authorities,2013-07-23 08:52:00-04:00,NVS,neutral
935764.0,"Benzinga's M&A Chatter for Monday July 22, 2013",2013-07-22 17:12:00-04:00,NVS,neutral
935765.0,"Bloomberg Reporting Pfizer, Novartis, AstraZeneca Said to Be Preparing Onyx Pharma Bids",2013-07-22 12:10:00-04:00,NVS,neutral
935766.0,"UPDATE: Novartis Posts 4.7% Fall In Q2 Profit, Lifts Sales Forecast",2013-07-17 04:53:00-04:00,NVS,positive
935767.0,"Short Interest Rises in Gilead Sciences, Onyx Pharmaceuticals (BIIB, GILD, ONXX)",2013-07-11 12:47:00-04:00,NVS,positive
935768.0,A Peek Into The Market Before The Trading Starts,2013-07-08 07:18:00-04:00,NVS,neutral
935769.0,Novartis and Biological E Enter License Agreement,2013-07-08 06:05:00-04:00,NVS,positive
935770.0,Novartis Announces Secukinumab Demonstrated Superiority to Enbrel,2013-07-08 06:04:00-04:00,NVS,positive
935771.0,5 Healthcare Stocks With The Highest Revenue,2013-07-05 07:27:00-04:00,NVS,neutral
935772.0,Financial Times Reporting That China Is Investigating 33 Foreign Pharmaceutical Companies For Pricing Irregularities,2013-07-04 07:27:00-04:00,NVS,neutral
935773.0,Novartis Files Suit Against Intas Pharma Claiming Patent Infringement on Generic Myfortic,2013-07-03 10:19:00-04:00,NVS,negative
935774.0,"Pfizer and Novartis Could Be Eyeing Onyx (PFE, NVS, ONXX)",2013-07-02 08:58:00-04:00,NVS,neutral
935775.0,Afternoon Market Losers,2013-07-01 13:53:00-04:00,NVS,negative
935776.0,"Lazard Calls Insmed's Arikace 'Still Viable' Following Competitor Concern, Continues to See Massive Upside in Shares",2013-07-01 12:00:00-04:00,NVS,positive
935777.0,Novartis reports Omalizumab Met All Primary and Secondary Endpoints in Pivotal GLACIAL Study ,2013-06-26 06:18:00-04:00,NVS,neutral
935778.0,ViroPharma and Other Biotech Stocks Recommended by Oppenheimer (VPHM),2013-06-24 15:16:00-04:00,NVS,positive
935779.0,"Leerink Swann's Gerberry Sees a Likely Win or Settle from Actavis in Litigation with Novartis, Maintains Market Perform",2013-06-14 09:57:00-04:00,NVS,positive
935780.0,UPDATE: Novartis Spokesperson Says 'Has Confidence in Integrity' of Gleevac Patent,2013-06-13 09:20:00-04:00,NVS,positive
935781.0,Sun Pharma Challenges Novartis Patent on Gleevec Crystal Form in US District Court in NJ,2013-06-13 09:19:00-04:00,NVS,positive
935782.0,"Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB)",2013-06-12 13:29:00-04:00,NVS,positive
935783.0,Jefferies Says Questcor's Acquisition of Synacthen Rights Should Soothe Investor Fears,2013-06-11 11:53:00-04:00,NVS,negative
935784.0,UPDATE: Questcor Rises 23% Pre-Market on Synacthen Rights Acquisition from Novartis,2013-06-11 09:06:00-04:00,NVS,neutral
935785.0,UPDATE: Questcor Rises 20% Pre-Market on Synacthen Acquisition from Novartis,2013-06-11 08:15:00-04:00,NVS,neutral
935786.0,UPDATE: Questcor Rises 12% Pre-Market on Synacthen Acquisition ,2013-06-11 07:44:00-04:00,NVS,neutral
935787.0,Questcor Acquires Rights to Synacthen from Novartis,2013-06-11 07:01:00-04:00,NVS,neutral
935788.0,"AstraZeneca to Acquire Pearl Therapeutics to Gain Foothold into Lucrative Market (AZN, GSK, NVS)",2013-06-10 09:18:00-04:00,NVS,positive
935789.0,"Top-Performing Dividend Payers in Health Care with the Most Upside Potential (AET, ENSG, QCOR)",2013-06-08 12:47:00-04:00,NVS,positive
935790.0,"Drug Company Profits Set to Increase from Additions to DSM-5 (LLY, NVS, PFE)",2013-06-06 08:59:00-04:00,NVS,positive
935791.0,Novartis Receives FDA Warning Over Austria Ebewe Plant - FiercePharma,2013-06-05 13:20:00-04:00,NVS,negative
935792.0,Novartis Says Breakthrough Therapy LDK378 Shows Marked Clinical Response,2013-06-03 11:32:00-04:00,NVS,neutral
935793.0,Novartis Afinitor Pivotal Phase 3 Trial Shows Significant Delay in Tumor Growth In HER2 Positive Advanced Breast Cancer ,2013-06-02 09:09:00-04:00,NVS,negative
935794.0,Novartis Wins Positive Opinion for Patients with Myopic Choroidal Neovascularization Showing Vision  Gains with Only Two Injections,2013-05-31 07:25:00-04:00,NVS,positive
935795.0,"Short Interest in Vertex Rises, in Biogen Idec Falls",2013-05-29 13:19:00-04:00,NVS,positive
935796.0,Valeant Pharmaceuticals to Buy Bausch & Lomb,2013-05-28 12:20:00-04:00,NVS,neutral
935797.0,"New data reinforces strength of Novartis once-daily COPD portfolio in improving lung function, shortness of breath and                         reducing rate of exacerbations",2013-05-21 08:22:00-04:00,NVS,positive
935798.0,Novartis Says New Data Reinforce Strength of Once-Daily COPD Portfolio,2013-05-21 08:19:00-04:00,NVS,positive
935800.0,Bloomberg Reporting Novartis Spokesperson Says Has 'No Intention' of Pursuing Actavis Bid,2013-05-16 08:14:00-04:00,NVS,negative
935801.0,Novartis Sued by US for Paying Kickbacks to Doctors,2013-04-26 13:53:00-04:00,NVS,neutral
935802.0,"Short Sellers Move into Celgene, Regeneron",2013-04-26 13:25:00-04:00,NVS,neutral
935803.0,"Novartis Says Vaccines, Diagnostics Unit Received Subpoena from US Attorney in Q1 Related to Quality",2013-04-24 10:52:00-04:00,NVS,neutral
935804.0,Novartis AG Reports Q1 Revenue of $14.02B vs $13.98B Est,2013-04-24 07:54:00-04:00,NVS,neutral
935805.0,"Earnings Scheduled For April 24, 2013",2013-04-24 04:22:00-04:00,NVS,neutral
935806.0,"Benzinga's M&A Chatter for Thursday April 11, 2013",2013-04-11 18:14:00-04:00,NVS,neutral
935807.0,ETF Showdown: A Pharma Fight,2013-04-11 16:21:00-04:00,NVS,negative
935808.0,Novartis Spokesperson Declines Comment on Rumor of Bid for Prolor Biotech,2013-04-11 11:00:00-04:00,NVS,neutral
935809.0,Globes Says Earlier Takeover Chatter in Prolor Biotech is Not True,2013-04-11 10:23:00-04:00,NVS,negative
935810.0,Hearing Unconfirmed Takeover Chatter in Prolor Biotech,2013-04-11 09:47:00-04:00,NVS,negative
935811.0,UPDATE: Bank of America Upgrades Novartis AG to Neutral on Sector Re-Rating,2013-04-08 08:28:00-04:00,NVS,neutral
935812.0,A Peek Into The Market Before The Trading Starts,2013-04-08 07:47:00-04:00,NVS,neutral
935813.0,"Bank of America Upgrades Novartis AG to Neutral, Raises to $74.71",2013-04-08 06:11:00-04:00,NVS,neutral
935814.0,"Four Dow Components Due for a Dividend Hike (CVX, XOM, IBM, JNJ)",2013-04-04 12:41:00-04:00,NVS,neutral
935815.0,"Moves in Smaller Health Care Stocks (ANAC, HALO, PBYI, QCOR)",2013-03-23 11:33:00-04:00,NVS,positive
935816.0,UPDATE: JP Morgan Upgrades Novartis to Overweight; Multiple Should Approach Peers,2013-03-15 08:25:00-04:00,NVS,neutral
935817.0,JP Morgan Upgrades Novartis AG to Overweight,2013-03-15 06:37:00-04:00,NVS,neutral
935818.0,3 ADR ETFs Your Broker Forgot to Mention,2013-03-05 14:42:00-05:00,NVS,neutral
935819.0,Are Global Health Care ETFs Worth Prescribing?,2013-02-22 11:24:00-05:00,NVS,positive
935820.0,Moody's Cuts Novartis Long-Term Rating to Aa3 from Aa2 ,2013-02-08 06:09:00-05:00,NVS,negative
935821.0,"Apple Finds A Sweet Spot In China, But Other American Brands?",2013-01-25 14:37:00-05:00,NVS,positive
935822.0,FDA Approves Exjade to Remove Excess Iron in Some Patients; Exjade Marketed by Novartis,2013-01-23 14:11:00-05:00,NVS,positive
935823.0,Citigroup Upgrades Novartis AG to Buy,2013-01-23 08:55:00-05:00,NVS,neutral
935824.0,Novartis AG Reports Q4 EPS of $1.27 vs $1.19 Est; Revenue of $14.80B vs $14.42B Est,2013-01-23 06:29:00-05:00,NVS,neutral
935825.0,UPDATE: Novartis Posts Rise In Q4 Profit,2013-01-23 03:59:00-05:00,NVS,positive
935826.0,"EMA Says Novartis, Regeneron Win Backing for Ilaris",2013-01-18 07:45:00-05:00,NVS,positive
935827.0,Hamburger Sparkasse Downgraded Novartis AG to Hold,2013-01-16 12:08:00-05:00,NVS,neutral
935828.0,Three Stocks to Buy for Flu Season,2013-01-11 13:57:00-05:00,NVS,negative
935829.0,"Endo Health, Novartis Mutually Ended Master Development/Toll Pact",2013-01-07 09:00:00-05:00,NVS,neutral
935830.0,"Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)",2012-12-28 11:10:00-05:00,NVS,positive
935831.0,Dendreon Announces Sale of New Jersey Plant to Novartis for $43M in Cash,2012-12-20 08:44:00-05:00,NVS,neutral
935832.0,Benzinga's Top Downgrades,2012-12-12 07:21:00-05:00,NVS,positive
935833.0,Deutsche Bank Downgrades Novartis AG to Hold,2012-12-12 06:09:00-05:00,NVS,neutral
935834.0,"Three More Defensive Stock Picks for 2013 (LLY, PFE, VTR)",2012-12-10 15:12:00-05:00,NVS,positive
935835.0,10 For '13: Top Picks Among Europe ETFs For 2013,2012-12-10 07:04:00-05:00,NVS,positive
935836.0,Barron's Recap (12/8/12): Ten Stock Picks for 2013,2012-12-08 13:07:00-05:00,NVS,neutral
935837.0,Novartis's FlucelVax Receives FDA Approval,2012-11-20 16:35:00-05:00,NVS,positive
935838.0,"Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)",2012-11-12 13:24:00-05:00,NVS,positive
935839.0,Novartis Announces Signifor for Cushing's Disease Recommended by FDA Panel,2012-11-07 16:29:00-05:00,NVS,positive
935840.0,"Three Biotech Stocks Analysts Are Keen On (ARIA, MACK, GEVA)",2012-10-03 14:57:00-04:00,NVS,positive
935841.0,"FDA Cancels November 8, 2012 Oncologic Drugs Advisory Committee Meeting",2012-10-03 14:45:00-04:00,NVS,negative
935842.0,ETF Showdown: Swiss Beats,2012-09-28 07:22:00-04:00,NVS,neutral
935843.0,Warning of New SARS-Like Virus -WantChinaTimes,2012-09-25 06:34:00-04:00,NVS,negative
935844.0,Benzinga's Top Upgrades,2012-09-17 07:19:00-04:00,NVS,positive
935845.0,FDA approves Novartis Afinitor Disperz for Children with Rare Brain Tumor,2012-08-30 09:19:00-04:00,NVS,neutral
935846.0,UPDATE: Novartis Posts Upbeat Q2 Profit,2012-07-19 03:30:00-04:00,NVS,positive
935847.0,"Benzinga's M&A Chatter for Tuesday June 26, 2012",2012-06-26 18:04:00-04:00,NVS,neutral
935848.0,Spokesperson for Novartis Declines Comment on Amylin Bid,2012-06-26 15:00:00-04:00,NVS,neutral
935849.0,Spokesperson for Amylin Pharmaceuticals Won't Comment on Rumor of Bids from Pharma Companies,2012-06-26 13:17:00-04:00,NVS,neutral
935850.0,"Novartis, Sanofi, Merck, Bristol, AstraZeneca Weigh Amylin Final Bids; Amylin Expects Final Bids Starting End of the Week -Reuters ",2012-06-26 11:38:00-04:00,NVS,neutral
935851.0,5 Healthcare Stocks With The Highest Revenue,2012-06-12 07:45:00-04:00,NVS,neutral
935852.0,"Blueberries, Gold Bond, Ovaltine and Obesity: The Makings for a Very Good Story (Part 1)",2012-05-23 17:03:00-04:00,NVS,positive
935853.0,"Novartis Sues Lupin, Torrent Over Blood-Pressure Drug -Bloomberg",2012-05-14 10:12:00-04:00,NVS,neutral
935854.0,Novartis Will Buy Fougera Pharma for $1.525B,2012-05-02 16:19:00-04:00,NVS,neutral
935855.0,Novartis AG Reports Q1 EPS $1.27 vs $1.32 Est; Revenues $13.73B vs $13.95B Est,2012-04-24 07:09:00-04:00,NVS,neutral
935856.0,UPDATE: Novartis Reports Decline In Q1 Profit,2012-04-24 04:37:00-04:00,NVS,positive
935857.0,"Benzinga's M&A Chatter for Tuesday March 20, 2012",2012-03-20 20:03:00-04:00,NVS,neutral
935858.0,Novartis Spokesperson Would Not Comment on Rumor of Hospira Takeover by Sandoz,2012-03-20 15:56:00-04:00,NVS,neutral
935859.0,"Barron's Recap: Home Prices on the Rebound, the BATS Global Markets IPO",2012-03-18 11:05:00-04:00,NVS,neutral
935860.0,EMA Says Novartis Withdraws Applications For Revastigmine Extn,2012-03-15 11:13:00-04:00,NVS,neutral
935861.0,Positive Rumors Circulate About Celgene,2012-03-13 10:24:00-04:00,NVS,positive
935862.0,UPDATE: JP Morgan Downgrades Novartis to Neutral,2012-03-06 09:49:00-05:00,NVS,positive
935863.0,Benzinga's Top Downgrades,2012-03-06 08:08:00-05:00,NVS,positive
935864.0,"Financial Breakfast: Morning News Summary for March 6, 2012",2012-03-06 07:23:00-05:00,NVS,neutral
935865.0,JP Morgan Downgrades Novartis AG from Overweight to Neutral,2012-03-06 06:00:00-05:00,NVS,neutral
935866.0,FDA Approves Important Safety Label Changes For The Class Of Cholesterol-Lowering Drugs Known As Statins -Reuters,2012-02-28 13:20:00-05:00,NVS,positive
935867.0,"Option Alert: Heavy Call Buying in Novartis, April 50, 52.5, 55 Calls",2012-02-24 14:10:00-05:00,NVS,positive
935868.0,UPDATE: Bank of America Downgrades Novartis to Underperform,2012-02-06 09:20:00-05:00,NVS,neutral
935869.0,From Earlier: FDA Approves Novartis Drug Gleevec Label Recommending Extending Treatment to Three Years for Certain GIST Patients After Surgery  ,2012-02-01 06:52:00-05:00,NVS,positive
935870.0,Earnings Roundup,2012-01-25 09:25:00-05:00,NVS,neutral
935871.0,"Financial Breakfast: Morning News Summary for January 25, 2012",2012-01-25 07:26:00-05:00,NVS,neutral
935872.0,Novartis AG Reports Q4 EPS $1.23 vs $1.24 Est; Revenues $14.78B vs $14.93B Est 				,2012-01-25 06:45:00-05:00,NVS,neutral
935873.0,Novartis Q4 Net Profit Drops 46%,2012-01-25 03:46:00-05:00,NVS,positive
935874.0,"Benzinga's M&A Chatter for Tuesday January 17, 2012",2012-01-17 20:00:00-05:00,NVS,neutral
935875.0,"Drug Failures and Firings will Hurt Novartis, But Can a Dividend Heal All Ills? ",2012-01-13 08:06:00-05:00,NVS,negative
935876.0,US Stock Futures Mixed; J.P. Morgan Earnings In Focus ,2012-01-13 06:27:00-05:00,NVS,neutral
935877.0,"Novartis To Lower 1,960 Job",2012-01-13 04:57:00-05:00,NVS,negative
935878.0,Stocks To Watch For January 13,2012-01-13 03:20:00-05:00,NVS,neutral
935879.0,How to Trade Biotechs Based on the JP Morgan Health Care Conference,2012-01-11 15:48:00-05:00,NVS,positive
935880.0,Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target?,2012-01-10 14:54:00-05:00,NVS,neutral
935881.0,Will the Swiss Guide Europe?,2012-01-09 12:09:00-05:00,NVS,neutral
935882.0,Stay Safe in 2012 With These 5 Stocks,2011-12-29 16:28:00-05:00,NVS,positive
935883.0,Best Biotech Stocks of 2011,2011-12-27 10:39:00-05:00,NVS,positive
935884.0,"Benzinga's M&A Chatter for Tuesday December 20, 2011",2011-12-20 17:09:00-05:00,NVS,neutral
935885.0,Notable Call Options Activity in Novartis,2011-12-20 10:40:00-05:00,NVS,neutral
935886.0,Dendreon Spiking Higher on Rumored Discussion with Novartis,2011-12-20 10:33:00-05:00,NVS,neutral
935887.0,Key Phase IIb Clinical Trial Results Await Smoking Cessation Player This Week,2011-12-19 11:45:00-05:00,NVS,positive
935888.0,Notable Put Options Activity in Novartis,2011-12-12 15:07:00-05:00,NVS,neutral
935889.0,Novartis Says Patient Died Day After Beginning Gilenya Therapy,2011-12-12 11:29:00-05:00,NVS,negative
935890.0,Five Biotech Stocks to Watch Going into Big Doctors' Meeting,2011-12-09 13:06:00-05:00,NVS,neutral
935891.0,GenVec Achieves Second Milestone in Collaboration ,2011-12-06 07:58:00-05:00,NVS,neutral
935892.0,Citigroup Initiates Novartis at Neutral,2011-11-29 12:56:00-05:00,NVS,neutral
935893.0,Novartis AG Hits 52-Week Low of $51.75,2011-11-25 09:30:00-05:00,NVS,negative
935894.0,Mad Money Lightning Round: Cramer Likes Waste Management,2011-11-22 04:33:00-05:00,NVS,negative
935895.0,Will Incyte's Blood Cancer Drug Bring Dividends?,2011-11-18 10:27:00-05:00,NVS,negative
935896.0,Study Shows Novartis Malaria Drug Kills Bugs at Earliest Stage,2011-11-17 14:00:00-05:00,NVS,negative
935897.0,Intellipharmaceutics Announces Milestone; Analysts Raise Firm's Price Targets Ahead of Another ,2011-11-01 00:57:00-04:00,NVS,neutral
935898.0,Watch for YM BioSciences' Upcoming Clinical Data Catalyst,2011-10-31 23:15:00-04:00,NVS,neutral
935899.0,"End-of-Day Market Summary for October 25, 2011",2011-10-25 16:15:00-04:00,NVS,neutral
935900.0,What Does Novartis' Earnings Release Really Mean for the Company?,2011-10-25 14:11:00-04:00,NVS,neutral
935901.0,Novartis Spiking Lower on Heavy Volume,2011-10-25 11:56:00-04:00,NVS,negative
935902.0,Earnings Roundup ,2011-10-25 09:48:00-04:00,NVS,neutral
935903.0,From Earlier: Novartis Reports Q3 EPS $1.45 vs $1.45 Est; Revenues $14.8B vs $15.09B Est			,2011-10-25 09:04:00-04:00,NVS,neutral
935904.0,Novartis Reports 7.9% Rise In Q3 Net Profit,2011-10-25 07:15:00-04:00,NVS,positive
935905.0,13 Drug Companies Trying to Beat the Odds in Pancreatic Cancer,2011-10-24 12:00:00-04:00,NVS,negative
935906.0,Regeneron Shares Falling On Competitor Concerns,2011-10-05 14:39:00-04:00,NVS,positive
935907.0,New Novartis Data Show Potential Of Respiratory Portfolio To Help COPD Patients Maintain Active And Productive Lives,2011-09-27 06:57:00-04:00,NVS,positive
935908.0,UPDATE: Novartis Drug Gives Relief Of Symptoms In 84% Of Study Patients; Will File Ilaris For SJIA Indication Next Year,2011-09-16 11:30:00-04:00,NVS,positive
935909.0,Novartis: Ilaris Gives Good Results In Study,2011-09-16 11:30:00-04:00,NVS,positive
935910.0,Novartis gets European Commission Approval for Afinitor to Treat Advanced Pancreatic Tumors,2011-09-05 16:21:00-04:00,NVS,positive
935911.0,How to Profit from Swiss Central Bank's Efforts to Halt Rise of Swiss Franc,2011-08-10 05:56:00-04:00,NVS,positive
935912.0,Calls Purchased on Novartis,2011-08-08 10:23:00-04:00,NVS,neutral
935913.0,Swiss Stocks: The Last Haven?,2011-08-05 18:01:00-04:00,NVS,neutral
935914.0,Amneal Announces Four New Generic Drugs ,2011-08-02 10:31:00-04:00,NVS,neutral
935915.0,Watson Pharmaceuticals Earnings Preview,2011-07-25 11:13:00-04:00,NVS,neutral
935916.0,"Earnings Preview: Mylan Laboratories EPS, Revenue Expected to Rise from Previous Quarter",2011-07-22 11:38:00-04:00,NVS,neutral
935917.0,Earnings Roundup ,2011-07-19 09:01:00-04:00,NVS,neutral
935918.0,UPDATE: Novartis Reports 12% Rise In Q2 Net Profit,2011-07-19 06:35:00-04:00,NVS,positive
935919.0,Novartis: Earnings Preview ,2011-07-18 19:09:00-04:00,NVS,neutral
935920.0,Five Undervalued Blue Chips with Above-average and Growing Yield,2011-07-08 08:26:00-04:00,NVS,positive
935921.0,Five Undervalued Blue Chips with Above-average and Growing Yield,2011-07-07 16:17:00-04:00,NVS,positive
935922.0,"News Summary for July 5, 2011",2011-07-05 07:59:00-04:00,NVS,neutral
935923.0,Novartis Drug Afinitor® Met Primary Endpoint Of Phase III Study In Women,2011-07-05 07:40:00-04:00,NVS,neutral
935924.0,Stocks To Watch For July 5,2011-07-05 04:05:00-04:00,NVS,neutral
935925.0,"Novartis Receives Approval In Japan For Onbrez; Inhalation Capsules, For Patients With COPD",2011-07-01 11:34:00-04:00,NVS,positive
935926.0,Forest Labs and Watson Pharma to Open Near 52-Week Highs,2011-06-23 08:44:00-04:00,NVS,neutral
935927.0,UPDATE: The Panel has Voted 11-1 Against the Approval of the Novartis Drug,2011-06-21 15:32:00-04:00,NVS,positive
935928.0,UPDATE: FDA Voting on Novartis Approval,2011-06-21 15:28:00-04:00,NVS,positive
935929.0,FDA Panel has Voted 12-0 that Novartis Gout Drug is Not Considered Safe,2011-06-21 15:12:00-04:00,NVS,negative
935930.0,"Gen-Probe Incorporated: Hearing Chatter of Novartis and ""Expensive"" Assets, According to Sources",2011-06-17 14:54:00-04:00,NVS,positive
935931.0,"FDA Comments in Staff Report About Novartis Drug Ilaris Reducing Gout Pain, May Increase Risk of Infection ",2011-06-17 08:12:00-04:00,NVS,negative
935932.0,Novartis Application for Expanded Menveo Indication from 2 Months of Age Accepted for Review by FDA  ,2011-06-16 07:16:00-04:00,NVS,positive
935933.0,It's Inverted Hammertime!  06-06-2011,2011-06-06 15:25:00-04:00,NVS,neutral
935934.0,Parkinson's Disease Bacteria Link Discovered: Companies Looking for a Cure,2011-05-23 23:04:00-04:00,NVS,neutral
935935.0,Europe's sovereign-debt crisis Effects on Drug Stocks,2011-05-23 14:27:00-04:00,NVS,negative
935936.0,Top Healthcare and Major Drugs stocks to watch- Sector Performance,2011-05-22 14:55:00-04:00,NVS,positive
935937.0,"WSJ: Novartis, Life Technologies Also In The Mix For Gen-Probe - Sources",2011-05-18 15:09:00-04:00,NVS,neutral
935938.0,10 Stocks Billionaire Steven Cohen Is Buying,2011-05-17 14:00:00-04:00,NVS,neutral
935939.0,CEOWORLD Most Promising Top Dividend Stock Picks To Buy Right Now,2011-05-15 10:11:00-04:00,NVS,positive
935940.0,Emerging Markets,2011-05-11 08:11:00-04:00,NVS,neutral
935941.0,Novartis Fires Senior Managers for Misconduct -WSJ (NVS),2011-05-10 07:38:00-04:00,NVS,neutral
935942.0,UPDATE: FDA Approves New Treatment for Rare Type of Pancreatic Cancer (NVS),2011-05-06 10:00:00-04:00,NVS,negative
935943.0,"Top Gainers and Losers Stock Picks based on mkt cap (5/5/11)- PG, INTC, MSFT, NVS, GMCR, BHP, PBR, VALE, VALE.P, PBR.A",2011-05-05 06:35:00-04:00,NVS,negative
935944.0,"CEOWORLD Top 5 Analyst Calls of the Week- DNDN, INSP, MCP, SIRI, VICL",2011-05-02 03:32:00-04:00,NVS,positive
935945.0,"Potential Buyers For Gen-Probe (GPRO, ABT, CELG, NVS, TMO)",2011-04-28 11:12:00-04:00,NVS,neutral
935946.0,"Earnings Preview For Celgene Corporation (CELG, NVS)",2011-04-27 16:02:00-04:00,NVS,neutral
935947.0,"Five Stocks that May End Up, umm, Higher, if Marijuana is Legalized",2011-04-20 11:02:00-04:00,NVS,neutral
935948.0,Novartis Reports Q1 EPS of $1.41,2011-04-19 06:29:00-04:00,NVS,neutral
935949.0,"Hapoalim Securities Reiterates Buy Rating, $15 PT On VNDA",2011-04-12 08:11:00-04:00,NVS,positive
935950.0,"LifeTech Capital Comments On Merck Acquisition (MRK, ISPH)",2011-04-07 08:42:00-04:00,NVS,neutral
935951.0,"Unconfirmed Rumors circulate that Novartis AG (NVS) Is in talks with Star Scientific, Inc. (CIGX) on a major Joint Venture.Would be huge positive for (CIGX).",2011-02-16 11:50:00-05:00,NVS,positive
935952.0,Valentine's KISS  02-14-2011,2011-02-14 14:58:00-05:00,NVS,positive
935953.0,Vanda Pharmaceuticals Falling On Disappointing Drug Sales (VNDA),2011-02-04 12:21:00-05:00,NVS,negative
935954.0,Biogen Beats by a Wide Margin - Analyst Blog,2011-02-01 14:24:00-05:00,NVS,neutral
935955.0,Biogen Beats by a Wide Margin - Analyst Blog,2011-02-01 14:00:00-05:00,NVS,neutral
935956.0,Onyx Makes Headway with Carfilzomib - Analyst Blog,2011-02-01 10:31:00-05:00,NVS,neutral
935957.0,Onyx Makes Headway with Carfilzomib - Analyst Blog,2011-02-01 10:00:00-05:00,NVS,neutral
935958.0,Piper Jaffray Defends THRX Following Delayed Sell-Off,2011-01-31 09:15:00-05:00,NVS,negative
935959.0,Vaccines Pull Down NVS Q4 Earnings  - Analyst Blog,2011-01-28 10:31:00-05:00,NVS,neutral
935960.0,Vaccines Pull Down NVS Q4 Earnings  - Analyst Blog,2011-01-28 10:15:00-05:00,NVS,neutral
935961.0,Novartis to Buy Genoptix - Analyst Blog,2011-01-28 08:40:00-05:00,NVS,neutral
935962.0,Novartis to Buy Genoptix - Analyst Blog,2011-01-28 08:15:00-05:00,NVS,neutral
935963.0,Alcon's Winning Streak Continues - Analyst Blog,2011-01-27 12:01:00-05:00,NVS,positive
935964.0,Alcon's Winning Streak Continues - Analyst Blog,2011-01-27 11:30:00-05:00,NVS,positive
935965.0,"Market Roundup (HAL, GXDX, NVS, INTC, AXP, CSX, TXN)",2011-01-24 11:28:00-05:00,NVS,neutral
935966.0,"Top Narrow Based Indexes For January 24 (CLDA, LDK, GXDX)",2011-01-24 11:09:00-05:00,NVS,positive
935967.0,"Benzinga's Volume Movers (GXDX, CLDA, HUGH, LPHI)",2011-01-24 10:48:00-05:00,NVS,neutral
935968.0,"Morning Market Movers (CLDA, OCCF, SSCC, GXDX)",2011-01-24 09:54:00-05:00,NVS,neutral
935969.0,"Benzinga's Top Pre-Market NASDAQ Gainers (CLDA, GXDX, NVDA, ATPG)",2011-01-24 08:20:00-05:00,NVS,positive
935970.0,5 Drug Stocks With Upside Potential of 25%,2011-01-20 10:13:00-05:00,NVS,neutral
935971.0,MannKind in Jeopardy - Analyst Blog,2011-01-20 10:01:00-05:00,NVS,negative
935972.0,MannKind in Jeopardy - Analyst Blog,2011-01-20 09:45:00-05:00,NVS,negative
935973.0,Cooper Launches Avaira Toric - Analyst Blog,2011-01-19 08:31:00-05:00,NVS,neutral
935974.0,Cooper Launches Avaira Toric - Analyst Blog,2011-01-19 08:00:00-05:00,NVS,neutral
935975.0,Biogen's Business Update - Analyst Blog,2011-01-13 12:01:00-05:00,NVS,neutral
935976.0,Biogen's Business Update - Analyst Blog,2011-01-13 11:30:00-05:00,NVS,neutral
935977.0,Lucentis Gains EU Approval for DME - Analyst Blog,2011-01-13 08:46:00-05:00,NVS,positive
935978.0,Lucentis Gains EU Approval for DME - Analyst Blog,2011-01-13 08:00:00-05:00,NVS,positive
935979.0,Xoma: Key Diabetes Drug Study Preview,2011-01-03 19:03:00-05:00,NVS,neutral
935980.0,"XOMA Shares Climb 8.6% (XOMA, NVG, MRK)",2010-12-30 14:23:00-05:00,NVS,positive
935981.0,"Thursday's Put/Call Ratio Leaders (CTXS, NTAP, BCS, NVS, MDT)",2010-12-30 12:34:00-05:00,NVS,neutral
935982.0,Top 10 Emerging Markets Stocks in 2010,2010-12-30 11:13:00-05:00,NVS,positive
935983.0,INCY's INC424 Meets Goal - Analyst Blog,2010-12-22 11:33:00-05:00,NVS,neutral
935984.0,INCY's INC424 Meets Goal - Analyst Blog,2010-12-22 11:15:00-05:00,NVS,neutral
935985.0,Cooper Remains at Outperform - Analyst Blog,2010-12-21 18:03:00-05:00,NVS,neutral
935986.0,Cooper Remains at Outperform - Analyst Blog,2010-12-21 18:03:00-05:00,NVS,neutral
935987.0,Cooper Remains at Outperform - Analyst Blog,2010-12-21 17:27:00-05:00,NVS,neutral
935988.0,Cooper Remains at Outperform - Analyst Blog,2010-12-21 17:27:00-05:00,NVS,neutral
935989.0,Big Pharma in Frenzy of Drug Deals,2010-12-21 11:34:00-05:00,NVS,negative
935990.0,Genzyme Up After Analyst Day (GENZ),2010-12-20 15:04:00-05:00,NVS,neutral
935991.0,Novartis Commits $500 Million to Russia,2010-12-20 04:38:00-05:00,NVS,neutral
935992.0,Amgen Drug Meets Primary Endpoint - Analyst Blog,2010-12-17 18:03:00-05:00,NVS,neutral
935993.0,Amgen Drug Meets Primary Endpoint - Analyst Blog,2010-12-17 17:42:00-05:00,NVS,neutral
935994.0,Watching the Strength of this Uptrend  12-16-2010,2010-12-16 15:11:00-05:00,NVS,positive
935995.0,Novartis to Wrap Up Alcon Buy - Analyst Blog,2010-12-16 12:24:00-05:00,NVS,neutral
935996.0,Novartis to Wrap Up Alcon Buy - Analyst Blog,2010-12-16 12:00:00-05:00,NVS,neutral
935997.0,"Stock Market News for Dec 16, 2010 - Market News",2010-12-16 09:33:00-05:00,NVS,neutral
935998.0,Novartis Trading Lower Today,2010-12-16 09:22:00-05:00,NVS,negative
935999.0,"Stock Market News for Dec 16, 2010 - Market News",2010-12-16 09:06:00-05:00,NVS,neutral
936000.0,Good Data on Teva's Laquinimod - Analyst Blog,2010-12-15 17:03:00-05:00,NVS,positive
936001.0,Good Data on Teva's Laquinimod - Analyst Blog,2010-12-15 16:42:00-05:00,NVS,positive
936002.0,"Large Cap Winners & Losers (NVS, CAT, HDB, FBR)",2010-12-15 13:43:00-05:00,NVS,negative
936003.0,Novartis' Zometa Disappoints - Analyst Blog,2010-12-15 12:00:00-05:00,NVS,negative
936004.0,Novartis' Zometa Disappoints - Analyst Blog,2010-12-15 11:45:00-05:00,NVS,negative
936005.0,"Company News for December 15, 2010 - Corporate Summary",2010-12-15 10:33:00-05:00,NVS,neutral
936006.0,"Company News for December 15, 2010 - Corporate Summary",2010-12-15 10:10:00-05:00,NVS,neutral
936007.0,"M&A News (CYPB, NVS, ACL, RF)",2010-12-15 08:46:00-05:00,NVS,neutral
936008.0,A Peek Into The Market Before The Trading Starts,2010-12-15 07:48:00-05:00,NVS,neutral
936009.0,Novartis Completes Takeover Of Alcon,2010-12-15 07:35:00-05:00,NVS,neutral
936010.0,US Stock Futures Down As Investors Await Economic Data,2010-12-15 06:56:00-05:00,NVS,positive
936011.0,Novartis Buys Rest of Alcon Stake for $12.9B,2010-12-15 03:54:00-05:00,NVS,neutral
936012.0,Novartis Presents Positive Data  - Analyst Blog,2010-12-14 12:30:00-05:00,NVS,positive
936013.0,Novartis Presents Positive Data  - Analyst Blog,2010-12-14 11:30:00-05:00,NVS,positive
936014.0,NVS Presents Positive Data at ASH - Analyst Blog,2010-12-10 12:57:00-05:00,NVS,positive
936015.0,"Friday's Put/Call Ratio Leaders (NVS, STD, BPOP, GCI, MU)",2010-12-10 12:12:00-05:00,NVS,neutral
936016.0,NVS Presents Positive Data at ASH - Analyst Blog,2010-12-10 10:47:00-05:00,NVS,positive
936017.0,"Cooper Outperforms, Profit Zooms - Analyst Blog",2010-12-09 06:03:00-05:00,NVS,positive
936018.0,"Cooper Outperforms, Profit Zooms - Analyst Blog",2010-12-08 15:33:00-05:00,NVS,positive
936019.0,"Cooper Outperforms, Profit Zooms - Analyst Blog",2010-12-08 15:06:00-05:00,NVS,positive
936020.0,"Cooper Outperforms, Profit Zooms - Analyst Blog",2010-12-08 15:06:00-05:00,NVS,positive
936021.0,Some Good News for Onyx Pharma - Analyst Blog,2010-12-08 14:03:00-05:00,NVS,positive
936022.0,Some Good News for Onyx Pharma - Analyst Blog,2010-12-08 13:19:00-05:00,NVS,positive
936023.0,"Wednesday's Put/Call Ratio Leaders (NVS, JDSU, DHI, FLR, DG)",2010-12-08 12:28:00-05:00,NVS,neutral
936024.0,Phase III Data on PFE's Bosutinib - Analyst Blog,2010-12-08 11:33:00-05:00,NVS,neutral
936025.0,Phase III Data on PFE's Bosutinib - Analyst Blog,2010-12-08 10:48:00-05:00,NVS,neutral
936026.0,Good News for Bristol-Myers - Analyst Blog,2010-12-07 14:00:00-05:00,NVS,positive
936027.0,Good News for Bristol-Myers - Analyst Blog,2010-12-07 13:54:00-05:00,NVS,positive
936028.0,"Benzinga's Top Upgrades (GFI, NVS, VE, TEL)",2010-12-07 13:53:00-05:00,NVS,positive
936029.0,Neutral on Incyte - Analyst Blog,2010-12-03 17:00:00-05:00,NVS,neutral
936030.0,Neutral on Incyte - Analyst Blog,2010-12-03 16:17:00-05:00,NVS,neutral
936031.0,CBST's Fast-Injection Cubicin OK'd - Analyst Blog,2010-12-03 16:01:00-05:00,NVS,neutral
936032.0,CBST's Fast-Injection Cubicin OK'd - Analyst Blog,2010-12-03 15:32:00-05:00,NVS,neutral
936033.0,Economy Adds Fewer Jobs in November,2010-12-03 08:43:00-05:00,NVS,neutral
936034.0,"ADP: November Payrolls Rise 93,000",2010-12-01 08:34:00-05:00,NVS,neutral
936035.0,Neutral on Regeneron - Analyst Blog,2010-11-29 15:00:00-05:00,NVS,neutral
936036.0,Neutral on Regeneron - Analyst Blog,2010-11-29 09:37:00-05:00,NVS,neutral
936037.0,"Tuesday's Put/Call Ratio Leaders (IFF, GVA, NVS, ANN, TLAB)",2010-11-23 12:26:00-05:00,NVS,neutral
936038.0,"Unconfirmed Rumors continue to swirl that Questcor Pharmaceuticals, Inc. (QCOR) will be acquired by a Major Pharma at $24.00 a share ",2010-11-19 10:01:00-05:00,NVS,positive
936039.0,Amgen's Xgeva Approved  - Analyst Blog,2010-11-19 08:03:00-05:00,NVS,positive
936040.0,Amgen's Xgeva Approved  - Analyst Blog,2010-11-19 02:30:00-05:00,NVS,positive
936041.0,"WCRX Beats on Earnings, Ups Outlook - Analyst Blog",2010-11-17 10:03:00-05:00,NVS,neutral
936042.0,"WCRX Beats on Earnings, Ups Outlook - Analyst Blog",2010-11-17 04:40:00-05:00,NVS,neutral
936043.0,Ardea Biosciences Evenly Poised - Analyst Blog,2010-11-16 18:33:00-05:00,NVS,positive
936044.0,"Tuesday's Put/Call Ratio Leaders (CADX, ROC, LH, MNTA, NVS)",2010-11-16 13:10:00-05:00,NVS,neutral
936045.0,Positive on Biogen - Analyst Blog,2010-11-16 11:33:00-05:00,NVS,positive
936046.0,"PDLI Meets EPS, Beats on Top Line - Analyst Blog",2010-11-16 11:06:00-05:00,NVS,positive
936047.0,"PDLI Meets EPS, Beats on Top Line - Analyst Blog",2010-11-16 11:06:00-05:00,NVS,positive
936048.0,"PDLI Meets EPS, Beats on Top Line - Analyst Blog",2010-11-16 11:06:00-05:00,NVS,positive
936049.0,Deflation Takes Back Seat  11-15-2010,2010-11-15 18:27:00-05:00,NVS,neutral
936050.0,Financials Show Strength  11-15-2010,2010-11-15 18:25:00-05:00,NVS,positive
936051.0,"Monday's Mid-Day Options Volume Leaders (NVS, QCOM, F, AAPL, CSCO)",2010-11-15 11:23:00-05:00,NVS,neutral
936052.0,"Zacks Analyst Blog Highlights: Alnylam Pharmaceuticals, Roche, Novartis, Cubist Pharmaceuticals and Biogen Idec     - Press Releases",2010-11-11 10:33:00-05:00,NVS,neutral
936053.0,"Unconfirmed Rumor: Novartis AG to Acquire Onyx Pharmaceuticals (NVS, ONXX)",2010-11-08 09:42:00-05:00,NVS,negative
936054.0,Positive Results In Study of Novartis Drug Afinitor (NVS),2010-11-03 17:33:00-04:00,NVS,positive
936055.0,"Benzinga's Top ETF Decliners (SRTY, EPV, EDZ, TMV)",2010-11-02 16:52:00-04:00,NVS,positive
936056.0,"Friday's Put/Call Ratio Leaders (NWL, RYL, NVS, QSII, BMY)",2010-10-29 12:52:00-04:00,NVS,neutral
936057.0,"Benzinga's Top ETF Decliners (AGA, ZSL, DZZ, EPV)",2010-10-28 17:40:00-04:00,NVS,positive
936058.0,"Thursday's Put/Call Ratio Leaders (LBTYA, MFN, RYL, NVS, GENZ)",2010-10-28 12:56:00-04:00,NVS,neutral
936059.0,"Zacks Bull and Bear of the Day Highlights: Gilead Sciences, Linear Technology, Biogen Idec, Elan and Novartis     - Press Releases",2010-10-27 15:33:00-04:00,NVS,neutral
936060.0,"Benzinga's Top ETF Gainers (TMV, TBT, PALL, DPK)",2010-10-26 17:36:00-04:00,NVS,positive
936061.0,New Products Drive Novartis - Analyst Blog,2010-10-21 13:00:00-04:00,NVS,neutral
936062.0,"Earnings Scheduled For October 21 (MCD, CAT, T, LLY, CS, UAL, BAX, NVS, UNP, UPS, BBT, PM, RAI, CTXS, SNDK, JBLU, AXP, TRV, LUV, AMZN, STI, HSY, XRX, CB)",2010-10-21 04:27:00-04:00,NVS,neutral
936063.0,S&P Downgrades Novartis AG (NVS)  From Buy to Hold ,2010-10-06 16:55:00-04:00,NVS,neutral
936064.0,"Tuesday's Put/Call Ratio Leaders (CAVM, WL, AVP, CHTP, NVS)",2010-10-05 12:40:00-04:00,NVS,neutral
936065.0,Bristol Myers at Neutral - Analyst Blog,2010-10-04 23:21:00-04:00,NVS,neutral
936066.0,Biogen Cut to Neutral - Analyst Blog,2010-10-03 19:30:00-04:00,NVS,negative
936067.0,"Wednesday's Put/Call Ratio Leaders (NVS, DTV, JWN, CIM, MOT)",2010-09-29 12:52:00-04:00,NVS,neutral
936068.0,Jefferies Raises Price Target On Warner Chilcott  (WCRX),2010-09-27 07:12:00-04:00,NVS,neutral
936069.0,Piper Jaffray Neutral On Alnylam Pharmaceuticals  (ALNY),2010-09-24 07:40:00-04:00,NVS,neutral
936070.0,Biogen Falling On Novartis Approval ,2010-09-22 11:52:00-04:00,NVS,positive
936071.0,US Stock Futures Signals A Low Start After Federal Reserve Warning On Economic Recovery,2010-09-22 08:06:00-04:00,NVS,negative
936072.0,"Top 4 Large-Cap Stocks In The Drug Manufacturers–Major Industry With The Highest EPS Estimates (AZN, NVS, ABT, GSK)",2010-09-22 05:24:00-04:00,NVS,positive
936073.0,J&J Makes a Pitch for Crucell - Analyst Blog,2010-09-18 11:06:00-04:00,NVS,neutral
936074.0,"Cooper Profit Grows, Lifts View - Analyst Blog",2010-09-03 15:36:00-04:00,NVS,positive
936075.0,Bausch + Lomb to Acquire Miochol(R)-E  (NVS),2010-09-03 12:21:00-04:00,NVS,neutral
936076.0,Upside Purchased on Novartis AG (NVS),2010-09-02 10:21:00-04:00,NVS,neutral
936077.0,New Dosages of Solodyn Approved - Analyst Blog,2010-08-31 14:06:00-04:00,NVS,positive
936078.0,Novartis' Tekamlo Gains FDA Nod - Analyst Blog,2010-08-30 18:36:00-04:00,NVS,positive
936079.0,Incyte Evenly Poised - Analyst Blog,2010-08-30 13:03:00-04:00,NVS,positive
936080.0,NVS Acquires Majority Share in ACL - Analyst Blog,2010-08-26 11:54:00-04:00,NVS,positive
936081.0,Generic Risk For Gilead's Hepsera  - Analyst Blog,2010-08-23 08:21:00-04:00,NVS,negative
936082.0,FDA to Withdraw Shire Drug Approval  - Analyst Blog,2010-08-19 15:04:00-04:00,NVS,positive
936083.0,Puts Purchased on Novartis AG (NVS),2010-08-18 10:15:00-04:00,NVS,neutral
936084.0,Ardea remains Neutral  - Analyst Blog,2010-08-17 16:38:00-04:00,NVS,neutral
936085.0,"Zacks Analyst Blog Highlights: Elan, Transition Therapeutics, Pfizer, Novartis AG, Johnson & Johnson and Forest Laboratories - Press Releases",2010-08-17 10:43:00-04:00,NVS,neutral
936086.0,Lower Q2 Loss at Marina  - Analyst Blog,2010-08-17 00:24:00-04:00,NVS,negative
936087.0,Elan to Move ELND005 to Phase III  - Analyst Blog,2010-08-16 15:37:00-04:00,NVS,neutral
936088.0,Fed's Mood Altering Statement  08-10-2010,2010-08-10 19:40:00-04:00,NVS,neutral
936089.0,Q2 Loss Widens at Ardea - Analyst Blog,2010-08-09 12:09:00-04:00,NVS,negative
936090.0,Finally There Is A Cure For Tobacco Addiction (CIGX),2010-08-09 10:17:00-04:00,NVS,neutral
936091.0,ALNY's 2Q Loss Down on Lower Costs - Analyst Blog,2010-08-05 14:44:00-04:00,NVS,negative
936092.0,Gen-Probe Leaps Ahead of Forecast  - Analyst Blog,2010-07-30 17:09:00-04:00,NVS,neutral
936093.0,"Pharma Names Rallying on FDA Decision about Lovenox (INSM, MNTA, ABC, MHS)",2010-07-23 11:17:00-04:00,NVS,neutral
936094.0,"Benzinga's Top ETF Decliners (DRV, TZA, SRTY, DPK)",2010-07-22 16:57:00-04:00,NVS,positive
936095.0,Citigroup Reiterates Buy Rating on Novartis (NVS),2010-07-16 09:23:00-04:00,NVS,neutral
936096.0,"Company News for July 15, 2010 - Corporate Summary",2010-07-15 09:34:00-04:00,NVS,neutral
936097.0,"Miller Tabak Likes Bristol Myers Squibb (BMY), Novartis (NVS) And Merck (MRK)",2010-07-13 14:30:00-04:00,NVS,positive
936098.0,Bid Lacks Conviction  07-07-2010,2010-07-07 14:45:00-04:00,NVS,neutral
936099.0,"Alcon, Inc.Acquires LenSx, Still In Negotiations With Novartis (ACL, NVS)",2010-07-07 12:11:00-04:00,NVS,neutral
936100.0,"Is Star Scientific Being Shopped? (CIGX, NVS)",2010-06-25 10:27:00-04:00,NVS,neutral
936101.0,"Safety Concerns Main Topic of Novartis' Gilenia FDA Meeting Tomorrow (NVS, TEVA, BIIB)",2010-06-09 11:23:00-04:00,NVS,positive
936102.0,Puts Purchased on Novartis (NVS),2010-05-28 13:36:00-04:00,NVS,neutral
936103.0,"Karen Finerman Sees An Opportunity In ACL, ARG, SII, GGP",2010-05-24 20:07:00-04:00,NVS,positive
936104.0,Calls Sold on Novartis (NVS),2010-05-21 12:25:00-04:00,NVS,neutral
936105.0,Bulls Target Novartis (NVS),2010-05-20 12:58:00-04:00,NVS,neutral
936106.0,"Market Roundup (HON, NVS, FNXMF, QADMF, GS)",2010-05-19 14:42:00-04:00,NVS,neutral
936107.0,Put Volume Grows in Novartis (NVS),2010-05-18 15:54:00-04:00,NVS,neutral
936108.0,"Top 5 Stocks In The Healthcare Sector With Highest Cash (PFE, WLP, JNJ, NVS, AMGN)",2010-04-19 07:28:00-04:00,NVS,positive
936109.0,Pete Najarian Likes NVS,2010-04-13 19:49:00-04:00,NVS,positive
936110.0,"Sanofi-Aventis Settles Law Suit (SNY, TEVA, NVS)",2010-04-07 14:39:00-04:00,NVS,neutral
936111.0,Under The Hood: Europe 2001 HOLDRs,2010-03-25 04:48:00-04:00,NVS,neutral
936112.0,Human Genome Sciences (HGSI) and Novartis (NVS) Hepatitis Treatment Awaits Approval,2010-03-24 08:37:00-04:00,NVS,positive
936113.0,"US Stock Futures Mixed (PFE, TEVA, GSK, NKE, NVS, FDX)",2010-03-18 09:04:00-04:00,NVS,neutral
936114.0,"Top 5 NYSE Stocks In The Healthcare Sector With The Highest Dividend (ACL, AZN, GSK, NVS, JNJ)",2010-03-03 07:55:00-05:00,NVS,positive
936115.0,Novartis CEO Says Company Will Go For Bolt-On Acquisitions  (NVS),2010-02-26 19:17:00-05:00,NVS,neutral
936116.0,Merck (MRK) Is A Frontrunner Among Pharma Stocks,2010-02-04 05:25:00-05:00,NVS,neutral
936117.0,"Benzinga’s Volume Movers (MNTA, ISRG, TRGL, IPGP, JCOM)",2010-01-22 14:53:00-05:00,NVS,neutral
936118.0,M&A Funds Are Hot,2010-01-22 06:04:00-05:00,NVS,neutral
936119.0,"Market Round-up (C, BAC, BRK.A, XTO, XOM, ACL, NVS, AAPL, MSFT, GOOG)",2010-01-20 14:57:00-05:00,NVS,neutral
936120.0,ACL’s Stock To Be Volatile On Novartis Deal ,2010-01-14 13:29:00-05:00,NVS,neutral
936121.0,"Alcon (ACL), Novartis (NVS), Nestle (NSRGY) Sued By Pension Fund",2010-01-13 12:45:00-05:00,NVS,neutral
936122.0,"Alcon (ACL) CEO To Recuse Himself, (NVS)",2010-01-13 11:54:00-05:00,NVS,neutral
936123.0,Novartis (NVS) To Raise Bid For Alcon (ACL),2010-01-13 08:39:00-05:00,NVS,neutral
936124.0,"Market Round-Up (INTC, WMT, ACL, NVS, NSRGY.PK, KBH)",2010-01-12 14:37:00-05:00,NVS,neutral
936125.0,Novartis (NVS) Launches Schizophrenia Treatment Fanapt,2010-01-11 14:04:00-05:00,NVS,neutral
936126.0,NVS Acquiring ACL,2010-01-04 09:34:00-05:00,NVS,neutral
936127.0,"Company News for January 04, 2010 - Corporate Summary",2010-01-04 09:07:00-05:00,NVS,neutral
936128.0,"Benzinga’s Top Pre-Market Gainers (OSIS, BFRM, ACL, BIOD, CHK, MAGS, WYNN)",2010-01-04 08:18:00-05:00,NVS,positive
936129.0,"Benzinga’s News Roundup (BFRM, INTC, NVS, SYT, ITMN, CHK, MS)",2010-01-04 07:48:00-05:00,NVS,neutral
936130.0,"Benzinga’s Top Stocks Picks of 2010 (NVS, CAT, SMBL)",2009-12-31 06:18:00-05:00,NVS,positive
936131.0,"Pfizer (PFE), Gold (GLD) Are Big Picks",2009-12-14 16:42:00-05:00,NVS,neutral
936132.0,BarclaysTreats Novartis (NVS) With Care,2009-12-09 13:00:00-05:00,NVS,positive
936133.0,"Fast Money Guys Share Their Dividend Play (VZ, JNJ, JPM, DUK, BP, MCD, NVS, TE, DD, DVY)",2009-12-07 19:09:00-05:00,NVS,positive
936134.0,"Cowen stays Neutral On Santarus (SNTS), Cites Litigation Concerns , PRX, MRK, AZN, NVS",2009-12-02 12:20:00-05:00,NVS,negative
936135.0,"Benzinga’s Top Gainers (RTK, INCY, HEV, QADI, JDSU)",2009-11-25 12:30:00-05:00,NVS,positive
936136.0,"Benzinga’s News Roundup (TIF, WBD, NVS)",2009-11-25 09:29:00-05:00,NVS,neutral
936137.0,"Benzinga’s Top Pre- Market Gainers (TIF, RFMD, AIXG, INCY, SOLF, QGEN, CYTX, SVA)",2009-11-25 08:40:00-05:00,NVS,positive
936138.0,"Cramer Talks About VIP, T, VZ, NVS, SNY, CIEN",2009-11-24 06:56:00-05:00,NVS,positive
936139.0,"Barron's Stock List For A Solid Retirement Plan, STD, JNJ, NVS, MCD, NSRGY, INTC, CVX",2009-11-23 08:40:00-05:00,NVS,positive
936140.0,"Benzinga's ETF Gainers (FRN, SZO, REC, EPV, ERY, DUG, DPK)",2009-11-20 15:49:00-05:00,NVS,neutral
936141.0,"Tim Seymour Is Keen On DIS, NVS, CSCO",2009-11-04 19:22:00-05:00,NVS,positive
936142.0,Novartis (NVS) On Track To Deliver 90M Units of The H1N1 Vaccine ,2009-10-29 08:14:00-04:00,NVS,neutral
936143.0,Human Genome Sciences Discusses The Company's Products (HGSI),2009-10-29 08:05:00-04:00,NVS,neutral
936144.0,Looking To Europe For A Long ETF Play (IEV),2009-10-26 21:15:00-04:00,NVS,positive
936145.0,Novartis AG (NYSE: NVS) Reports Net Income Of $2.1 Billion,2009-10-22 01:50:00-04:00,NVS,neutral
936146.0,"Trends in the U.K. and Irish Pharmaceutical and Biotechnology Industry, an Industrial Info News Alert",2009-08-17 05:01:00-04:00,NVS,positive
936147.0,"AnalystChoice.com Brings You the Best Complimentary Research Report on MDU, NVS, BKS, MA, NGD and NBR",2009-08-13 07:44:00-04:00,NVS,positive
